BCoD Access Dermatology - September / October 2023

BCOD CONFERENCE 2023 Get ready for San Antonio

MEMBER SURVEY

Shop talk and key findings

EVOLVING NEEDS

Increasing importance of BC role

SEPTEMBER

OCTOBER 2023

STREAMLINE THE PROCESS Discover new workflow systems

TOPICAL THERAPY

Psoriasis, PAs and treatment

Painting by Andrew Wilkie, 2023. Image provided by Incyte Corporation.

COV1_JBCOD_Sept/Oct_2023.indd 1

10/11/23 9:48 AM

Explore Innovation in Dermatology

Please scan the code above to visit EUCRISAhcp.com and see the full Prescribing Information and Medication Guide.

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 2

Please scan the code above to visit CIBINQOhcp.com and see Brief Summary of Prescribing Information, including BOXED WARNING, at the end of this advertisement.

Please scan the code above to visit LITFULOhcp.com and see Brief Summary of Prescribing Information, including BOXED WARNING, at the end of this advertisement.

9/18/23 2:31 PM

it mary ng f

TM

Confidence in Patient Support

Helping patients unlock access and reimbursement support for Pfizer dermatology medication

Coverage Assistance

Pfizer Dermatology Patient Access (PDPA) can provide assistance throughout the coverage process, including benefits investigation, prior authorization, and the appeals process.

TM

Financial Assistance

No matter what type of insurance your patients have, PDPA can help identify financial support options.

Pharmacy Coordination

PDPA strives to make prescription fulfillment through the pharmacy as smooth as possible.

Live, Personal Support

You and your patients can connect with a Patient Support Representative by calling 1-833-956-DERM (1-833-956-3376), Monday-Friday, 8AM-8PM ET.

A Pfizer Field Reimbursement Manager (FRM) can support your patients enrolled in Pfizer Dermatology Patient Access by providing your office with access and reimbursement requirements. Visit PfizerDermFRM.com or scan the QR code to the right to find your local FRM.

© 2023 Pfizer Inc. All rights reserved. September 2023. PP-CIB-USA-0916

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 1

9/18/23 2:31 PM

LITFULO™ (ritlecitinib) capsules, for oral use

Brief Summary of full Prescribing Information

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS • Increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment if serious infection occurs until the infection is controlled. LITFULO should not be given to patients with active TB. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test • Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase (JAK) inhibitor vs TNF blockers in rheumatoid arthritis (RA) patients. LITFULO is not approved for use in RA patients • Malignancies have occurred in patients treated with LITFULO. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs TNF blockers in RA patients • Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs TNF blockers in RA patients • Thrombosis has occurred in patients treated with LITFULO. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs TNF blockers INDICATIONS AND USAGE LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.

DOSAGE AND ADMINISTRATION Recommended Evaluations and Immunizations Prior to Treatment With LITFULO • TB infection evaluation: LITFULO initiation is not recommended in patients with active TB. For patients with latent TB or those with a negative latent TB test who are at high risk for TB, start preventive therapy for latent TB prior to initiation of LITFULO • Viral hepatitis screening in accordance with clinical guidelines: LITFULO initiation is not recommended in patients with hepatitis B or hepatitis C • Treatment with LITFULO should not be initiated in patients with absolute lymphocyte count (ALC) <500/mm3 or a platelet count <100,000/mm3 • Update immunizations according to current immunization guidelines Recommended Dosage The recommended dosage of LITFULO is 50 mg orally once daily with or without food.

LITFULO capsules should be swallowed whole; not crushed, split, or chewed.

If a dose is missed, the dose should be taken as soon as possible unless it is less than 8 hours before the next dose; in which case, skip the missed dose and resume dosing at the regular scheduled time.

Patients With Severe Hepatic Impairment LITFULO is not recommended in patients with severe (Child Pugh C) hepatic impairment.

DOSAGE FORMS AND STRENGTHS Capsules: 50 mg of ritlecitinib, size 3, opaque capsules with yellow body and blue cap. The body is printed with “RCB 50” and the cap is printed with “Pfizer” in black.

CONTRAINDICATIONS LITFULO is contraindicated in patients with known hypersensitivity to ritlecitinib or any of its excipients.

WARNINGS AND PRECAUTIONS Serious infections have been reported in patients receiving LITFULO. The most frequent serious infections have been appendicitis, COVID-19 infection (including pneumonia), and sepsis. Among opportunistic infections, multi-dermatomal herpes zoster was reported with LITFULO. Avoid use of LITFULO in patients with an active, serious infection. Consider the risks and benefits of treatment prior to initiating LITFULO in patients: • with chronic or recurrent infection • who have been exposed to TB • with a history of serious infection or an opportunistic infection • who have resided or traveled in areas of endemic TB or mycoses, or • with underlying conditions that may predispose them to infection Closely monitor patients for the development of signs and symptoms of infection during and after treatment with LITFULO. Interrupt LITFULO if a patient develops a serious or opportunistic infection. A patient who develops a new infection during treatment with LITFULO should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient, appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored. LITFULO may be resumed once the infection is controlled.

Tuberculosis Screen patients for TB before starting therapy. LITFULO should not be given to patients with active TB. Anti-TB therapy should be started prior to initiating therapy with LITFULO in patients with a new diagnosis of latent TB or previously untreated latent TB. In patients with a negative latent TB test, consider anti-TB therapy before initiating treatment with LITFULO in those at high risk and consider screening patients at high risk for TB during treatment with LITFULO. Viral Reactivation Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), was reported in clinical trials. If a patient develops herpes zoster, consider interrupting treatment until the episode resolves.

Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy with LITFULO. Patients with evidence of HIV infection or hepatitis B or C infection were excluded from clinical trials.

Mortality In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients treated with the JAK inhibitor compared with TNF blockers. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with LITFULO. Malignancy and lymphoproliferative disorders, including nonmelanoma skin cancer (NMSC), were observed in clinical trials of LITFULO. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding NMSC) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.

The risks and benefits of LITFULO treatment should be considered prior to initiating or continuing therapy in patients with a known malignancy other than a successfully treated NMSC or cervical cancer.

Treatment Interruption or Discontinuation If treatment interruption is indicated, a temporary treatment interruption for less than 6 weeks is not expected to result in significant loss of regrown scalp hair.

Hematologic Abnormalities • Treatment with LITFULO should be discontinued if platelet count is <50,000/mm3 • Treatment with LITFULO should be interrupted if ALC is <500/mm3 and may be restarted once ALC returns above this value ALC and platelet counts are recommended before treatment initiation and at 4 weeks after treatment initiation, and Periodic skin examination is recommended for patients who thereafter according to routine patient management. are at increased risk for skin cancer.

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 2

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

Major Adverse Cardiovascular Events In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of MACE defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers.

Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with LITFULO, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue LITFULO in patients that have experienced an MI or stroke.

Thromboembolic Events An event of pulmonary embolism (PE) was reported in a patient receiving LITFULO. In a ritlecitinib higher dosing group, 1 patient reported an event of retinal artery occlusion.

In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, deep vein thrombosis, and PE were observed compared to those treated with TNF blockers.

Avoid LITFULO in patients who may be at increased risk of thrombosis. If symptoms of thrombosis or embolism occur, patients should interrupt LITFULO and be evaluated promptly and treated appropriately.

Hypersensitivity Serious reactions including anaphylactic reactions, urticaria, and rash have been observed in patients receiving LITFULO in clinical trials. If a clinically significant hypersensitivity reaction occurs, discontinue LITFULO and institute appropriate therapy.

Laboratory Abnormalities Treatment with LITFULO was associated with decreases in lymphocytes and platelets.

Prior to LITFULO initiation, perform ALC and platelet counts. After initiating treatment with LITFULO, treatment interruption or discontinuation are recommended based on ALC and platelet count abnormalities.

Liver Enzyme Elevations: treatment with LITFULO was associated with increased incidence of liver enzyme elevation compared to placebo. Increases of ALT ≥5 times the upper limit of normal (ULN) and increases of AST ≥5 times the ULN were observed in patients in LITFULO clinical trials. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt LITFULO until this diagnosis is excluded.

Creatine Phosphokinase (CPK) Elevations: treatment with LITFULO was associated with increased incidence of CPK elevation compared to placebo.

Vaccinations No data are available on the response to vaccination in patients receiving LITFULO. Use of live attenuated vaccines should be avoided during or shortly prior to initiating treatment. Prior to initiating LITFULO, it is recommended that patients be brought up to date with all immunizations, including prophylactic herpes zoster vaccinations, in agreement with current immunization guidelines.

ADVERSE REACTIONS Clinical Trials Experience The safety of LITFULO was evaluated in three randomized, placebo-controlled clinical trials and one long-term trial in patients with alopecia areata, including alopecia totalis and alopecia universalis, who were 12 years of age and older. A total of 1628 patients were treated with LITFULO representing 2085 patient-years of exposure. There were 1011 patients with at least 1 year of exposure to LITFULO. In the placebo-controlled period of clinical trials in alopecia areata, a total of 668 patients were exposed to LITFULO with 130 receiving 50 mg once daily for up to 24 weeks. The median age of patients was 33 years, 105 (11.9%) patients were 12 to <18 years old and 22 (2.5%) patients were 65 years of age or older. The majority of patients were White (70.7%) and female (63.6%).

Adverse reactions occurring at ≥1% in the treated groups and at a higher rate than placebo are presented in the following table. A total of 2 (1.5%) patients treated with LITFULO 50 mg were discontinued from the trials due to adverse reactions.

9/18/23 2:31 PM

LITFULO™ (ritlecitinib) capsules, for oral use

Brief Summary of full Prescribing Information

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

arch, and/or fused thoracic centra), and skeletal variations LITFULO Placebo Adverse Reactions in Clinical (delayed ossification) at 75 mg/kg/day (55 times the MRHD 50 mg based on AUC comparison). There was no developmental Trials of LITFULO for the N=213 N=130 toxicity at doses up to 25 mg/kg/day (12 times the MRHD Treatment of Alopecia Areata n (%) n (%) based on AUC comparison).

Headache 14 (10.8) 18 (8.5) In a pre- and postnatal development study in rats, oral administration of ritlecitinib from gestation day 6 through Diarrhea 13 (10.0) 8 (3.8) lactation day 20 had no effects on pre- and postnatal Acne 8 (6.2) 10 (4.7) development at doses up to 75 mg/kg/day (14 times the Rash 7 (5.4) 2 (0.9) MRHD based on AUC comparison). At 175 mg/kg/day (41 times the MRHD based on AUC comparison), ritlecitinib Urticaria 6 (4.6) 3 (1.4) caused adverse lower postnatal survival and lower offspring Folliculitis 4 (3.1) 4 (1.9) body weights, which correlated with delayed sexual maturation in both sexes. Bred females in the F1 generation Pyrexia 4 (3.1) 0 also exhibited lower mean numbers of corpora lutea at Dermatitis atopic 3 (2.3) 1 (0.5) 175 mg/kg/day.

Dizziness 3 (2.3) 3 (1.4) Lactation Blood CPK increased 2 (1.5) 0 Risk Summary There are no data on the presence of ritlecitinib in human Herpes zoster 2 (1.5) 0 DRUG INTERACTIONS milk, the effects on the breastfed infant, or the effects on Effects of LITFULO on Other Drugs Red blood cell count decreased 2 (1.5) 0 milk production. Ritlecitinib is present in the milk of lactating CYP3A Substrates Stomatitis 2 (1.5) 0 rats. When a drug is present in animal milk, it is likely that Ritlecitinib is a CYP3A inhibitor. Concomitant use of it will be present in human milk. Because of the serious ritlecitinib increases area under the curve (AUC) and Cmax of adverse effects in adults, including risks of serious infection Specific Adverse Reactions CYP3A substrates, which may increase the risk of adverse and malignancy, advise women not to breastfeed during Exposure adjusted incidence rates were adjusted by clinical reactions of these substrates. treatment with LITFULO and for approximately 14 hours trial size for all adverse reactions reported in this section.

Consider additional monitoring and dosage adjustment after the last dose (approximately 6 elimination half-lives). in accordance with approved product labeling of CYP3A Overall Infections Data In the placebo-controlled trials, for up to 24 weeks, overall substrates where small concentration changes may lead After a single oral 30 mg/kg dose of ritlecitinib to lactating to serious adverse reactions when used with LITFULO. infections were reported in 66 patients (80.35 per 100 rats, ritlecitinib concentrations in milk over time were higher patient-years) treated with placebo and 43 patients (74.53 CYP1A2 Substrates per 100 patient-years) treated with LITFULO 50 mg. Across Ritlecitinib is a CYP1A2 inhibitor. Concomitant use of ritlecitinib than those in plasma. The mean milk to plasma AUC ratio was determined to be 2.2. clinical trials, including the long-term trial, overall infections increases AUC and Cmax of CYP1A2 substrates, which may were reported in 645 patients (50.71 per 100 patient-years) increase the risk of adverse reactions of these substrates. Pediatric Use treated with LITFULO 50 mg or higher.

The safety and effectiveness of LITFULO for alopecia areata Consider additional monitoring and dosage adjustment in have been established in pediatric patients ages 12 years Serious Infections accordance with the approved product labeling of CYP1A2 and older. A total of 181 pediatric patients ages 12 to <18 In the placebo-controlled trials, for up to 24 weeks, 3 patients substrates where small concentration changes may lead to years were enrolled in alopecia areata clinical trials, with 105 reported serious infections across all ritlecitinib doses serious adverse reactions when used with LITFULO. pediatric patients ages 12 to <18 years with alopecia areata studied. Across clinical trials, including the long-term trial, randomized in a pivotal, double-blind, placebo-controlled trial serious infections were reported in 12 patients (0.66 per Effects of Other Drugs on LITFULO (Trial AA-I). Efficacy was consistent between the pediatric 100 patient-years) treated with LITFULO 50 mg or higher.

CYP3A Inducers The most common serious infections were related to appendicitis, Concomitant use of strong CYP3A inducer (e.g., rifampin) patients and adults. The adverse reaction profile in the COVID-19 infection (including pneumonia), and sepsis. may decrease AUC and Cmax of ritlecitinib, which may result pediatric patients was similar to adults.

Herpes Zoster in loss of or reduced clinical response. Coadministration with The safety and efficacy of LITFULO have not been established in pediatric patients under 12 years of age.

In the placebo-controlled trials, for up to 24 weeks, herpes strong inducers of CYP3A is not recommended. zoster was reported in 4 patients across all ritlecitinib doses Geriatric Use USE IN SPECIFIC POPULATIONS studied and 0 patients treated with placebo. Across clinical No dose adjustment is required for patients ≥65 years Pregnancy trials, including the long-term trial, herpes zoster was of age.

Pregnancy Exposure Registry reported in 21 patients (1.17 per 100 patient-years) treated A total of 28 patients enrolled in alopecia areata trials were with LITFULO 50 mg or higher. Opportunistic infections of If a patient becomes pregnant while receiving LITFULO, 65 years of age and older, and none were 75 years of age multi-dermatomal herpes zoster were reported in 1 patient healthcare providers should report LITFULO exposure by and older. Clinical trials of LITFULO did not include sufficient (0.50 per 100 patient-years) treated with the ritlecitinib calling 1-877-390-2940. numbers of patients 65 years of age and older to determine higher dose in the placebo-controlled trials and 2 patients Risk Summary whether they respond differently from younger adult patients.

(0.1 per 100 patient-years) treated with LITFULO 50 mg or Available data from clinical trials with LITFULO use in higher in all clinical trials.

As there is a higher incidence of infections in the elderly pregnant women are insufficient to identify a drug-associated population in general, caution should be used when treating Malignancy risk of major birth defects, miscarriage, or other adverse the elderly.

In the placebo-controlled trials, for up to 24 weeks, maternal or fetal outcomes. In animal reproduction studies, 1 malignancy (breast cancer) was reported in 1 patient Hepatic Impairment oral administration of ritlecitinib to pregnant rats and (1.33 per 100 patient-years) treated with ritlecitinib higher rabbits during organogenesis caused fetotoxicity and fetal No dose adjustment is required in patients with mild dose and no malignancy was reported in patients treated malformations at exposures equal to 49 and 55 times the (Child Pugh A) or moderate (Child Pugh B) hepatic with placebo. Across clinical trials, including the long-term maximum recommended human dose (MRHD) based on an impairment. LITFULO is not recommended in patients with trial, malignancies excluding NMSC were reported in severe (Child Pugh C) hepatic impairment.

AUC comparison, respectively.

7 patients (0.37 per 100 patient-years) treated with The background risks of major birth defects and OVERDOSAGE LITFULO 50 mg or higher. miscarriage for the indicated population are unknown.

LITFULO was administered in clinical trials up to a single Thromboembolic Events All pregnancies carry some risk of birth defects, loss, or oral dose of 800 mg. Adverse reactions were comparable Across clinical trials, including the long-term trial, PE was other adverse outcomes.

The estimated background risks to those seen at lower doses and no specific toxicities were reported in 1 patient (0.06 per 100 patient-years) treated with in the U.S. general population of major birth defects and identified. Pharmacokinetics data up to and including a single LITFULO. There was 1 report of retinal artery occlusion and miscarriages are 2-4% and 15-20% of clinically recognized oral dose of 800 mg in healthy adult volunteers indicate that 1 report of acute MI. pregnancies, respectively. more than 90% of the administered dose is expected to be Urticaria eliminated within 48 hours.

In the placebo-controlled trials, for up to 24 weeks, urticaria Data There is no specific antidote for overdose with LITFULO. Animal Data was reported in 28 patients treated in all ritlecitinib doses Treatment should be symptomatic and supportive, and studied and 3 patients treated with placebo. The rate of In an embryo-fetal development study in pregnant rats, monitor patients for signs and symptoms of adverse urticaria was 8.23 per 100 patient-years in patients treated oral administration of ritlecitinib from gestation days 6 to reactions. with LITFULO 50 mg and 4.03 per 100 patient-years in 17 decreased fetal body weights and caused fetal skeletal patients treated with placebo. Across clinical trials, including malformations (malformed vertebrae and ribs) and variations In case of an overdose, call Poison Control Center the long-term trial, urticaria was reported in 76 patients at 1-800-222-1222 for latest recommendations. (delayed ossification) at doses ≥175 mg/kg/day (49 times treated with LITFULO 50 mg or higher. Among all patients the MRHD based on AUC comparison). Maternal toxicity This brief summary is based on LITFULOTM (ritlecitinib) treated with LITFULO 50 mg or higher in the integrated safety (lower body weights) was noted at 325 mg/kg/day (102 times Prescribing Information LAB-1469-0.5. analysis, the rate of urticaria was 4.10 per 100 patient-years.

Issued: June 2023.

The median time to onset of an initial event was 8 weeks; the MRHD based on AUC comparison). There was no developmental toxicity at 75 mg/kg/day (16 times the MRHD The product’s label may have been updated. median duration of urticaria was 7 days. Most of the cases based on AUC comparison). were mild to moderate in severity.

For full Prescribing Information, visit LITFULOHCP.com.

In an embryo-fetal development study in pregnant rabbits, Decreased Lymphocyte Counts oral administration of ritlecitinib from gestation days 7 to Across clinical trials, including the long-term trial, confirmed 19 decreased mean fetal body weights and increased ALC <500/mm3 occurred in 1 patient (<0.1%) treated with LITFULO 50 mg. Age appeared to be a risk factor for lower visceral malformations (malpositioned kidneys), skeletal © 2023 Pfizer Inc. All rights reserved.

ALC in patients ≥65 years of age. malformations (supernumerary sternebrae, absent thoracic PP-RIL-USA-0414 June 2023 Decreased Platelet Count In the placebo-controlled trials, for up to 24 weeks, treatment with LITFULO was associated with a decrease in platelet count. Maximum effects on platelets were observed within 4 weeks, after which platelet count remained stable at a lower level with continued therapy. Across clinical trials, including the long-term trial, 1 patient (<0.1%) had a confirmed platelet count <100,000/mm3. No patient had a confirmed platelet count <75,000/mm3.

CPK Elevations In the placebo-controlled trials, for up to 24 weeks, events of blood CPK increased were reported in 2 (1.5%) patients treated with LITFULO 50 mg and 0 patients treated with placebo.

Liver Enzyme Elevations In the placebo-controlled trials, for up to 24 weeks, events of increases in liver enzymes ≥3 times the ULN were observed in patients treated with LITFULO.

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 3

9/18/23 2:32 PM

CIBINQO™ (abrocitinib) tablets, for oral use

Brief Summary of full Prescribing Information; Initial Approval: January 2022

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS Serious Infections Patients treated with CIBINQO may be at increased risk for developing serious infections that may lead to hospitalization or death; The most frequent serious infections reported with CIBINQO were herpes simplex, herpes zoster, and pneumonia.

If a serious or opportunistic infection develops, discontinue CIBINQO and control the infection.

Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions: • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test.

• Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.

• Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

Avoid use of CIBINQO in patients with an active, serious infection including localized infections.

The risks and benefits of treatment with CIBINQO should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIBINQO, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Mortality In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another JAK inhibitor to TNF blocker treatment, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor. CIBINQO is not approved for use in RA patients.

Malignancies Malignancies were reported in patients treated with CIBINQO. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions.

In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers.

Patients who are current or past smokers are at additional increased risk.

Major Adverse Cardiovascular Events Major adverse cardiovascular events were reported in patients treated with CIBINQO. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.

Thrombosis Deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with CIBINQO. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death.

In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers.

Avoid CIBINQO in patients at risk. If symptoms of thrombosis occur, discontinue CIBINQO and treat appropriately.

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 4

INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

DOSAGE AND ADMINISTRATION Recommended Testing, Evaluations, and Procedures Prior to Treatment Initiation Perform the following tests and evaluations prior to CIBINQO initiation: • Tuberculosis (TB) infection evaluation – CIBINQO initiation is not recommended in patients with active TB. For patients with latent TB or those with a negative latent TB test who are at high risk for TB, start preventive therapy for latent TB prior to initiation of CIBINQO • Viral hepatitis screening in accordance with clinical guidelines – CIBINQO initiation is not recommended in patients with active hepatitis B or hepatitis C • A complete blood count (CBC) – CIBINQO initiation is not recommended in patients with a platelet count <150,000/mm3, an absolute lymphocyte count <500/mm3, an absolute neutrophil count <1,000/mm3, or a hemoglobin value <8 g/dL Complete any necessary immunizations, including herpes zoster vaccinations, in agreement with current immunization guidelines prior to CIBINQO initiation.

Recommended Dosage The recommended dosage of CIBINQO is 100 mg orally once daily.

If an adequate response is not achieved with CIBINQO 100 mg orally daily after 12 weeks, consider increasing dosage to 200 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 200 mg once daily.

CIBINQO can be used with or without topical corticosteroids.

If a dose is missed, administer the dose as soon as possible unless it is less than 12 hours before the next dose, in which case skip the missed dose. Thereafter, resume dosing at the regular scheduled time.

Recommended Dosage in Patients with Renal Impairment Renal Impairment CIBINQO dosage recommendation in patients with mild renal impairment (60-89 mL/minute) is 100 mg once daily.

For patients with moderate renal impairment (30-59 mL/ minute), the recommended dosage is 50 mg once daily.

CIBINQO is not recommended for patients with severe or End-Stage Renal Disease (ESRD). Severe renal impairment and End-Stage Renal Disease include patients on renal replacement therapy.

In subjects with mild and moderate renal impairment, if an adequate response is not achieved after 12 weeks, dose of CIBINQO can be doubled.

CIBINQO is not recommended for patients with severe renal impairment or ESRD. Recommended Dosage in CYP2C19 Poor Metabolizers In patients who are known or suspected to be CYP2C19 poor metabolizers, the recommended dosage of CIBINQO is 50 mg once daily. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.

Dosage Modifications due to Strong Inhibitors In patients taking strong inhibitors of cytochrome P450 (CYP) 2C19 reduce the dosage to 50 mg once daily. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.

Treatment Discontinuation due to Serious Infections or Hematologic Adverse Reactions Serious or Opportunistic Infections If a patient develops a serious or opportunistic infection, discontinue CIBINQO and control the infection. The risks and benefits of treatment with CIBINQO should be carefully considered prior to reinitiating therapy with CIBINQO. Hematologic Abnormalities • Discontinue CIBINQO if platelet count <50,000/mm3 and

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

follow with CBC until >100,000/mm3 • Treatment should be temporarily discontinued if ALC is less than 500 cells/mm3 and may be restarted once ALC return above this value • Treatment should be temporarily discontinued if ANC is less than 1,000 cells/mm3 and may be restarted once ANC return above this value • Treatment should be temporarily discontinued if Hb is less than 8 g/dL and may be restarted once Hb return above this value CBC evaluations are recommended at baseline, 4 weeks after treatment initiation and 4 weeks after dosing increase of CIBINQO. Laboratory evaluations may be extended for patients on chronic CIBINQO therapy who develop hematologic abnormalities.

DOSAGE FORMS AND STRENGTHS • 50 mg: Pink, oval, film-coated tablet debossed with “PFE” on one side and “ABR 50” on the other.

• 100 mg: Pink, round, film-coated tablet debossed with “PFE” on one side and “ABR 100” on the other.

• 200 mg: Pink, oval, film-coated tablet debossed with “PFE” on one side and “ABR 200” on the other.

CONTRAINDICATIONS CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.

WARNINGS AND PRECAUTIONS Serious Infections The most frequent serious infections reported in clinical studies with CIBINQO for atopic dermatitis were herpes simplex, herpes zoster, and pneumonia. Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving JAK inhibitors used to treat inflammatory conditions.

Avoid use of CIBINQO in patients with active, serious infection including localized infections.

Consider the risks and benefits of treatment prior to initiating CIBINQO in patients: • with chronic or recurrent infection • who have been exposed to tuberculosis • with a history of a serious or an opportunistic infection • who have resided or traveled in areas of endemic tuberculosis or endemic mycoses • with underlying conditions that may predispose them to infection Closely monitor patients for the development of signs and symptoms of infection during and after treatment with CIBINQO. If a patient develops a serious or opportunistic infection, discontinue CIBINQO. Initiate complete diagnostic testing and appropriate antimicrobial therapy. The risks and benefits of treatment with CIBINQO should be carefully considered prior to reinitiating therapy with CIBINQO. Tuberculosis Evaluate and test patients for TB before starting CIBINQO therapy and consider yearly screening for patients in highly endemic areas for TB. CIBINQO is not recommended for use in patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, or for patients with a negative test for latent TB but who are at high risk for TB infection, start preventive therapy for latent TB prior to initiation of CIBINQO. Monitor patients for the development of signs and symptoms of TB, including patients who were tested negative for latent TB infection prior to initiating therapy.

Viral Reactivation Viral reactivation, including herpes virus reactivation (e.g., herpes zoster, herpes simplex), was reported in clinical studies with CIBINQO. If a patient develops herpes zoster, consider interrupting CIBINQO until the episode resolves.

Hepatitis B virus (HBV) reactivation has been reported in patients receiving JAK inhibitors. Perform viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO. CIBINQO is not recommended for use in patients with active hepatitis B or hepatitis C. Monitor patients with inactive HBV for expression of HBV DNA during therapy with CIBINQO. If HBV DNA is detected during therapy with CIBINQO, consult a liver specialist.

Mortality In a large, randomized, postmarketing safety study of another JAK inhibitor in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients

9/18/23 2:32 PM

CIBINQO™ (abrocitinib) tablets, for oral use Mortality (continued) treated with the JAK inhibitor compared with TNF blockers.

CIBINQO is not approved for use in RA. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO. Malignancy and Lymphoproliferative Disorders Malignancies, including non-melanoma skin cancer (NMSC), were observed in clinical studies with CIBINQO for atopic dermatitis.

Perform periodic skin examination for patients who are at increased risk for skin cancer. Exposure to sunlight and UV light should be limited by wearing protective clothing and using broad-spectrum sunscreen.

Malignancies, including lymphomas, have occurred in patients receiving JAK inhibitors used to treat inflammatory conditions. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. CIBINQO is not approved for use in RA. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers.

Major Adverse Cardiovascular Events Major adverse cardiovascular events were reported in clinical studies of CIBINQO for atopic dermatitis.

In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers.

CIBINQO is not approved for use in RA. Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.

Thrombosis Deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in patients receiving CIBINQO in the clinical studies for atopic dermatitis.

Thrombosis, including DVT, PE, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death.

In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers. CIBINQO is not approved for use in RA. Avoid CIBINQO in patients that may be at increased risk of thrombosis. If symptoms of thrombosis occur, discontinue CIBINQO and evaluate and treat patients appropriately.

Laboratory Abnormalities Hematologic Abnormalities Treatment with CIBINQO was associated with an increased incidence of thrombocytopenia and lymphopenia. Prior to CIBINQO initiation, perform a CBC. CBC evaluations are recommended at 4 weeks after initiation and 4 weeks after dose increase of CIBINQO. Discontinuation of CIBINQO therapy is required for certain laboratory abnormalities.

Lipid Elevations Dose-dependent increase in blood lipid parameters were reported in patients treated with CIBINQO. Lipid parameters should be assessed approximately 4 weeks following initiation of CIBINQO therapy and thereafter patients should be managed according to clinical guidelines for hyperlipidemia. The effect of these lipid parameter

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 5

elevations on cardiovascular morbidity and mortality has not been determined.

Immunizations Prior to initiating CIBINQO, complete all age-appropriate vaccinations as recommended by current immunization guidelines including prophylactic herpes zoster vaccinations.

Avoid vaccination with live vaccines immediately prior to, during, and immediately after CIBINQO therapy.

ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Major Adverse • Serious Infections Cardiovascular Events • Mortality • Thrombosis • Malignancy and • Laboratory Abnormalities Lymphoproliferative Disorders Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of CIBINQO was evaluated in four randomized, placebo-controlled clinical trials (2 monotherapy, 1 combination therapy with topical corticosteroid, and 1 dose-ranging) and one long-term extension trial in subjects with moderate to severe atopic dermatitis (AD). A total of 1623 subjects with moderate to severe atopic dermatitis were treated with CIBINQO in these clinical trials representing 1428 patient-years of exposure. There were 634 subjects with at least 1 year of exposure to CIBINQO. In the placebo-controlled clinical trials, a total of 1198 subjects were exposed to CIBINQO with 608 subjects receiving CIBINQO 100 mg once daily and 590 subjects receiving CIBINQO 200 mg once daily for up to 16 weeks.

The median age of subjects was 33.0 years, 124 subjects (8.1%) were 12 to less than 18 years old and 94 subjects (6.1%) were 65 years of age or older. The majority of subjects were White (68.7%) and male (53.9%).

Adverse reactions occurring at ≥1% in any of the treated groups and at a higher rate than in the placebo group are presented in the table below. A total of 61 (5.1%) subjects treated with CIBINQO were discontinued from the trials due to adverse reactions. The safety profile of CIBINQO in the monotherapy and the combination trial(s) were similar.

Adverse Reactions from Placebo-Controlled Trials Reported in ≥1% of CIBINQO Treated Subjects with Moderate to Severe Atopic Dermatitis and at Higher Rate than Placebo for up to 16 Weeks Weeks 0-16 CIBINQO CIBINQO PLACEBO 200 mg 100 mg N=342 N=590 N=608 n (%a) a a n (% ) n (% ) Nasopharyngitis 51 (8.7) 75 (12.4) 27 (7.9) Nausea 86 (14.5) 37 (6.0) 7 (2.1) Headache 46 (7.8) 36 (6.0) 12 (3.5) b Herpes simplex 25 (4.2) 20 (3.3) 6 (1.8) Increased blood 17 (2.9) 14 (2.3) 5 (1.5) creatine phosphokinase Dizziness 17 (2.9) 11 (1.8) 3 (0.9) Urinary tract infection 13 (2.2) 10 (1.7) 4 (1.2) Fatigue 8 (1.3) 10 (1.6) 2 (0.5) Acne 28 (4.7) 10 (1.6) 0 (0.0) Vomiting 19 (3.2) 9 (1.5) 3 (0.9) Impetigo 3 (0.5) 9 (1.5) 1 (0.3) Oropharyngeal pain 6 (1.0) 8 (1.4) 2 (0.6) Hypertension 5 (0.8) 7 (1.2) 2 (0.7) Influenza 6 (1.1) 7 (1.2) 0 (0.0) Gastroenteritis 8 (1.3) 7 (1.1) 2 (0.6) Dermatitis contact 3 (0.5) 6 (1.1) 1 (0.3) Abdominal pain upper 11 (1.9) 4 (0.6) 0 (0.0) Abdominal discomfort 7 (1.2) 3 (0.5) 1 (0.3) Herpes zoster 7 (1.2) 2 (0.3) 0 (0.0) Thrombocytopenia 9 (1.5) 0 (0.0) 0 (0.0) a Study size adjusted percentages b Herpes simplex also includes oral herpes, ophthalmic herpes, herpes

dermatitis, genital herpes.

Specific Adverse Reactions Exposure adjusted incidence rates were adjusted by trial size for all the adverse reactions reported in this section.

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

Overall Infections In the placebo-controlled trials, for up to 16 weeks, overall infections were reported in 90 subjects (126.8 per 100 patient-years) treated with placebo, 211 subjects (168.8 per 100 patient-years) treated with CIBINQO 100 mg and 204 subjects (159.5 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, overall infections were reported in 427 subjects (91.8 per 100 patient-years) treated with CIBINQO 100 mg and 394 subjects (103.2 per 100 patient-years) treated with CIBINQO 200 mg.

Serious Infections In the placebo-controlled trials, for up to 16 weeks, serious infections were reported in 2 subjects (2.6 per 100 patient-years) treated with placebo, 6 subjects (3.9 per 100 patient-years) treated with CIBINQO 100 mg, and 2 subjects (1.3 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, serious infections were reported in 18 subjects (2.3 per 100 patient-years) treated with CIBINQO 100 mg and 16 subjects (2.3 per 100 patient-years) treated with CIBINQO 200 mg. The most commonly reported serious infections were herpes simplex, herpes zoster, and pneumonia.

Herpes Zoster In the placebo-controlled trials, for up to 16 weeks, opportunistic infections were generally cases of multidermatomal cutaneous herpes zoster. Herpes zoster was reported in 0 subjects treated with placebo, 3 subjects (1.9 per 100 patient-years) treated with CIBINQO 100 mg and 8 subjects (5.1 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, herpes zoster was reported in 16 subjects (2.0 per 100 patient-years) treated with CIBINQO 100 mg and 35 subjects (5.2 per 100 patient-years) treated with CIBINQO 200 mg.

Malignancy In the placebo-controlled trials, for up to 16 weeks, no malignancy was reported in subjects treated with placebo or CIBINQO 100 mg and in 1 patient (0.65 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, malignancy was reported in 4 subjects (0.5 per 100 patient-years) treated with CIBINQO 100 mg and 2 subjects (0.3 per 100 patient-years) treated with CIBINQO 200 mg.

Thrombosis In all clinical trials, including the long-term extension trial, pulmonary embolism was reported in 3 subjects (0.4 per 100 patient-years), who were treated with CIBINQO 200 mg. Deep vein thrombosis was reported in 2 subjects (0.3 per 100 patient-years) who were treated with CIBINQO 200 mg. No thrombosis occurred in subjects treated with CIBINQO 100 mg.

Major Adverse Cardiovascular Events In the placebocontrolled trials, for up to 16 weeks, major adverse cardiovascular event (MACE) was reported in 1 subject (0.6 per 100 patient-years) treated with CIBINQO 100 mg.

In all 5 clinical trials, including the long-term extension trial, MACE was reported in 1 patient (0.1 per 100 patient-years) treated with CIBINQO 100 mg and 2 subjects (0.3 per 100 patient-years) treated with CIBINQO 200 mg.

Thrombocytopenia In the placebo-controlled trials, for up to 16 weeks, treatment with CIBINQO was associated with a dose-related decrease in platelet count. Maximum effects on platelets were observed within 4 weeks, after which the platelet count returned towards baseline despite continued therapy. In all 5 clinical trials, including the long-term extension trial 6 subjects (0.9 per 100 patient-years) treated with CIBINQO 200 mg had adverse reactions of thrombocytopenia, no subjects treated with CIBINQO 100 mg had an adverse reaction of thrombocytopenia.

Lymphopenia In the placebo-controlled trials, for up to 16 weeks, confirmed ALC <500/mm3 occurred in 2 subjects (1.2 per 100 patient-years) treated with CIBINQO 200 mg and 0 subjects treated with CIBINQO 100 mg or placebo.

Both cases occurred in the first 4 weeks of exposure.

Lipid Elevations In the placebo-controlled trials, for up to 16 weeks, there was a dose-related percent increase in low-density lipoprotein cholesterol (LDL-c), total cholesterol, and high-density lipoprotein cholesterol (HDL-c) relative to placebo at Week 4 which remained elevated through the final visit in the treatment period. Adverse reactions related to hyperlipidemia occurred in 1 subject (0.6 per 100 patient-years) exposed to CIBINQO 100 mg, 3 subjects (2.0 per 100 patient-years) exposed to CIBINQO 200 mg.

Retinal Detachment In the placebo-controlled trials, for up to 16 weeks, retinal detachment occurred in 1 subject (0.6 per 100 patient-years) treated with CIBINQO 100 mg. In all 5 clinical trials, including the long-term extension trial, retinal detachment occurred in 2 subjects (0.3 per 100 patient-years) treated with CIBINQO 100 mg.

9/18/23 2:32 PM

CIBINQO™ (abrocitinib) tablets, for oral use Specific Adverse Reactions (continued) Creatine Phosphokinase Elevations (CPK) In the placebocontrolled trials, for up to 16 weeks, events of blood CPK increased were reported in 6 subjects (7.5 per 100 patient-years) treated with placebo, 11 subjects (6.9 per 100 patient-years) treated with 100 mg of CIBINQO and 19 subjects (12.3 per 100 patient-years) treated with 200 mg of CIBINQO. Most elevations were transient, there were no reported adverse reactions of rhabdomyolysis.

Adolescent Subjects (12 to less than 18 years of age) The safety of CIBINQO was assessed in a trial of 284 subjects 12 to less than 18 years of age with moderate-to-severe atopic dermatitis (Trial-AD-4). The safety profile of CIBINQO in these subjects, assessed through the initial treatment period of 12 weeks and the long-term period (213 with at least 52 weeks of abrocitinib exposure), was similar to the safety profile from trials in adults with atopic dermatitis.

DRUG INTERACTIONS Effects of Other Drugs on CIBINQO The table below includes drugs with clinically significant drug interactions affecting CIBINQO. Clinically Significant Drug Interactions Affecting CIBINQO

Strong CYP2C19 Inhibitors Clinical Impact

Coadministration of CIBINQO with strong CYP2C19 inhibitors increases the combined exposure of abrocitinib and its two active metabolites, M1 and M2 which may increase the adverse reactions of CIBINQO.

Intervention Dosage reduction of CIBINQO is recommended when coadministered with strong CYP2C19 inhibitors.

Moderate to Strong Inhibitors of both CYP2C19 and CYP2C9 Clinical Impact

Coadministration of CIBINQO with drugs that are moderate to strong inhibitors of both CYP2C19 and CYP2C9 increases the exposure of abrocitinib and its two active metabolites, M1 and M2 which may increase the adverse reactions of CIBINQO.

Intervention Avoid concomitant use of CIBINQO with drugs that are moderate to strong inhibitors of both CYP2C19 and CYP2C9.

Strong CYP2C19 or CYP2C9 Inducers Clinical Impact

Coadministration of CIBINQO with strong CYP2C19 or CYP2C9 inducers decreases the combined exposure of abrocitinib and its two active metabolites, M1 and M2, which may result in loss of or reduced clinical response.

Intervention Avoid concomitant use of CIBINQO with strong CYP2C19 or CYP2C9 inducers.

Effects of CIBINQO on Other Drugs The table below includes clinically significant drug interactions affecting other drugs.

Clinically Significant Interactions Affecting Other Drugs

P-gp Substrate Where Small Concentration Changes May Lead to Serious or Life-threatening Toxicities Clinical Coadministration of CIBINQO with P-gp Impact substrate increases plasma concentrations of P-gp substrates and may result in potential adverse reactions of the P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities (e.g., digoxin).

Intervention Monitor appropriately or dose titrate P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities when coadministered with CIBINQO. Antiplatelet Therapy Drugs Clinical Coadministration of CIBINQO with antiplatelet Impact therapy drugs may increase the risk of bleeding with thrombocytopenia.

Intervention Antiplatelet drugs, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment are contraindicated with CIBINQO.

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 6

USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770 or visit CIBINQOPregnancyRegistry.com.

Risk Summary Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of abrocitinib to pregnant rats and rabbits during organogenesis at exposure 11 or 4 times the maximum recommended human dose (MRHD) based on AUC comparison, respectively, resulted in maternal dystocia and skeletal variations in rats and no adverse effects in rabbits (see Animal Data).

The background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies carry some risk of birth defects, loss, or other adverse outcomes. The background risks in the U.S. general population of major birth defects and miscarriages are 2-4% and 15-20% of clinically recognized pregnancies, respectively.

Animal Data In an embryofetal development study, abrocitinib was administered orally to pregnant rats at doses of 10, 30, or 60 mg/kg/day during the period of organogenesis. No fetal malformations were observed. Abrocitinib increased the incidence of skeletal variations of short 13th ribs at 30 mg/kg/ day (11 times the MRHD based on AUC comparison).

Increased embryofetal lethality and additional skeletal variations (cervical arches with reduced ventral processes, thickened ribs, and unossified metatarsals) were noted at 60 mg/kg/day (17 times the MRHD based on AUC comparison).

In an embryofetal development study, abrocitinib was administered orally to pregnant rabbits at doses of 10, 30, or 75 mg/kg/day during the period of organogenesis. No abrocitinib-related maternal or developmental toxicity was noted at doses up to 75 mg/kg/day (4 times the MRHD based on AUC comparison).

In a prenatal and postnatal development study, abrocitinib was administered orally to pregnant rats at doses of 10, 30, and 60 mg/kg/day beginning on gestation day 6 and continuing through lactation day 20. Dystocia with prolonged parturition and reduced offspring body weights were noted at 30 mg/kg/ day (11 times the MRHD based on AUC comparison).

Postnatal survival was markedly decreased at 60 mg/kg/day (17 times the MRHD based on AUC comparison). No maternal toxicity was observed at 10 mg/kg/day (2.4 times the MRHD based on AUC comparison). No abrocitinib-related effects on postnatal developmental, neurobehavioral, or reproductive performance of offspring was noted at doses up to 30 mg/kg/ day (11 times the MRHD based on AUC comparison).

Lactation Risk Summary There are no data on the presence of abrocitinib in human milk, the effects on the breast-fed infant, or the effects on milk production. Abrocitinib was secreted in milk of lactating rats (see Animal Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the serious adverse findings in adults, including risks of serious infections, malignancy, and thrombosis, advise women not to breastfeed during treatment with CIBINQO and for one day after the last dose (approximately 5-6 elimination half-lives).

Animal Data Lactating female rats were orally administered a single dose of 10 mg/kg abrocitinib on lactation day 12.

Abrocitinib AUC was approximately 5 times greater in milk than in plasma.

Females and Males of Reproductive Potential Infertility Females Based on the findings in rats, oral administration of CIBINQO may impair female fertility. Impaired fertility in female rats was reversible 1 month after cessation of abrocitinib oral administration.

Pediatric Use The safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older weighing 25 kg or more with atopic dermatitis has been established. In trials Trial-AD-1 and Trial-AD-2, 124 adolescent subjects 12 to less than 18 years old with moderate-to-severe atopic dermatitis were enrolled and randomized to receive either CIBINQO 100 mg (N=51), 200 mg (N=48), or matching placebo (N=25) in monotherapy.

Additional 284 adolescent subjects 12 to less than 18 years of age with moderate-to-severe atopic dermatitis, were enrolled and randomized to receive either CIBINQO 100 mg (N=95) or 200 mg (N=94) or matching placebo (N=95) in combination with topical corticosteroids in Trial-AD-4. Efficacy and adverse reaction profile were consistent between the pediatric patients and adults.

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

The safety and effectiveness of CIBINQO have not been established in pediatric patients below 12 years of age.

Juvenile Animal Toxicity Data In a juvenile animal toxicity study, abrocitinib was administered orally to juvenile rats at doses of 5, 25, and 75 mg/kg/day beginning on postnatal day 10 (approximately equivalent to a human infant) and continuing through postnatal day 63 (approximately equivalent to an adolescent). Abrocitinib caused a reversible, dose-related decrease in the primary spongiosa in the metaphysis of the proximal tibia and distal femur. Abrocitinib produced adverse effects on bone development at all dose levels. Abrocitinib caused irreversible dose-related small or misshapen femoral heads at doses ≥5 mg/kg/day (0.8 times the MRHD based on AUC comparison).

Abrocitinib also irreversibly decreased femur size and caused paw malrotation and limb impairment at doses ≥25 mg/kg/day (7.2 times the MRHD based on AUC comparison). At 75 mg/kg/ day (27 times the MRHD based on AUC comparison), paw fractures generally corresponded to limb impairment, a fractured tibia was noted in a single female. Irreversible bone findings have not been observed in older animals.

Geriatric Use A total of 145 (4.6%) patients 65 years of age and older, while 25 (0.8%) were 75 years of age and older, were enrolled in CIBINQO clinical trials. Clinical trials of CIBINQO did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

A higher proportion of patients 65 years of age and older discontinued from clinical trials compared to younger patients.

Among all patients exposed to CIBINQO, including the long-term extension trial, confirmed ALC <500/mm3 occurred only in patients 65 years of age and older. A higher proportion of patients 65 years of age and older had platelet counts <75,000/ mm3. The incidence rate of herpes zoster in patients 65 years of age and older treated with CIBINQO (7.40 per 100 patient-years) was higher than that of patients 18 to less than 65 years of age (3.44 per 100 patient-years).

Renal Impairment In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30-59 mL/min) renal impairment, the combined exposure (AUCinf,u) of abrocitinib and its two active metabolites, M1 and M2, is increased compared to patients with normal renal function (eGFR ≥90 mL/min). This may increase the risk of adverse reactions such as infections.

CIBINQO is not recommended for use in patients with severe renal impairment and ESRD including those on renal replacement therapy.

A dosage reduction in patient with moderate renal impairment is recommended. No dosage adjustment is required in patients with mild renal impairment (eGFR 60-89 mL/min).

CIBINQO has not been studied in patients on renal replacement therapy. In Phase 3 clinical trials, CIBINQO was not evaluated in patients with atopic dermatitis with baseline creatinine clearance values less than 40 mL/min.

Hepatic Impairment Avoid use of CIBINQO in patients with severe (Child Pugh C) hepatic impairment.

Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment based on similar combined exposure (AUCinf,u) of abrocitinib and its two active metabolites, M1 and M2 compared to patients with normal hepatic function. In clinical trials, CIBINQO was not evaluated in patients with severe (Child Pugh C) hepatic impairment.

CYP2C19 Poor Metabolizers In patients who are CYP2C19 poor metabolizers, the AUC of abrocitinib is increased compared to CYP2C19 normal metabolizers due to reduced metabolic clearance. Dosage reduction of CIBINQO is recommended in patients who are known or suspected to be CYP2C19 poor metabolizers based on genotype or previous history/experience with other CYP2C19 substrates.

OVERDOSAGE There is no experience regarding human overdosage with CIBINQO. There is no specific antidote for overdose with CIBINQO. In case of an overdose, call Poison Control Center at 1-800-222-1222 for latest recommendations.

Rx only This brief summary is based on CIBINQO™ (abrocitinib) Prescribing Information LAB-1424-2.0.

Issued: February 2023.

The product’s label may have been updated. For full Prescribing Information, visit CIBINQOPI.com.

See CIBINQO full Prescribing Information at CIBINQOPI.com.

© 2023 Pfizer Inc. All rights reserved.

February 2023. PP-CIB-USA-0485

9/18/23 2:32 PM

ACCESS DERMATOLOGY

A magazine dedicated to supporting patient access with practical information and lifestyle content

ISSUE 6 | September/October 2023

MISSION STATEMENT: Access Dermatology aims to educate and empower the biologic coordinator by keeping them informed of the complex and everchanging drug and patient access landscape. Readers are engaged with editorial and lifestyle content equally suitable for dermatologic patients, so they too may gain a better sense of therapies and the patient services programs that can assist in their therapeutic journey.

EXECUTIVE DIRECTOR Craig Schuette EDITOR Elizabeth Hole CREATIVE DIRECTOR Venera Alexandrova ASSISTANT ART DIRECTOR Lisa Servidio PRODUCTION DIRECTOR Tim Carr

CORRESPONDENCE: Communications regarding original articles as well as editorial suggestions for future issues should be addressed to Craig Schuette at cs@bcofdermatology.com.

Any content forwarded to the publisher assumes no liability for the safety or return of unsolicited art, photographs, or manuscripts.

Cover Art Painting by Andrew Wilkie, 2023.

Image provided by Incyte Corporation.

PRESIDENT Jonathan W. Moffly

DISPLAY ADVERTISING:

VICE PRESIDENT/BUSINESS Elena V. Moffly

Contact Craig Schuette at cs@bcofdermatology.com.

MOFFLY CUSTOM MEDIA 205 Main Street, Westport, CT 06880 telephone: 203-222-0600 email: mail@MofflyCustomMedia.com

Follow the Biologic Coordinators of Dermatology

FACEBOOK LINKEDIN

© 2023 Access Dermatology and Biologic Coordinators of Dermatology. ALL RIGHTS RESERVED. The material in this publication is published by Moffly Custom Media and may not be reproduced or transmitted in any manner, in whole or in part, without the express written permission of Access Dermatology and Moffly Custom Media. NOTICE: The information contained within articles of this magazine represent the views and opinions of the original authors and do not necessarily represent the views and opinions of Access Dermatology or its affiliates. The mere appearance of content in the magazine does not constitute an endorsement by Access Dermatology or its affiliates. The content has been made available for informational and educational purposes only. Editorial advice is not specific, and readers are advised to seek medical, professional, or reimbursement help for individual circumstances. Access Dermatology hereby disclaims all liability to any party for any direct, indirect, implied, punitive, special, incidental, or other consequential damages arising directly or indirectly from any use of the content. CIRCULATION: To be added to the circulation, visit www.bcofdermatolgy.com/ magazine. REPRINTS: For educational, commercial, or promotional reprints, including author off-prints, please email contact@bcofdermatology.com.

bcofdermatology.com

7

COV2_07_JBCOD_1pg Masthead_Sept/Oct_2023.indd 7

9/18/23 2:32 PM

contents ACCESS DERMATOLOGY

ISSUE 6

FEATU R ES

12 Evolving Needs The increasing importance of biologic coordinators in dermatology 22 Streamline the Process Simplifying the job with technology-enabled workplace systems 66 Building a Note Keys to success for getting biologic therapies approved 98 Topical Therapy Psoriasis, Prior Authorizations and ZORYVE (ROFLUMILAST) CREAM 0.3%

CO M M U N I TY 32 Member Survey Shop talk and key findings about the job 46 Dermatology Specialty Drug Guide Resource page courtesy of OPTUM 49 BCoD Conference 2023 Thank you to our sponsors 70 BC Spotlight Recognizing five committed biologic coordinators

L I FESTYL E 80 The Great Pumpkin Get crafty and carve up some spooky fun 84 Mental Wellness Six tips for maintaining your well-being this fall 90 A Little He Time Discover the latest spa trends for men to feel youthful and healthy ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

8

08_09_JBCOD_2pgs Table of Contents Sept/Oct_2023.indd 8

9/18/23 2:53 PM

12 22

98 32 bcofdermatology.com

9

08_09_JBCOD_2pgs Table of Contents Sept/Oct_2023.indd 9

9/18/23 2:53 PM

letter from the founder / Craig Schuette

Expanding the BC Community I

t feels like yesterday when BCoD brought biologic coordinators together for the first time in Charleston to share best practices, learn from industry experts, and meet peers who share in the fight for the patient.

Since then, BCoD has grown to become a community that welcomes more than one new member per day. As a result, we have a deeper drive and capability than ever before to enhance education and training for the BC. We share our passion with you: our members. In our 2023 survey, you showed your love for the field of dermatology and the battle for the script! Those fights translate into remarkable prior authorization approval levels. Furthermore, our coaching programs demonstrate a significant percentage increase in appeal and approval times and even a quicker transfer out of bridge.

And we're not letting up. Some of the developments that we are excited to share with our members include: • CERTIFICATION: BCoD has collaborated with healthcare organizations to offer the most significant training program for individuals seeking BC certification.

• FIELD REIMBURSEMENT FINDER: Effective communication between BCs and FRMs/FRAs is crucial, and our locator tool has helped to improve it.

• CREATIVE PARTNERSHIPS: We're making connections and building relationships to bring more innovation to our members' workflows.

coaching sessions to help you and your patients with drug use.

Our gratitude comes from those who believe in us and trust us to assist with workflow and patients. I want to personally thank the BCoD team and our many contributing educational managers and volunteers for creating a space of nourishment and community. And I want to thank our partners for equally trusting us with your programs and the patients they serve. The patient suffers if there are cracks in the process and misunderstanding of programs. Our members are armed with the information to enhance access and change lives through collaboration!

We are excited to see you in San Antonio.

We were almost at total capacity when writing this (early September), but we'll reserve space for you! New to the agenda this year, we're holding a Partner Pavilion and a Tough Case Blitz to help you through those bottlenecked cases.

If you can't make it this year, rest assured that we'll bring you recaps of the information presented. If you still need to join BCoD, we hope you take the time to reach out to us online at bcofdermatology.com or speak directly with our education team to learn more.

We look forward to welcoming you to our community, and we honor the work you do for patients every day.

With appreciation, CRAIG SCHUETTE

• BUILDING COMMUNITY: Our education managers guide tough cases through group and one-on-one ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

10

10_11_JBCOD_1pg Founders Letter_Sept/Oct_2023.indd 10

9/18/23 2:07 PM

Bringing collections that balance technical innovation and iconic design to fit the active lifestyle of today’s sophisticated and conscious woman.

10_11_JBCOD_1pg Founders Letter_Sept/Oct_2023.indd 11

9/18/23 2:07 PM

EVOLV NG NEEDS FRESHIDEA - STOCK.ADOBE.COM

THE INCREASING IMPORTANCE OF BIOLOGIC COORDINATORS IN DERMATOLOGY

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

12

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 12

9/18/23 2:56 PM

By And rew Baker

PA-C, MBA, WEST OHIO DERMATOLOGY

& Samanth a Smith

RN, WEST OHIO DERMATOLOGY

ABSTRACT Biologic coordinators work in dermatology offices to increase access to innovative treatment options. The burdensome process to get a biologic medication approved and ready for patient use continues to become more complex. With the number of biologics medications expected to increase, the role of biologic coordinators will likely also increase. Healthcare providers recognize the utility of biologic coordinators and their ability to streamline many processes to enhance patient care. This article highlights the integral part biologic coordinators play within a dermatology office now and in the future. bcofdermatology.com

13

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 13

9/18/23 2:56 PM

“BCs play a central role in

OVERCOMING THESE CHALLENGES TO PROVIDE ACCESS TO THESE AGENTS BY NAVIGATING BENEFITS, COMMUNICATING

and advocating for individual patients."

LITERATURE REVIEW

Over the last several years, there has been an increasing number of innovative therapy options and technologies available to dermatology health care providers (HCPs). The mechanism of action (MOA) of these novel biologic medications are readily applied toward individual patient care.

For some diseases, there are numerous biologic medications available with varying routes of administration and MOA. Along with the expanded use of biologics, the amount of time and labor for patients to successfully get access to these treatments is also increasing. The role of a biologic coordinator (BC) within a dermatology practice has been acknowledged and becoming recognized as a crucial staff member. The number of BCs are growing nationwide due to their versatility within a dermatology practice, along with the

need for improved patient care and patient satisfaction. These individuals have many roles within a dermatology office, all of which increase the flow of patients and enhance access to medication. With physician assistants (PAs) and nurse practitioners (NPs) prescribing increasingly more biologics, the need for BCs is paramount. In 2023, PAs and NPs accounted for 54% of prescribed biologics 1 (Chart on opposite page).

Additionally, the amount of current phase 2 and phase 3 clinical trials in the dermatology space suggests the number of FDA approved biologics is only going to escalate 2.

BCs specialize in supporting dermatology offices by streamlining the process to get specialty medications approved and offer continued support tailored to the officespecific patient needs. BCs have been shown to modernize the process of getting patient therapy initiated by identifying potential issues to access and adherence.

Allowing both the office, patient, pharmacy and pharmaceutical company to have a single point of contact enhances patient satisfaction and improves patient outcomes. BCs face several challenges; however, as they work to ensure that

patients receive timely access to therapy.

For example, patients do not always inform their providers when there have been changes in benefits or insurance carriers, which can result in denial or delayed access.

Currently, the two most common conditions associated with an increased number of biologics are psoriasis and atopic dermatitis. Understanding the immunological process of forming psoriasis or atopic dermatitis is integral to the prescriber. A comprehensive understanding of the disease process will certainly help dermatology HCPs better care for their patients. For example, for psoriasis, different classes of biologics are now available, including tumor necrosis factor (TNF)-α interleukin (IL) – 4, IL – 13, IL-12/23, IL-17 and IL-23 inhibitors.

TNF-α inhibitors were the first biologics introduced for psoriasis treatment and include etanercept, infliximab, adalimumab and certolizumab.

The availability of biosimilars at a lower cost compared to originators is dramatically changing the landscape of patient access to treatment. In the coming years, studies will be ongoing to better identify subgroups of patients based on biomarkers for a

ANDREAS BERHEIDE - STOCK.ADOBE.COM

WITH INSURANCE COMPANIES

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

14

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 14

9/18/23 2:56 PM

more personalized treatment approach.

The biosimilar medications will likely continue to flood the biologic market, further necessitating the need for BCs. The challenge of dealing with insurance companies who want to take charge of therapeutic decision-making for patients will be an ongoing issue, resulting in more denials and more time to get approvals.

HCPs have certainly noticed the approval process for biologics becoming increasingly cumbersome. The amount of insurance denials and excluded specialty medications can interfere with their ability to treat patients. HCPs are now being required to initiate prior authorizations, appeals and patient assistance programs. To get a biologic approved for the most affordable price, the patient, specialty pharmacy, insurance and dermatology office need to effectively communicate.

Prior to prescribing biologic medications, it is imperative the patient understands the process and anticipated timeline to

% of Biologic Prescriptions 100% 80% 60% 40% 20% 0%

PA/NP

Dermatologist

% of treatment

ensure they will adhere to treatment plan.

BCs are the point of contact for all the moving parts during this process. Insurance changes, lack of insurance coverage, and high co-pays can make it increasingly difficult for patients to begin and continue therapy.

Without ongoing assistance, patients may put their treatment on hold or completely stop. Without an experienced BC in the dermatology office, it threatens HCPs ability to adequately treat patients due to the amount of time required to receive approval and shipment of these medications. BCs

play a central role in overcoming these challenges to provide access to these agents by navigating benefits, communicating with insurance companies and advocating for individual patients. BCs effectively communicate with pharmaceutical teams, such as reimbursement specialists and sales representatives, ensuring the appropriate resources required to treat patients with biologics is met.

Dermatology is a fast-paced area of medicine. HCPs, collectively, need congruency when prescribing biologics as well as consistent resource availability.

Frequent checks on patients to confirm the receipt of their medication and reinforce the importance of medication adherence are imperative to successful treatment.

Streamlining the process of patient care has many positive outcomes for patients and the dermatology practice. Look for BCs to increase in number and become even more of an integral part of dermatology, both in and out of the office.

NNDANKO - STOCK.ADOBE.COM

REFERENCES • IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. May 2019. www.iqvia.com/-/media/iqvia/ pdfs/institute-reports/medicine-use-and-spending-in-the-us---a-review-of-2018-outlook-to-2023.pdf. Accessed April 20, 2020.

• Drug Topics. (2023). The 2023 Dermatology Drug Pipeline. Retrieved from https://www.drugtopics.com/view/the-2023-dermatology-drug-pipeline

bcofdermatology.com

15

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 15

9/18/23 2:56 PM

9"

CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

To learn more about CIBINQO efficacy, visit CIBINQOhcp.com or scan QR code.

"

C JAK=Janus kinase; AD=atopic dermatitis.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, AND THROMBOSIS SERIOUS INFECTIONS Patients treated with CIBINQO may be at increased risk for developing serious infections that may lead to hospitalization or death. The most frequent serious infections reported with CIBINQO were herpes simplex, herpes zoster, and pneumonia.

If a serious or opportunistic infection develops, discontinue CIBINQO and control the infection.

Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions: • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test.

• Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.

• Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 16

Avoid use of CIBINQO in patients with an active, serious infection, including localized infections. The risks and benefits of treatment with CIBINQO should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections or those who have resided or traveled in areas of endemic tuberculosis or endemic mycoses.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIBINQO, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Consider yearly screening for patients in highly endemic areas for TB. CIBINQO is not recommended for use in patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, or for patients with a negative test for latent TB but who are at high risk for TB infection, start preventive therapy for latent TB prior to initiation of CIBINQO. Viral reactivation, including herpes virus reactivation (eg, herpes zoster, herpes simplex), was reported in clinical studies with CIBINQO. If a patient develops herpes zoster, consider interrupting CIBINQO until the episode resolves.

Hepatitis B virus reactivation has been reported in patients receiving JAK inhibitors. Perform viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO. CIBINQO is not recommended for use in patients with active hepatitis B or hepatitis C.

9/18/23 2:57 PM

B C a

•

• •

•

•

•

9"

TM

Committed to Patient Support Helping patients unlock access and reimbursement support for CIBINQO™ (abrocitinib)

With the Copay Savings Card, eligible commercially insured patients may

pay as little as $

0 per month*

Visit PDPACopayCard.com

*Eligibility required. No membership fees. This is not health insurance.

The maximum benefit per patient is $15,000 per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the copay card.

See full terms and conditions below.

Copay Savings Card: TERMS AND CONDITIONS By using the Pfizer Dermatology Patient AccessTM Copay Savings Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below: • You are not eligible to use this card if you are enrolled in a state or federally funded prescription insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).

• You must have commercial insurance. Offer is not valid for cash-paying patients.

• By using this copay card at participating pharmacies, eligible patients with commercial prescription drug insurance coverage for CIBINQO™ (abrocitinib) may pay as little as $0 per month. Eligible patients with commercial prescription drug coverage may receive a maximum benefit of $15,000 per calendar year, which is defined by the date of enrollment through December 31st of the enrollment year. After a maximum of $15,000, you will be responsible for paying the remaining monthly out-of-pocket costs.

• By using this copay card at participating pharmacies, eligible patients with commercial prescription drug insurance coverage for EUCRISA® (crisaborole) may pay as little as $10 per tube. Eligible patients with commercial prescription drug insurance coverage that does not cover EUCRISA may pay as little as $100 per tube. Individual savings are limited to $970 per tube. Individual patient savings are limited to $3,880 in maximum total savings per calendar year.

• This copay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your commercial insurance plan or any other health or pharmacy benefit program.

• You must deduct the value of this copay card from any reimbursement request submitted to your commercial insurance plan, either directly by you or on your behalf.

• You are responsible for reporting use of the copay card to any commercial insurer, health plan, or other third party that pays for or reimburses any part of the prescription filled using the copay card, as may be required. You should not use the copay card if your insurer or health plan prohibits use of manufacturer copay cards.

• This copay card is not valid where prohibited by law.

• Copay card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.

• Copay card will be accepted only at participating pharmacies.

• If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.

• This copay card is not health insurance.

• Offer good only in the United States and Puerto Rico.

• Copay card is limited to 1 per person during this offering period and is not transferable.

• A copay card may not be redeemed more than once per 30 days per patient.

• No other purchase is necessary.

• Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you.

• Pfizer reserves the right to rescind, revoke, or amend this offer at any time without notice.

• Offer expires 12/31/2025.

For questions or additional support, call 1-833-956-3376, write to Pfizer Inc. at PO Box 29387, Mission, KS 66201, or visit the CIBINQO website at www.CIBINQO.com or the EUCRISA website at www.EUCRISA.com.

Please see additional Important Safety Information and Brief Summary of full Prescribing Information on the following pages.

For full Prescribing Information, including BOXED WARNING and Medication Guide, visit CIBINQOhcp.com.

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 17

9/18/23 2:57 PM

"

9"

IMPORTANT SAFETY INFORMATION & INDICATION MORTALITY In a large, randomized postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another JAK inhibitor to TNF blocker treatment, a higher rate of all-cause mortality (including sudden cardiovascular death) was observed with the JAK inhibitor. CIBINQO is not approved for use in RA patients.

MALIGNANCIES Malignancies, including non-melanoma skin cancer (NMSC), were reported in patients treated with CIBINQO. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions. Perform periodic skin examination for patients who are at increased risk for skin cancer. Exposure to sunlight and UV light should be limited by wearing protective clothing and using broad-spectrum sunscreen.

In a large, randomized postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer [NMSC]) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers.

CIBINQO is not approved for use in RA patients. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers.

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) Major adverse cardiovascular events were reported in patients treated with CIBINQO. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. CIBINQO is not approved for use in RA patients.

Patients who are current or past smokers are at additional increased risk.

Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

THROMBOSIS Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with CIBINQO. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of overall thrombosis, DVT, and PE were observed when compared with TNF blockers. CIBINQO is not approved for use in RA patients.

Avoid CIBINQO in patients that may be at increased risk of thrombosis.

If symptoms of thrombosis occur, discontinue CIBINQO and treat patients appropriately.

CONTRAINDICATION CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤ 81 mg daily), during the first 3 months of treatment.

LABORATORY ABNORMALITIES Hematologic Abnormalities: Treatment with CIBINQO was associated with an increased incidence of thrombocytopenia and lymphopenia.

Prior to CIBINQO initiation, perform a complete blood count (CBC). CBC evaluations are recommended at 4 weeks after initiation and 4 weeks after dose increase of CIBINQO. Discontinuation of CIBINQO therapy is required for certain laboratory abnormalities.

Lipid Elevations: Dose-dependent increase in blood lipid parameters were reported in patients treated with CIBINQO. Lipid parameters should be assessed approximately 4 weeks following initiation of CIBINQO therapy, and thereafter patients should be managed according to clinical guidelines for hyperlipidemia. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.

IMMUNIZATIONS Prior to initiating CIBINQO, complete all age-appropriate vaccinations as recommended by current immunization guidelines, including prophylactic herpes zoster vaccinations. Avoid vaccination with live vaccines immediately prior to, during, and immediately after CIBINQO therapy.

RENAL IMPAIRMENT Avoid use in patients with severe renal impairment or end stage renal disease, including those on renal replacement therapy.

HEPATIC IMPAIRMENT Avoid use in patients with severe hepatic impairment.

ADVERSE REACTIONS Most common adverse reactions (≥ 1%) in subjects receiving 100 mg and 200 mg include: nasopharyngitis, nausea, headache, herpes simplex, increased blood creatine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, oropharyngeal pain, influenza, gastroenteritis.

Most common adverse reactions (≥ 1%) in subjects receiving either 100 mg or 200 mg also include: impetigo, hypertension, contact dermatitis, upper abdominal pain, abdominal discomfort, herpes zoster, and thrombocytopenia.

Inform patients that retinal detachment has been reported in CIBINQO clinical trials. Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision.

DRUG INTERACTIONS Monitor appropriately or dose titrate P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities when coadministered with CIBINQO. See Prescribing Information for clinically relevant drug interactions.

USE IN PREGNANCY Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Advise females of reproductive potential that CIBINQO may impair fertility.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770 or visit CIBINQOPregnancyRegistry.com.

LACTATION Advise women not to breastfeed during treatment with CIBINQO and for one day after the last dose.

INDICATION

CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

Please see full Important Safety Information throughout and full Prescribing Information, including BOXED WARNING, and Medication Guide. © 2023 Pfizer Inc. All rights reserved.

May 2023. PP-CIB-USA-0665

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 18

9/18/23 2:57 PM

9"

CIBINQO™ (abrocitinib) tablets, for oral use

Brief Summary of full Prescribing Information; Initial Approval: January 2022

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS Serious Infections Patients treated with CIBINQO may be at increased risk for developing serious infections that may lead to hospitalization or death; The most frequent serious infections reported with CIBINQO were herpes simplex, herpes zoster, and pneumonia.

If a serious or opportunistic infection develops, discontinue CIBINQO and control the infection.

Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions: • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test.

• Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.

• Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

Avoid use of CIBINQO in patients with an active, serious infection including localized infections.

The risks and benefits of treatment with CIBINQO should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIBINQO, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Mortality In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another JAK inhibitor to TNF blocker treatment, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor. CIBINQO is not approved for use in RA patients.

Malignancies Malignancies were reported in patients treated with CIBINQO. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions.

In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers.

Patients who are current or past smokers are at additional increased risk.

Major Adverse Cardiovascular Events Major adverse cardiovascular events were reported in patients treated with CIBINQO. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.

Thrombosis Deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with CIBINQO. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death.

In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers.

Avoid CIBINQO in patients at risk. If symptoms of thrombosis occur, discontinue CIBINQO and treat appropriately.

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 19

INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

DOSAGE AND ADMINISTRATION Recommended Testing, Evaluations, and Procedures Prior to Treatment Initiation Perform the following tests and evaluations prior to CIBINQO initiation: • Tuberculosis (TB) infection evaluation – CIBINQO initiation is not recommended in patients with active TB. For patients with latent TB or those with a negative latent TB test who are at high risk for TB, start preventive therapy for latent TB prior to initiation of CIBINQO • Viral hepatitis screening in accordance with clinical guidelines – CIBINQO initiation is not recommended in patients with active hepatitis B or hepatitis C • A complete blood count (CBC) – CIBINQO initiation is not recommended in patients with a platelet count <150,000/mm3, an absolute lymphocyte count <500/mm3, an absolute neutrophil count <1,000/mm3, or a hemoglobin value <8 g/dL Complete any necessary immunizations, including herpes zoster vaccinations, in agreement with current immunization guidelines prior to CIBINQO initiation.

Recommended Dosage The recommended dosage of CIBINQO is 100 mg orally once daily.

If an adequate response is not achieved with CIBINQO 100 mg orally daily after 12 weeks, consider increasing dosage to 200 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 200 mg once daily.

CIBINQO can be used with or without topical corticosteroids.

If a dose is missed, administer the dose as soon as possible unless it is less than 12 hours before the next dose, in which case skip the missed dose. Thereafter, resume dosing at the regular scheduled time.

Recommended Dosage in Patients with Renal Impairment Renal Impairment CIBINQO dosage recommendation in patients with mild renal impairment (60-89 mL/minute) is 100 mg once daily.

For patients with moderate renal impairment (30-59 mL/ minute), the recommended dosage is 50 mg once daily.

CIBINQO is not recommended for patients with severe or End-Stage Renal Disease (ESRD). Severe renal impairment and End-Stage Renal Disease include patients on renal replacement therapy.

In subjects with mild and moderate renal impairment, if an adequate response is not achieved after 12 weeks, dose of CIBINQO can be doubled.

CIBINQO is not recommended for patients with severe renal impairment or ESRD. Recommended Dosage in CYP2C19 Poor Metabolizers In patients who are known or suspected to be CYP2C19 poor metabolizers, the recommended dosage of CIBINQO is 50 mg once daily. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.

Dosage Modifications due to Strong Inhibitors In patients taking strong inhibitors of cytochrome P450 (CYP) 2C19 reduce the dosage to 50 mg once daily. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.

Treatment Discontinuation due to Serious Infections or Hematologic Adverse Reactions Serious or Opportunistic Infections If a patient develops a serious or opportunistic infection, discontinue CIBINQO and control the infection. The risks and benefits of treatment with CIBINQO should be carefully considered prior to reinitiating therapy with CIBINQO. Hematologic Abnormalities • Discontinue CIBINQO if platelet count <50,000/mm3 and

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

follow with CBC until >100,000/mm3 • Treatment should be temporarily discontinued if ALC is less than 500 cells/mm3 and may be restarted once ALC return above this value • Treatment should be temporarily discontinued if ANC is less than 1,000 cells/mm3 and may be restarted once ANC return above this value • Treatment should be temporarily discontinued if Hb is less than 8 g/dL and may be restarted once Hb return above this value CBC evaluations are recommended at baseline, 4 weeks after treatment initiation and 4 weeks after dosing increase of CIBINQO. Laboratory evaluations may be extended for patients on chronic CIBINQO therapy who develop hematologic abnormalities.

DOSAGE FORMS AND STRENGTHS • 50 mg: Pink, oval, film-coated tablet debossed with “PFE” on one side and “ABR 50” on the other.

• 100 mg: Pink, round, film-coated tablet debossed with “PFE” on one side and “ABR 100” on the other.

• 200 mg: Pink, oval, film-coated tablet debossed with “PFE” on one side and “ABR 200” on the other.

CONTRAINDICATIONS CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.

WARNINGS AND PRECAUTIONS Serious Infections The most frequent serious infections reported in clinical studies with CIBINQO for atopic dermatitis were herpes simplex, herpes zoster, and pneumonia. Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving JAK inhibitors used to treat inflammatory conditions.

Avoid use of CIBINQO in patients with active, serious infection including localized infections.

Consider the risks and benefits of treatment prior to initiating CIBINQO in patients: • with chronic or recurrent infection • who have been exposed to tuberculosis • with a history of a serious or an opportunistic infection • who have resided or traveled in areas of endemic tuberculosis or endemic mycoses • with underlying conditions that may predispose them to infection Closely monitor patients for the development of signs and symptoms of infection during and after treatment with CIBINQO. If a patient develops a serious or opportunistic infection, discontinue CIBINQO. Initiate complete diagnostic testing and appropriate antimicrobial therapy. The risks and benefits of treatment with CIBINQO should be carefully considered prior to reinitiating therapy with CIBINQO. Tuberculosis Evaluate and test patients for TB before starting CIBINQO therapy and consider yearly screening for patients in highly endemic areas for TB. CIBINQO is not recommended for use in patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, or for patients with a negative test for latent TB but who are at high risk for TB infection, start preventive therapy for latent TB prior to initiation of CIBINQO. Monitor patients for the development of signs and symptoms of TB, including patients who were tested negative for latent TB infection prior to initiating therapy.

Viral Reactivation Viral reactivation, including herpes virus reactivation (e.g., herpes zoster, herpes simplex), was reported in clinical studies with CIBINQO. If a patient develops herpes zoster, consider interrupting CIBINQO until the episode resolves.

Hepatitis B virus (HBV) reactivation has been reported in patients receiving JAK inhibitors. Perform viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO. CIBINQO is not recommended for use in patients with active hepatitis B or hepatitis C. Monitor patients with inactive HBV for expression of HBV DNA during therapy with CIBINQO. If HBV DNA is detected during therapy with CIBINQO, consult a liver specialist.

Mortality In a large, randomized, postmarketing safety study of another JAK inhibitor in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients

9/18/23 2:57 PM

"

9"

CIBINQO™ (abrocitinib) tablets, for oral use Mortality (continued) treated with the JAK inhibitor compared with TNF blockers.

CIBINQO is not approved for use in RA. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO. Malignancy and Lymphoproliferative Disorders Malignancies, including non-melanoma skin cancer (NMSC), were observed in clinical studies with CIBINQO for atopic dermatitis.

Perform periodic skin examination for patients who are at increased risk for skin cancer. Exposure to sunlight and UV light should be limited by wearing protective clothing and using broad-spectrum sunscreen.

Malignancies, including lymphomas, have occurred in patients receiving JAK inhibitors used to treat inflammatory conditions. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. CIBINQO is not approved for use in RA. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers.

Major Adverse Cardiovascular Events Major adverse cardiovascular events were reported in clinical studies of CIBINQO for atopic dermatitis.

In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers.

CIBINQO is not approved for use in RA. Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.

Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.

Thrombosis Deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in patients receiving CIBINQO in the clinical studies for atopic dermatitis.

Thrombosis, including DVT, PE, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death.

In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers. CIBINQO is not approved for use in RA. Avoid CIBINQO in patients that may be at increased risk of thrombosis. If symptoms of thrombosis occur, discontinue CIBINQO and evaluate and treat patients appropriately.

Laboratory Abnormalities Hematologic Abnormalities Treatment with CIBINQO was associated with an increased incidence of thrombocytopenia and lymphopenia. Prior to CIBINQO initiation, perform a CBC. CBC evaluations are recommended at 4 weeks after initiation and 4 weeks after dose increase of CIBINQO. Discontinuation of CIBINQO therapy is required for certain laboratory abnormalities.

Lipid Elevations Dose-dependent increase in blood lipid parameters were reported in patients treated with CIBINQO. Lipid parameters should be assessed approximately 4 weeks following initiation of CIBINQO therapy and thereafter patients should be managed according to clinical guidelines for hyperlipidemia. The effect of these lipid parameter

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 20

elevations on cardiovascular morbidity and mortality has not been determined.

Immunizations Prior to initiating CIBINQO, complete all age-appropriate vaccinations as recommended by current immunization guidelines including prophylactic herpes zoster vaccinations.

Avoid vaccination with live vaccines immediately prior to, during, and immediately after CIBINQO therapy.

ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Major Adverse • Serious Infections Cardiovascular Events • Mortality • Thrombosis • Malignancy and • Laboratory Abnormalities Lymphoproliferative Disorders Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of CIBINQO was evaluated in four randomized, placebo-controlled clinical trials (2 monotherapy, 1 combination therapy with topical corticosteroid, and 1 dose-ranging) and one long-term extension trial in subjects with moderate to severe atopic dermatitis (AD). A total of 1623 subjects with moderate to severe atopic dermatitis were treated with CIBINQO in these clinical trials representing 1428 patient-years of exposure. There were 634 subjects with at least 1 year of exposure to CIBINQO. In the placebo-controlled clinical trials, a total of 1198 subjects were exposed to CIBINQO with 608 subjects receiving CIBINQO 100 mg once daily and 590 subjects receiving CIBINQO 200 mg once daily for up to 16 weeks.

The median age of subjects was 33.0 years, 124 subjects (8.1%) were 12 to less than 18 years old and 94 subjects (6.1%) were 65 years of age or older. The majority of subjects were White (68.7%) and male (53.9%).

Adverse reactions occurring at ≥1% in any of the treated groups and at a higher rate than in the placebo group are presented in the table below. A total of 61 (5.1%) subjects treated with CIBINQO were discontinued from the trials due to adverse reactions. The safety profile of CIBINQO in the monotherapy and the combination trial(s) were similar.

Adverse Reactions from Placebo-Controlled Trials Reported in ≥1% of CIBINQO Treated Subjects with Moderate to Severe Atopic Dermatitis and at Higher Rate than Placebo for up to 16 Weeks Weeks 0-16 CIBINQO CIBINQO PLACEBO 200 mg 100 mg N=342 N=590 N=608 n (%a) n (%a) n (%a) Nasopharyngitis 51 (8.7) 75 (12.4) 27 (7.9) Nausea 86 (14.5) 37 (6.0) 7 (2.1) Headache 46 (7.8) 36 (6.0) 12 (3.5) Herpes simplexb 25 (4.2) 20 (3.3) 6 (1.8) Increased blood 5 (1.5) creatine phosphokinase 17 (2.9) 14 (2.3) Dizziness 17 (2.9) 11 (1.8) 3 (0.9) Urinary tract infection 13 (2.2) 10 (1.7) 4 (1.2) Fatigue 8 (1.3) 10 (1.6) 2 (0.5) Acne 28 (4.7) 10 (1.6) 0 (0.0) Vomiting 19 (3.2) 9 (1.5) 3 (0.9) Impetigo 3 (0.5) 9 (1.5) 1 (0.3) Oropharyngeal pain 6 (1.0) 8 (1.4) 2 (0.6) Hypertension 5 (0.8) 7 (1.2) 2 (0.7) Influenza 6 (1.1) 7 (1.2) 0 (0.0) Gastroenteritis 8 (1.3) 7 (1.1) 2 (0.6) Dermatitis contact 3 (0.5) 6 (1.1) 1 (0.3) Abdominal pain upper 11 (1.9) 4 (0.6) 0 (0.0) Abdominal discomfort 7 (1.2) 3 (0.5) 1 (0.3) Herpes zoster 7 (1.2) 2 (0.3) 0 (0.0) Thrombocytopenia 9 (1.5) 0 (0.0) 0 (0.0) a Study size adjusted percentages b Herpes simplex also includes oral herpes, ophthalmic herpes, herpes

dermatitis, genital herpes.

Specific Adverse Reactions Exposure adjusted incidence rates were adjusted by trial size for all the adverse reactions reported in this section.

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

Overall Infections In the placebo-controlled trials, for up to 16 weeks, overall infections were reported in 90 subjects (126.8 per 100 patient-years) treated with placebo, 211 subjects (168.8 per 100 patient-years) treated with CIBINQO 100 mg and 204 subjects (159.5 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, overall infections were reported in 427 subjects (91.8 per 100 patient-years) treated with CIBINQO 100 mg and 394 subjects (103.2 per 100 patient-years) treated with CIBINQO 200 mg.

Serious Infections In the placebo-controlled trials, for up to 16 weeks, serious infections were reported in 2 subjects (2.6 per 100 patient-years) treated with placebo, 6 subjects (3.9 per 100 patient-years) treated with CIBINQO 100 mg, and 2 subjects (1.3 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, serious infections were reported in 18 subjects (2.3 per 100 patient-years) treated with CIBINQO 100 mg and 16 subjects (2.3 per 100 patient-years) treated with CIBINQO 200 mg. The most commonly reported serious infections were herpes simplex, herpes zoster, and pneumonia.

Herpes Zoster In the placebo-controlled trials, for up to 16 weeks, opportunistic infections were generally cases of multidermatomal cutaneous herpes zoster. Herpes zoster was reported in 0 subjects treated with placebo, 3 subjects (1.9 per 100 patient-years) treated with CIBINQO 100 mg and 8 subjects (5.1 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, herpes zoster was reported in 16 subjects (2.0 per 100 patient-years) treated with CIBINQO 100 mg and 35 subjects (5.2 per 100 patient-years) treated with CIBINQO 200 mg.

Malignancy In the placebo-controlled trials, for up to 16 weeks, no malignancy was reported in subjects treated with placebo or CIBINQO 100 mg and in 1 patient (0.65 per 100 patient-years) treated with CIBINQO 200 mg. In all 5 clinical trials, including the long-term extension trial, malignancy was reported in 4 subjects (0.5 per 100 patient-years) treated with CIBINQO 100 mg and 2 subjects (0.3 per 100 patient-years) treated with CIBINQO 200 mg.

Thrombosis In all clinical trials, including the long-term extension trial, pulmonary embolism was reported in 3 subjects (0.4 per 100 patient-years), who were treated with CIBINQO 200 mg. Deep vein thrombosis was reported in 2 subjects (0.3 per 100 patient-years) who were treated with CIBINQO 200 mg. No thrombosis occurred in subjects treated with CIBINQO 100 mg.

Major Adverse Cardiovascular Events In the placebocontrolled trials, for up to 16 weeks, major adverse cardiovascular event (MACE) was reported in 1 subject (0.6 per 100 patient-years) treated with CIBINQO 100 mg.

In all 5 clinical trials, including the long-term extension trial, MACE was reported in 1 patient (0.1 per 100 patient-years) treated with CIBINQO 100 mg and 2 subjects (0.3 per 100 patient-years) treated with CIBINQO 200 mg.

Thrombocytopenia In the placebo-controlled trials, for up to 16 weeks, treatment with CIBINQO was associated with a dose-related decrease in platelet count. Maximum effects on platelets were observed within 4 weeks, after which the platelet count returned towards baseline despite continued therapy. In all 5 clinical trials, including the long-term extension trial 6 subjects (0.9 per 100 patient-years) treated with CIBINQO 200 mg had adverse reactions of thrombocytopenia, no subjects treated with CIBINQO 100 mg had an adverse reaction of thrombocytopenia.

Lymphopenia In the placebo-controlled trials, for up to 16 weeks, confirmed ALC <500/mm3 occurred in 2 subjects (1.2 per 100 patient-years) treated with CIBINQO 200 mg and 0 subjects treated with CIBINQO 100 mg or placebo.

Both cases occurred in the first 4 weeks of exposure.

Lipid Elevations In the placebo-controlled trials, for up to 16 weeks, there was a dose-related percent increase in low-density lipoprotein cholesterol (LDL-c), total cholesterol, and high-density lipoprotein cholesterol (HDL-c) relative to placebo at Week 4 which remained elevated through the final visit in the treatment period. Adverse reactions related to hyperlipidemia occurred in 1 subject (0.6 per 100 patient-years) exposed to CIBINQO 100 mg, 3 subjects (2.0 per 100 patient-years) exposed to CIBINQO 200 mg.

Retinal Detachment In the placebo-controlled trials, for up to 16 weeks, retinal detachment occurred in 1 subject (0.6 per 100 patient-years) treated with CIBINQO 100 mg. In all 5 clinical trials, including the long-term extension trial, retinal detachment occurred in 2 subjects (0.3 per 100 patient-years) treated with CIBINQO 100 mg.

9/18/23 2:57 PM

9"

CIBINQO™ (abrocitinib) tablets, for oral use Specific Adverse Reactions (continued) Creatine Phosphokinase Elevations (CPK) In the placebocontrolled trials, for up to 16 weeks, events of blood CPK increased were reported in 6 subjects (7.5 per 100 patient-years) treated with placebo, 11 subjects (6.9 per 100 patient-years) treated with 100 mg of CIBINQO and 19 subjects (12.3 per 100 patient-years) treated with 200 mg of CIBINQO. Most elevations were transient, there were no reported adverse reactions of rhabdomyolysis.

Adolescent Subjects (12 to less than 18 years of age) The safety of CIBINQO was assessed in a trial of 284 subjects 12 to less than 18 years of age with moderate-to-severe atopic dermatitis (Trial-AD-4). The safety profile of CIBINQO in these subjects, assessed through the initial treatment period of 12 weeks and the long-term period (213 with at least 52 weeks of abrocitinib exposure), was similar to the safety profile from trials in adults with atopic dermatitis.

DRUG INTERACTIONS Effects of Other Drugs on CIBINQO The table below includes drugs with clinically significant drug interactions affecting CIBINQO. Clinically Significant Drug Interactions Affecting CIBINQO

Strong CYP2C19 Inhibitors Clinical Impact

Coadministration of CIBINQO with strong CYP2C19 inhibitors increases the combined exposure of abrocitinib and its two active metabolites, M1 and M2 which may increase the adverse reactions of CIBINQO.

Intervention Dosage reduction of CIBINQO is recommended when coadministered with strong CYP2C19 inhibitors.

Moderate to Strong Inhibitors of both CYP2C19 and CYP2C9 Clinical Impact

Coadministration of CIBINQO with drugs that are moderate to strong inhibitors of both CYP2C19 and CYP2C9 increases the exposure of abrocitinib and its two active metabolites, M1 and M2 which may increase the adverse reactions of CIBINQO.

Intervention Avoid concomitant use of CIBINQO with drugs that are moderate to strong inhibitors of both CYP2C19 and CYP2C9.

Strong CYP2C19 or CYP2C9 Inducers Clinical Impact

Coadministration of CIBINQO with strong CYP2C19 or CYP2C9 inducers decreases the combined exposure of abrocitinib and its two active metabolites, M1 and M2, which may result in loss of or reduced clinical response.

Intervention Avoid concomitant use of CIBINQO with strong CYP2C19 or CYP2C9 inducers.

Effects of CIBINQO on Other Drugs The table below includes clinically significant drug interactions affecting other drugs.

Clinically Significant Interactions Affecting Other Drugs

P-gp Substrate Where Small Concentration Changes May Lead to Serious or Life-threatening Toxicities Clinical Coadministration of CIBINQO with P-gp Impact substrate increases plasma concentrations of P-gp substrates and may result in potential adverse reactions of the P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities (e.g., digoxin).

Intervention Monitor appropriately or dose titrate P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities when coadministered with CIBINQO. Antiplatelet Therapy Drugs Clinical Coadministration of CIBINQO with antiplatelet Impact therapy drugs may increase the risk of bleeding with thrombocytopenia.

Intervention Antiplatelet drugs, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment are contraindicated with CIBINQO.

12_21_JBCOD_4pgs Evolving Needs_Sept/Oct_2023.indd 21

USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770 or visit CIBINQOPregnancyRegistry.com.

Risk Summary Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of abrocitinib to pregnant rats and rabbits during organogenesis at exposure 11 or 4 times the maximum recommended human dose (MRHD) based on AUC comparison, respectively, resulted in maternal dystocia and skeletal variations in rats and no adverse effects in rabbits (see Animal Data).

The background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies carry some risk of birth defects, loss, or other adverse outcomes. The background risks in the U.S. general population of major birth defects and miscarriages are 2-4% and 15-20% of clinically recognized pregnancies, respectively.

Animal Data In an embryofetal development study, abrocitinib was administered orally to pregnant rats at doses of 10, 30, or 60 mg/kg/day during the period of organogenesis. No fetal malformations were observed. Abrocitinib increased the incidence of skeletal variations of short 13th ribs at 30 mg/kg/ day (11 times the MRHD based on AUC comparison).

Increased embryofetal lethality and additional skeletal variations (cervical arches with reduced ventral processes, thickened ribs, and unossified metatarsals) were noted at 60 mg/kg/day (17 times the MRHD based on AUC comparison).

In an embryofetal development study, abrocitinib was administered orally to pregnant rabbits at doses of 10, 30, or 75 mg/kg/day during the period of organogenesis. No abrocitinib-related maternal or developmental toxicity was noted at doses up to 75 mg/kg/day (4 times the MRHD based on AUC comparison).

In a prenatal and postnatal development study, abrocitinib was administered orally to pregnant rats at doses of 10, 30, and 60 mg/kg/day beginning on gestation day 6 and continuing through lactation day 20. Dystocia with prolonged parturition and reduced offspring body weights were noted at 30 mg/kg/ day (11 times the MRHD based on AUC comparison).

Postnatal survival was markedly decreased at 60 mg/kg/day (17 times the MRHD based on AUC comparison). No maternal toxicity was observed at 10 mg/kg/day (2.4 times the MRHD based on AUC comparison). No abrocitinib-related effects on postnatal developmental, neurobehavioral, or reproductive performance of offspring was noted at doses up to 30 mg/kg/ day (11 times the MRHD based on AUC comparison).

Lactation Risk Summary There are no data on the presence of abrocitinib in human milk, the effects on the breast-fed infant, or the effects on milk production. Abrocitinib was secreted in milk of lactating rats (see Animal Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the serious adverse findings in adults, including risks of serious infections, malignancy, and thrombosis, advise women not to breastfeed during treatment with CIBINQO and for one day after the last dose (approximately 5-6 elimination half-lives).

Animal Data Lactating female rats were orally administered a single dose of 10 mg/kg abrocitinib on lactation day 12.

Abrocitinib AUC was approximately 5 times greater in milk than in plasma.

Females and Males of Reproductive Potential Infertility Females Based on the findings in rats, oral administration of CIBINQO may impair female fertility. Impaired fertility in female rats was reversible 1 month after cessation of abrocitinib oral administration.

Pediatric Use The safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older weighing 25 kg or more with atopic dermatitis has been established. In trials Trial-AD-1 and Trial-AD-2, 124 adolescent subjects 12 to less than 18 years old with moderate-to-severe atopic dermatitis were enrolled and randomized to receive either CIBINQO 100 mg (N=51), 200 mg (N=48), or matching placebo (N=25) in monotherapy.

Additional 284 adolescent subjects 12 to less than 18 years of age with moderate-to-severe atopic dermatitis, were enrolled and randomized to receive either CIBINQO 100 mg (N=95) or 200 mg (N=94) or matching placebo (N=95) in combination with topical corticosteroids in Trial-AD-4. Efficacy and adverse reaction profile were consistent between the pediatric patients and adults.

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

The safety and effectiveness of CIBINQO have not been established in pediatric patients below 12 years of age.

Juvenile Animal Toxicity Data In a juvenile animal toxicity study, abrocitinib was administered orally to juvenile rats at doses of 5, 25, and 75 mg/kg/day beginning on postnatal day 10 (approximately equivalent to a human infant) and continuing through postnatal day 63 (approximately equivalent to an adolescent). Abrocitinib caused a reversible, dose-related decrease in the primary spongiosa in the metaphysis of the proximal tibia and distal femur. Abrocitinib produced adverse effects on bone development at all dose levels. Abrocitinib caused irreversible dose-related small or misshapen femoral heads at doses ≥5 mg/kg/day (0.8 times the MRHD based on AUC comparison).

Abrocitinib also irreversibly decreased femur size and caused paw malrotation and limb impairment at doses ≥25 mg/kg/day (7.2 times the MRHD based on AUC comparison). At 75 mg/kg/ day (27 times the MRHD based on AUC comparison), paw fractures generally corresponded to limb impairment, a fractured tibia was noted in a single female. Irreversible bone findings have not been observed in older animals.

Geriatric Use A total of 145 (4.6%) patients 65 years of age and older, while 25 (0.8%) were 75 years of age and older, were enrolled in CIBINQO clinical trials. Clinical trials of CIBINQO did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

A higher proportion of patients 65 years of age and older discontinued from clinical trials compared to younger patients.

Among all patients exposed to CIBINQO, including the long-term extension trial, confirmed ALC <500/mm3 occurred only in patients 65 years of age and older. A higher proportion of patients 65 years of age and older had platelet counts <75,000/ mm3. The incidence rate of herpes zoster in patients 65 years of age and older treated with CIBINQO (7.40 per 100 patient-years) was higher than that of patients 18 to less than 65 years of age (3.44 per 100 patient-years).

Renal Impairment In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30-59 mL/min) renal impairment, the combined exposure (AUCinf,u) of abrocitinib and its two active metabolites, M1 and M2, is increased compared to patients with normal renal function (eGFR ≥90 mL/min). This may increase the risk of adverse reactions such as infections.

CIBINQO is not recommended for use in patients with severe renal impairment and ESRD including those on renal replacement therapy.

A dosage reduction in patient with moderate renal impairment is recommended. No dosage adjustment is required in patients with mild renal impairment (eGFR 60-89 mL/min).

CIBINQO has not been studied in patients on renal replacement therapy. In Phase 3 clinical trials, CIBINQO was not evaluated in patients with atopic dermatitis with baseline creatinine clearance values less than 40 mL/min.

Hepatic Impairment Avoid use of CIBINQO in patients with severe (Child Pugh C) hepatic impairment.

Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment based on similar combined exposure (AUCinf,u) of abrocitinib and its two active metabolites, M1 and M2 compared to patients with normal hepatic function. In clinical trials, CIBINQO was not evaluated in patients with severe (Child Pugh C) hepatic impairment.

CYP2C19 Poor Metabolizers In patients who are CYP2C19 poor metabolizers, the AUC of abrocitinib is increased compared to CYP2C19 normal metabolizers due to reduced metabolic clearance. Dosage reduction of CIBINQO is recommended in patients who are known or suspected to be CYP2C19 poor metabolizers based on genotype or previous history/experience with other CYP2C19 substrates.

OVERDOSAGE There is no experience regarding human overdosage with CIBINQO. There is no specific antidote for overdose with CIBINQO. In case of an overdose, call Poison Control Center at 1-800-222-1222 for latest recommendations.

Rx only This brief summary is based on CIBINQO™ (abrocitinib) Prescribing Information LAB-1424-2.0.

Issued: February 2023.

The product’s label may have been updated. For full Prescribing Information, visit CIBINQOPI.com.

See CIBINQO full Prescribing Information at CIBINQOPI.com.

© 2023 2023 Pfizer Pfizer Inc. All rights reserved.

May 2023.

PP-CIB-USA-0485 February 2023.

PP-CIB-USA-0485

9/18/23 2:57 PM

S TR

E AM

L I N

THE PROCE S S

E

SIMPLIFYING DRUG APPROVALS AND PATIENT COMMUNICATION WITH TECHNOLOGY ENABLED WORKFLOW SYSTEMS ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

22

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 22

9/18/23 2:47 PM

By Jay Mayers VICE PRESIDENT BUSINESS DEVELOPMENT - RXNEXUS™

I

n an era marked by groundbreaking advancements in health sciences, the field of medicine stands at the forefront of innovation. Novel specialty drugs,

tailored to address specific medical conditions, offer hope to patients who were once left grappling with limited treatment options. However, this progress is often diminished by the overwhelming challenges that ensue when attempting to secure access to these specialized medications. The coordination of healthcare access for specialty drugs has emerged as a burdensome ordeal for clinics, exacerbated by patient tracking issues, and leaving patients in a state of perplexity. The maze of paperwork, phone calls and manual data entry has not only resulted in administrative inefficiencies but also led to delays in patients receiving the medications crucial for their well-being. The integration of technologybased practice management solutions, however, has paved the way for a more coordinated and patient-centric approach. bcofdermatology.com

23

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 23

9/18/23 2:47 PM

“Using technology to streamline the medication approval process allows staff to spend less time on paperwork and more time with patients. Not only does this make the staff happier, but it also leads to more satisfied patients.”

–COLLIN M. BLATTNER, DO, FAAD

Clinics, traditionally seen as sanctuaries of healing, now find themselves entangled in a web of administrative complexities. The task of coordinating access to specialty drugs involves a convoluted dance between healthcare providers, pharmaceutical companies, insurance entities and regulatory bodies. Each step in this intricate process demands meticulous paperwork, hours of communication, and an unyielding persistence to ensure the seamless delivery of the required medication. The strain placed upon clinic resources by this bureaucratic battle diverts attention and resources away from the core mission of healthcare: to heal and alleviate suffering.

In this ever-evolving coverage environment, where precision and promptness can be the difference between a patient receiving treatment or ongoing suffering, the role of the biologic coordinator stands as a cornerstone to patient access and care. A crucial yet often overlooked aspect of this role’s success is the development of an access coordination strategy that leverages end-to-end workflow systems. Streamlined access coordination processes leveraging technological platforms with ongoing support can hold the potential to revolutionize the way BCs operate, save valuable resources, and ensure patients are connected to the process while facilitating improved quality of care for patients.

At its core, a technology-enabled workflow system for access coordination streamlines the intricate web of tasks, processes and

“The burden of medication approval and patient communication for specialty therapy is significant, even for our most experienced access coordinators and nursing staff. We are always looking for ways to improve the overall workflow for our staff and the patient experience. We have tried other technology solutions in the past without success. WHAT

IS REQUIRED IS A TRULY END-TO-END WORKFLOW SUPPORT SYSTEM FOR OUR STAFF AND PATIENTS SUCH AS RxNEXUS

to set expectations and manage their entire specialty therapy journey.”

–STEPHANIE BURKHOLDER, BSN, RN, DNC REGIONAL DIRECTOR, HEARTLAND DERMATOLOGY AND SKIN CANCER CENTER, PA

communications that biologic coordinators navigate on a daily basis. Beyond the enrollment process, staff can be supported in assisting therapy selection based on coverage, prior authorisations, appeals, renewals and connecting clinic tasks to patient engagement. Technology-enabled workflow systems help practices make access coordination less burdensome by synchronizing diverse elements to create seamless reimbursement operations. But the benefits extend far beyond operational fluidity.

A carefully optimized process leveraging a technology enabled workflow system enables BCs to allocate more time to patient-focused

activities. With administrative tasks efficiently managed, coordinators can engage in meaningful patient interactions, offering compassion, education and resources.

Ongoing automated digital communications to patients foster patient engagement and reinforce educational information about the patient’s disease and prescribed therapy. This personal touch, reinforced by technology, not only nurtures patient-clinic relationships but also fosters an environment where patients feel heard, cared for and engaged, leading to increased patient satisfaction and loyalty.

Leveraging end-to-end workflow platforms, such as RxNexus™, to optimize clinic access

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

24

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 24

9/18/23 2:47 PM

processes empower biologic coordinators to allocate resources with pinpoint accuracy.

From patient tracking and communications to therapy initiation and renewal, every aspect is finely calibrated based on real-time needs. This precision prevents wastage, ensures equitable resource distribution, and it enhances the overall cost-efficiency of healthcare operations.

In a world driven by data and technology, optimized workflows provide BCs with accurate and up-to-date information at their fingertips. This information-driven approach enables coordinators to make informed decisions swiftly, adapting to changing circumstances while maintaining an unwavering focus on patient well-being. Data insights also pave the way for continuous improvement, allowing administrators to fine-tune processes for better patient outcomes over time.

The administrative burden associated with specialty medication access coordination on healthcare professionals is well-documented, often leading to burnout and decreased job satisfaction. An optimized access coordination workflow can significantly alleviate this burden by automating repetitive tasks, minimizing manual data entry, and providing intelligent notifications and reminders. Such technological support frees up valuable time and mental energy for coordinators to engage in more intellectually stimulating and impactful activities, which in turn reduce the clinic administrative costs.

Healthcare is a collaborative effort, requiring seamless communication and coordination among diverse teams and departments. Optimized access workflows provide a common platform for streamlined communication, ensuring that all stakeholders are on the same page. This enhanced collaboration fosters a sense of unity, reduces misunderstandings, and ultimately leads to a more synchronized and effective healthcare ecosystem. It further reduces the impact of

“At Clear Choice Dermatology we want to offer the best possible patient experience.

This is often challenging with biologic and specialty medications due to challenges in medication approval. By incorporating software like RxNexus into our clinic workflow, we have been able to offer better care to our patients while making our processes more efficient.”

–NADIA VIZZA, MS, RHIA PRACTICE ADMINISTRATOR, CLEAR CHOICE DERMATOLOGY

administration on supporting prescribers and frees up their time to see more patients.

The potential benefits of a technology enabled workflow system to optimize processes for biologic coordinators and patient communications are vast and transformative. From enriching patient experiences through enhanced communications and fostering data-driven decision-making to reducing administrative burdens and promoting seamless collaboration, an optimized workflow holds the power to elevate healthcare operations to new heights of efficiency and excellence. As the healthcare access landscape continues to evolve, embracing and harnessing the potential of technology optimized workflows will undoubtedly be a defining factor in delivering superior access to specialty medications and overall patient care.

“A technology and service to reduce the burden of coordinating patient, PBM, mandated specialty pharmacy, copay assistant and manufacturer-free drug programs with the dermatology office is something that all practices need today. THE PROCESS NEEDS

TO BE TRACKED AND CLEAR TO THE PHYSICIAN, STAFF AND PATIENT ALIKE.

We must evolve past the era of ‘you didn’t complete the right form’ or ‘guess which pharmacy can fill it.’

This solution is long overdue.”

–ANTHONY NUARA, MD, PHD

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 25

9/18/23 2:47 PM

More than 75% of commercially insured patient lives have coverage for OPZELURA®1 Covered at any tier. PA and other restrictions may apply.

Coverage is plan specific and subject to change.

For patients 12 years of age and older

CONSIDER OPZELURA

®2

The First and Only FDA-Approved Treatment for Repigmentation in Nonsegmental Vitiligo2* Proven to Promote Skin Repigmentation in Phase III Clinical Trials2 Not an OPZELURA® patient.

F-VASI75 Results at Weeks 24 and 52 Data From Week 24 And an Open-Label Extension Nearly

1 in 3 patients

Nearly 1 in 3 patients achieved F-VASI75† at 24 weeks (primary endpoint; 29.9% vs 7.5% [P<0.0001] and 29.9% vs 12.9% [P<0.01]).2,3

51%

~

About half the patients remaining in the studies who applied OPZELURA® from day 1 achieved F-VASI75 at 52 weeks: ~51% for OPZELURA® and ~28% for vehicle-to-OPZELURA® (Week 24 to Week 52).

Data were reported as observed. No conclusions of safety or efficacy should be made based on these results.2,4

Limitations of an open-label extension: In an open-label extension, there is a potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.

OPZELURA® was studied in 2 double-blind, randomized, vehicle-controlled trials of identical design that enrolled 674 adult and adolescent patients with nonsegmental vitiligo ≥12 years of age. Patients had depigmented areas affecting ≥0.5% F-BSA, ≥3% nonfacial BSA, and total body vitiligo area (facial and nonfacial) of up to 10% BSA. Phototherapy was not permitted during the trials. In both trials, patients were randomized 2:1 to treatment with OPZELURA® or vehicle cream BID for 24 weeks followed by a 28-week open-label extension, wherein patients originally assigned to vehicle could switch to OPZELURA®. 2 BID, twice daily; BSA, body surface area; F-BSA, facial body surface area; FDA, Food and Drug Administration: F-VASI, Facial Vitiligo Scoring Index; F-VASI75, ≥75% improvement from baseline in Facial Vitiligo Area Scoring Index. *In patients 12 years of age and older. † F-VASI is a composite measurement of the overall area of facial vitiligo patches and degree of depigmentation within patches.

As assessed, the face did not include surface area of the lips, scalp, eyelids, ears, or neck. 5

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 26

9/18/23 2:47 PM

Common Prior Authorization Requirements Patient Age

The patient must be 12 years of age or older.

Indication

OPZELURA® is indicated for nonsegmental vitiligo

Tried and Failed Alternatives

This may include a topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). Be sure to include your patient’s most recent chart notes!

Body Surface Area (BSA)

Indicate the BSA that will be treated: • Nonsegmental vitiligo is up to 10%

Combination Use

Confirm OPZELURA® will not be used with: • Therapeutic biologics • Other JAK inhibitors • Potent immunosuppressants OPZELURA® was studied as a monotherapy treatment. Many plans do not approve combination use.

Turn the page to see the results with OPZELURA® at 52 weeks INDICATION OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Limitations of Use: Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONS Patients treated with oral Janus kinase inhibitors for inflammatory conditions are at risk for developing serious infections that may lead to hospitalization or death. Reported infections include: • Active tuberculosis, which may present with pulmonary or extrapulmonary disease.

• Invasive fungal infections, including cryptococcosis and pneumocystosis.

• Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

Avoid use of OPZELURA in patients with an active, serious infection, including localized infections. If a serious infection develops, interrupt OPZELURA until the infection is controlled. Carefully consider the benefits and risks of treatment prior to initiating OPZELURA

in patients with chronic or recurrent infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with OPZELURA. Serious lower respiratory tract infections were reported in the clinical development program with topical ruxolitinib.

No cases of active tuberculosis (TB) were reported in clinical trials with OPZELURA. Cases of active TB were reported in clinical trials of oral Janus kinase inhibitors used to treat inflammatory conditions. Consider evaluating patients for latent and active TB infection prior to administration of OPZELURA. During OPZELURA use, monitor patients for the development of signs and symptoms of TB. Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical trials with Janus kinase inhibitors used to treat inflammatory conditions including OPZELURA. If a patient develops herpes zoster, consider interrupting OPZELURA treatment until the episode resolves.

Hepatitis B viral load (HBV-DNA titer) increases, with or without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking oral ruxolitinib. OPZELURA initiation is not recommended in patients with active hepatitis B or hepatitis C.

Please see Important Safety Information continued on next page and Brief Summary of Full Prescribing Information, including Boxed Warning, on the following pages.

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 27

9/18/23 2:47 PM

52-Week Results for a Clinical Trial Participant Whose Repigmentation Met the Primary Endpoint of F-VASI75 at 24 Weeks6‡ PRIMARY ENDPOINT BASELINE

WEEK 24

WEEK 52

Week 0 F -VASI SCORE 1.5

Week 24 F -VASI SCORE 0.3

Week 52 F -VASI SCORE 0.3

80% Improvement From Baseline

80% Improvement From Baseline

‡

Results not typical. Actual patient treated with OPZELURA® in a clinical trial. Individual results may vary.

Not for ophthalmic, oral, or intravaginal use.

See the Possibilities for Your Members With OPZELURA®

IMPORTANT SAFETY INFORMATION (continued) MORTALITY In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing an oral JAK inhibitor to tumor necrosis factor (TNF) blocker treatment, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OPZELURA.

MALIGNANCIES

Malignancies were reported in patients treated with OPZELURA. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions. In RA patients treated with an oral JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 28

cancer (NMSC)) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OPZELURA, particularly in patients with a known malignancy (other than successfully treated non-melanoma skin cancers), patients who develop a malignancy when on treatment, and patients who are current or past smokers.

Non-melanoma skin cancers, including basal cell and squamous cell carcinoma, have occurred in patients treated with OPZELURA. Perform periodic skin examinations during OPZELURA treatment and following treatment as appropriate. Exposure to sunlight and UV light should be limited by wearing protective clothing and using broad-spectrum sunscreen.

9/18/23 2:47 PM

IMPORTANT SAFETY INFORMATION (continued) MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with an oral JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk.

Discontinue OPZELURA in patients who have experienced a myocardial infarction or stroke.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OPZELURA, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue OPZELURA in patients that have experienced a myocardial infarction or stroke.

THROMBOSIS

Thromboembolic events were observed in trials with OPZELURA. Thrombosis, including pulmonary embolism (PE), deep venous thrombosis (DVT), and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with an oral JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid OPZELURA in patients at risk.

If symptoms of thrombosis occur, discontinue OPZELURA and treat appropriately.

Thrombocytopenia, Anemia, and Neutropenia Thrombocytopenia, anemia, and neutropenia were reported in the clinical trials with OPZELURA. Consider the benefits and risks for individual patients who have a known history of these events prior to initiating therapy with OPZELURA. Perform CBC monitoring as clinically indicated.

If signs and/or symptoms of clinically significant thrombocytopenia, anemia, and neutropenia occur, patients should discontinue OPZELURA.

Lipid Elevations

Treatment with oral ruxolitinib has been associated with increases in lipid parameters including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.

Adverse Reactions

In nonsegmental vitiligo, the most common adverse reactions (incidence ≥1%) are application site acne (6%), application site pruritus (5%), nasopharyngitis (4%), headache (4%), urinary tract infection (2%), application site erythema (2%), and pyrexia (1%).

Pregnancy

There is a pregnancy registry that monitors pregnancy outcomes in pregnant persons exposed to OPZELURA during pregnancy.

Pregnant persons exposed to OPZELURA and healthcare providers should report OPZELURA exposure by calling 1-855-463-3463.

Lactation

Advise women not to breastfeed during treatment with OPZELURA and for approximately four weeks after the last dose (approximately 5-6 elimination half-lives).

Please see Brief Summary of Full Prescribing Information, including Boxed Warning, on the following pages.

References: 1. VANTAGE Fingertip Formulary, April 2023. 2. OPZELURA® (ruxolitinib) cream. Prescribing Information. Incyte Corporation. 3. Rosmarin D, Pandya AG, Grimes P, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo: 24-week results from 2 randomized, double-blind phase 3 studies. Abstract presented at: 30th European Academy of Dermatology and Venereology (EADV) Congress; September 29-October 2, 2021; virtual. 4. Rosmarin D, Passeron T, Pandya AG, et al. Efficacy and safety of ruxolitinib cream monotherapy for the treatment of vitiligo: results from two 52-week phase 3 studies. Presented at: American Academy of Dermatology Annual Meeting; March 25-29, 2022; Oral Presentation. 5. Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet.

2020;396(suppl):1-121. 6. Data on File. Incyte Corporation.

OPZELURA, the OPZELURA logo, Incyte, and the Incyte logo are registered trademarks of Incyte. © 2023, Incyte Corporation.

MAT-OPZ-01787 07/23

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 29

9/18/23 2:47 PM

initiatinginOPZELURA in patients: with chronic infection; or recurrent initiating OPZELURA patients: with chronic or recurrent withinfection; a historywith a history Thrombocy a serious or an opportunistic who have been exposed to tuberculosis; neutropenia of a serious orofan opportunistic infection; whoinfection; have been exposed to tuberculosis; who or have resided traveled in areastuberculosis of endemicor tuberculosis or endemic mycoses; and risks fo who have resided traveled in or areas of endemic endemic mycoses; or withconditions underlyingthat conditions that may them predispose them toClosely infection. Closely initiating th or with underlying may predispose to infection. monitor patients for the development signs andofsymptoms of infection during signs and/ monitor patients for the development of signs and of symptoms infection during and after treatment with Interrupt OPZELURA. InterruptifOPZELURA if a patient and after treatment with OPZELURA. OPZELURA a patient develops a develops a neutropenia OPZELURA® (ruxolitinib) OPZELURA®cream, (ruxolitinib) for topical cream, use for topical use serious an opportunistic infection, DoOPZELURA not resume OPZELURA Lipid Eleva serious infection, an infection, opportunistic infection, or sepsis.

Doornotsepsis. resume until is thecontrolled. infection is controlled. until the infection Brief Summary Brief of FULL Summary PRESCRIBING of FULL PRESCRIBING INFORMATIONINFORMATION in lipid pa cholesterol, Tuberculosis: Tuberculosis: No cases of active No cases tuberculosis of active (TB) tuberculosis were reported (TB) were in clinical reported trials in with clinical trials with INDICATIONSINDICATIONS AND USAGE:AND OPZELURA USAGE:isOPZELURA indicated for is indicated the topical for treatment the topicalof treatment of OPZELURA. Cases OPZELURA. of active Cases TB were of active reported TB were in clinical reported trials in clinical of oral Janus trials ofkinase oral Janus kinase ADVERSE R nonsegmentalnonsegmental vitiligo in adultvitiligo and pediatric in adult patients and pediatric 12 years patients of age 12and years older. of age and older. inhibitors usedinhibitors to treat inflammatory used to treat inflammatory conditions. Consider conditions. evaluating Consider patients evaluating for latent patients for latent Clinical Tria Limitations ofLimitations Use: Use ofofOPZELURA Use: Use of in combination OPZELURA inwith combination therapeutic withbiologics, therapeutic other biologics, other TBand and active infection activeprior TB infection to administration prior to administration of OPZELURA.ofDuring OPZELURA. OPZELURA Duringuse, OPZELURA use, conditions, a JAK inhibitors,JAK or potent inhibitors, immunosuppressants or potent immunosuppressants such as azathioprine such asorazathioprine cyclosporine or iscyclosporine is monitor patients monitor for the patients development for the of development signs and symptoms of signs and of TB. symptoms of TB. compared to not recommended. not recommended.

Viral Reactivation: Viral Reactivation: Viral reactivation, Viral including reactivation, cases including of herpes casesvirus of herpes reactivation virus reactivation in practice. (e.g., herpes zoster), (e.g., herpes were zoster), reportedwere in clinical reported trialsin with clinical Janus trialskinase with Janus inhibitors kinase usedinhibitors used 449 adult an WARNING: SERIOUS INFECTIONS, MALIGNANCY, MAJOR WARNING: SERIOUS INFECTIONS, MORTALITY, MORTALITY, MALIGNANCY, MAJOR to treat inflammatory to treat inflammatory conditions including conditions OPZELURA. including If OPZELURA. a patient develops If a patient herpes develops herpes treated with ADVERSE CARDIOVASCULAR AND THROMBOSIS ADVERSE CARDIOVASCULAR EVENTS, ANDEVENTS, THROMBOSIS were female zoster, consider zoster, interrupting considerOPZELURA interruptingtreatment OPZELURA untiltreatment the episode untilresolves. the episode resolves.

SERIOUS INFECTIONS SERIOUS INFECTIONS adverse reac Hepatitis B and Hepatitis C: The Bimpact and C:ofThe Janus impact kinase of Janus inhibitors kinase usedinhibitors to treat used inflammatory to treat inflammatory least 1% gre Patients treated withkinase oral Janus kinase for inflammatory Patients treated with oral Janus inhibitors forinhibitors inflammatory conditions conditions conditions conditions OPZELURA includingonOPZELURA chronic viral on hepatitis chronic viral reactivation hepatitis isreactivation unknown. is unknown. follows for O at risk forserious developing serious infections may lead to hospitalization or including are at risk forare developing infections that may leadthat to hospitalization or Patients with Patients a history with of hepatitis a historyB of or hepatitis C infection B or were C infection excludedwere fromexcluded clinical trials. from clinical trials. emergent ad death [see andand Precautions and Adverse Reactions]. death [see Warnings andWarnings Precautions Adverse Reactions].

Hepatitis B viral Hepatitis load (HBV-DNA B viral load titer) (HBV-DNA increases, titer) with increases, or withoutwith associated or without elevations associated elevations (1%), Applica Reported infections include: Reported infections include: in alanine in alanine aminotransferase and aspartateand aminotransferase, aspartate aminotransferase, have been reported have been in reported in 17 (4%) vs 6 • Active tuberculosis, maywith present with pulmonary or aminotransferase • Active tuberculosis, which maywhich present pulmonary or patients with chronic patientsHBV withinfections chronic HBV taking infections oral ruxolitinib. taking oral OPZELURA ruxolitinib.initiation OPZELURA is notinitiation is not vs 1 (<1%), a extrapulmonary disease. extrapulmonary disease. recommendedrecommended in patients with in active patients hepatitis with active B or hepatitis BC.or hepatitis C. Adverse rea • Invasive fungal infections, including cryptococcosis, and pneumocystosis.

• Invasive fungal infections, including cryptococcosis, and pneumocystosis.

Mortality: In a Mortality: large, randomized, In a large, postmarketing randomized, postmarketing safety study ofsafety an oral study JAKofinhibitor an oral JAK inhibitor the OPZELU Bacterial, viral, including herpes zoster,infections and otherdue infections due to • Bacterial, •viral, including herpes zoster, and other to in rheumatoidinarthritis rheumatoid (RA) arthritis patients (RA) 50 years patients of age 50 years and older of age with andat older least with one at least one hypertension opportunisticopportunistic pathogens. pathogens. cardiovascular cardiovascular risk factor, a risk higher factor, rate a of higher all-cause rate mortality, of all-cause including mortality, sudden including sudden dermatitis Avoid use ofinOPZELURA in patients with an active, serious infection, including Avoid use of OPZELURA patients with an active, serious infection, including influenza-lik cardiovascular cardiovascular death, was observed death, was in observed patients treated in patients with treated the JAK with inhibitor the JAK inhibitor localizedIf infections.

If a serious infection develops, interruptuntil OPZELURA until localized infections. a serious infection develops, interrupt OPZELURA compared withcompared TNF blockers. with TNF Consider blockers. the benefits Considerand therisks benefits for the andindividual risks for the patient individual patient DRUG INTE infection is controlled. the infectionthe is controlled. prior to initiating priorortocontinuing initiating or therapy continuing with OPZELURA. therapy with OPZELURA. Drug intera Thebenefits risks and benefits ofwith treatment with should OPZELURA should be carefully The risks and of treatment OPZELURA be carefully known to b Malignancy Malignancy and Lymphoproliferative and Lymphoproliferative Disorders: Malignancies, Disorders: Malignancies, including including considered prior to initiating therapy in patients with chronic or considered prior to initiating therapy in patients with chronic or lymphomas, lymphomas, were observed were in clinical observed trials in clinical of oral trials JAK inhibitors of oral JAK used inhibitors to treatused to treat may increa recurrent infection. recurrent infection. inflammatory inflammatory conditions. Patients conditions. who Patients are current whoorare past current smokers or past are at smokers additional are at additional decrease ru Patients should monitored be closelyfor monitored for the development and Patients should be closely the development of signs andof signs increased risk. increased Malignancies, risk.

Malignancies, including lymphomas, including lymphomas, have occurred have in patients occurred in patients Strong Inhi infection and afterwith treatment with [see OPZELURA [see symptoms ofsymptoms infection of during and during after treatment OPZELURA receiving JAK receiving inhibitors JAKused inhibitors to treat used inflammatory to treat inflammatory conditions. Inconditions. a large, In a large, inhibitors o and Precautions].

Warnings andWarnings Precautions]. randomized, postmarketing randomized, postmarketing safety study of safety an oral study JAKofinhibitor an oral JAK in RAinhibitor patients, in aRA patients, a ruxolitinib a MORTALITY MORTALITY higher rate ofhigher malignancies rate of malignancies (excluding non-melanoma (excluding non-melanoma skin cancer) was skin observed cancer) was observed USE IN SPE In a large, postmarketing randomized, postmarketing safety study inarthritis rheumatoid (RA) treated In a large, randomized, safety study in rheumatoid (RA) arthritis in patients in patients with treated the JAKwith inhibitor the JAK compared inhibitorto compared those treated to those with treated TNF with TNF Pregnancy patients 50 years of age and at least one cardiovascular patients 50 years of age and older with at older least with one cardiovascular risk factor risk factor blockers. A higher blockers. rateAofhigher lymphomas rate of was lymphomas observedwas in patients observedtreated in patients with the treated with the an oral to JAK inhibitor to tumor necrosis factor (TNF) blocker treatment, comparing ancomparing oral JAK inhibitor tumor necrosis factor (TNF) blocker treatment, Pregnancy JAK inhibitor JAK compared inhibitor to compared those treated to those with TNF treated blockers. with TNF A higher blockers. rateAofhigher lung rate of lung ratemortality, of all-cause mortality, including sudden cardiovascular a higher rate aofhigher all-cause including sudden cardiovascular death, was death, was outcomes i cancers was cancers observedwas in current observed or inpast current smokers or past treated smokers with treated the JAKwith inhibitor the JAK inhibitor with the JAK and Precautions]. observed withobserved the JAK inhibitor [see inhibitor Warnings[see andWarnings Precautions]. persons ex compared to those compared treated to those with TNF treated blockers. with TNF In this blockers. study, current In this study, or past current smokers or past smokers exposure by MALIGNANCIES MALIGNANCIES had an additional had an increased additional riskincreased of overallrisk malignancies. of overall malignancies.

Consider the Consider benefits and the benefits and were reportedtreated in patients with Lymphoma OPZELURA. Lymphoma MalignanciesMalignancies were reported in patients with treated OPZELURA. risks for therisks individual for thepatient individual prior patient to initiating prior to or initiating continuingor therapy continuing withtherapy with Risk Summa and other malignancies have beenin observed patientsJAK receiving JAK and other malignancies have been observed patients in receiving OPZELURA, OPZELURA, particularly in particularly patients in withpatients a known withmalignancy a known (other malignancy than (other than are not suffi inhibitors to treat inflammatory RA patients treatedsuccessfully with an inhibitors used to treat used inflammatory conditions. Inconditions.

RA patientsIntreated with an successfully treated non-melanoma treated non-melanoma skin cancers), skinpatients cancers), whopatients developwho a develop a or other ad administrati oral JAK inhibitor, higher rate of malignancies (excluding non-melanoma oral JAK inhibitor, a higher ratea of malignancies (excluding non-melanoma malignancy when malignancy on treatment, when on and treatment, patients who and patients are current whoorare past current smokers. or past smokers. resulted in a cancer waswhen observed whenwith compared with TNF blockers. skin cancer skin (NMSC)) was(NMSC)) observed compared TNF blockers.

Non-melanoma Non-melanoma Skin Cancers:Skin Non-melanoma Cancers: Non-melanoma skin cancers skin including cancers basal including cell andbasal cell and whoorare current or past are at additional increased risk [see Patients whoPatients are current past smokers are smokers at additional increased risk [see The backgr squamous cellsquamous carcinomacell have carcinoma occurredhave in patients occurred treated in patients with OPZELURA. treated withPerform OPZELURA. Perform and Precautions].

Warnings andWarnings Precautions]. populations periodic skin periodic examinations skin examinations during OPZELURA duringtreatment OPZELURA andtreatment followingand treatment following as treatment as other adver MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) appropriate. Exposure appropriate. to sunlight Exposure andtoUV sunlight light should and UVbelight limited should by wearing be limited protective by wearing protective birth defect In50 RAyears patients 50 years of age and at least one cardiovascular risk In RA patients of age and older with at older least with one cardiovascular risk clothing broad-spectrum and using broad-spectrum sunscreen. sunscreen. factor oral JAK inhibitor, higher of major clothing adverseand using factor treated withtreated an oralwith JAK an inhibitor, a higher ratea of majorrate adverse Data Major Adverse MajorCardiovascular Adverse Cardiovascular Events (MACE): EventsIn (MACE): a large, Inrandomized, a large, randomized, cardiovascular events (MACE) (defined as cardiovascular death, myocardial cardiovascular events (MACE) (defined as cardiovascular death, myocardial Animal Data: postmarketingpostmarketing safety study of safety an oral study JAKofinhibitor an oral JAK in RAinhibitor patientsin50 RAyears patients of age 50 years of age infarction, was observed whenwith compared with TNF blockers. infarction, and stroke), and wasstroke), observed when compared TNF blockers. of organoge who or arepast current or past are atincreased additionalrisk. increased Patients whoPatients are current smokers aresmokers at additional and risk. older withand at least olderone withcardiovascular at least one cardiovascular risk factor, a higher risk factor, rate of a higher major adverse rate of major adverse in rabbits. T in patients who have experienced Discontinue Discontinue OPZELURA inOPZELURA patients who have experienced a myocardiala myocardial cardiovascular cardiovascular events (MACE) events defined (MACE) as defined cardiovascular as cardiovascular death, non-fatal death, non-fatal weight of ap stroke [see and Precautions]. infarction or infarction stroke [seeorWarnings andWarnings Precautions]. myocardial infarction myocardial (MI), infarction and non-fatal (MI), and stroke non-fatal was observed stroke was withobserved the JAK inhibitor with the JAK inhibitor 60 mg/kg/da compared to compared those treated to those with treated TNF blockers. with TNF Patients blockers. whoPatients are current whoorarepast current or past systemic exp THROMBOSISTHROMBOSIS smokers are smokers at additional are at increased additional risk. increased Considerrisk. the Consider benefits and the benefits risks for and the risks for the exposure fro Thromboembolic were observed trials withThrombosis, OPZELURA. Thrombosis, Thromboembolic events were events observed in trials withinOPZELURA. individual priorpatient to initiating prior toor initiating continuingor therapy continuing withtherapy OPZELURA, with OPZELURA, affected bod including pulmonary embolism (PE), thrombosis deep venous(DVT), thrombosis (DVT), andindividual arterial patient including pulmonary embolism (PE), deep venous and arterial patients who in patients are current whoorare past current smokers or past andsmokers patients and withpatients other with other lower fetal w thrombosis have been reported in patients inhibitors to treat inparticularly thrombosis have been reported in patients receiving JAKreceiving inhibitorsJAK used to treat usedparticularly cardiovascular cardiovascular risk factors. risk Patients factors. should Patients be informed should be about informed the symptoms about theofsymptoms of highest and conditions.

Many of these adverse reactions and inflammatoryinflammatory conditions. Many of these adverse reactions were seriouswere and serious serious serious cardiovascular events and the events stepsandto the takesteps if they to occur. take if Discontinue they occur. Discontinue approximate resulted death. In50RAyears patients 50and years of age olderone with at least onecardiovascular some resultedsome in death.

In RAinpatients of age older withand at least cardiovascular risk factor an oral JAK inhibitor, rate of inOPZELURA cardiovascular risk factor treated with treated an oral with JAK inhibitor, a higher rateaofhigherOPZELURA patients that in patients have experienced that have aexperienced myocardial ainfarction myocardial or stroke. infarction or stroke. developmen thrombosis observed when compared with TNF blockers.

Avoid in thrombosis was observedwas when compared with TNF blockers.

Avoid OPZELURA in OPZELURA Thrombosis: Thrombosis: Thromboembolic Thromboembolic events were observed events were in clinical observed trialsinwith clinical OPZELURA. trials with OPZELURA. through lact patients at risk. Ifofsymptoms of occur, thrombosis occur, OPZELURA discontinue OPZELURA patients at risk.

If symptoms thrombosis discontinue Thrombosis, including Thrombosis, deepincluding vein thrombosis deep vein(DVT), thrombosis pulmonary (DVT),embolism pulmonary (PE), embolism and (PE), and on embryofe and treat appropriately and Precautions]. and treat appropriately [see Warnings[see andWarnings Precautions]. arterial thrombosis arterialhave thrombosis been reported have been in patients reportedreceiving in patients JAKreceiving inhibitorsJAK usedinhibitors to used to function at th treat inflammatory treat inflammatory conditions.

Many conditions. of these Many adverse of these reactions adverse were reactions serious were and serious and Lactation WARNINGS AND PRECAUTIONS WARNINGS AND PRECAUTIONS some resultedsome in death. resulted In a in large, death. randomized, In a large,postmarketing randomized, postmarketing safety study ofsafety an oral study of an oral Risk Summa Serious Serious Infections: and fatal sometimes fataldue infections due to bacterial, Serious Infections: and Serious sometimes infections to bacterial, JAK inhibitor inJAK RAinhibitor patientsin50RAyears patients of age 50and years older of age withand at least olderone withcardiovascular at least one cardiovascular on the breas invasive or other opportunistic pathogens mycobacterial,mycobacterial, invasive fungal, viral, fungal, or otherviral, opportunistic pathogens have been have been risk factor, higher risk factor, rates ofhigher overallrates thrombosis, of overallDVT, thrombosis, and PE were DVT,observed and PE were compared observed to compared to of lactating reported in patients oral Janus kinase inhibitors. lower respiratory reported in patients receiving oralreceiving Janus kinase inhibitors.

Serious lowerSerious respiratory those treated with thoseTNF treated blockers. with TNF Avoidblockers.

OPZELURA Avoid in patients OPZELURA whoin may patients be atwho increased may be at increased present in hu tract infections tract were infections reported were in the reported clinicalindevelopment the clinical development program withprogram topical with topical of thrombosis. risk of Ifthrombosis. symptoms Ifof symptoms thrombosisofoccur, thrombosis discontinue occur, OPZELURA discontinueand OPZELURA and serious infe ruxolitinib. Avoid ruxolitinib. use of Avoid OPZELURA use ofinOPZELURA patients with in patients an active, withserious an active, infection, seriousrisk infection, breastfeed d evaluate and treat evaluate patients and appropriately. treat patients appropriately. including localized including infections. localized Consider infections. the Consider risks and the benefits risks of andtreatment benefits prior of treatment to prior to last dose (ap

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 30

9/18/23 2:47 PM

Data: Lactating ratsLactating were administered rats were administered a single dosea ofsingle [14C]-labeled dose of [14C]-labeled ruxolitinib ruxolitinib th a history Thrombocytopenia, Thrombocytopenia, Anemia, andAnemia, Neutropenia: and Neutropenia: Thrombocytopenia, Thrombocytopenia, anemia, and anemia, and Data: (30benefits mg/kg) on(30 postnatal mg/kg)Day on postnatal 10, after which Day 10,plasma after which and milk plasma samples and milk weresamples collectedwere collected uberculosis; neutropenia were neutropenia reportedwere in thereported clinical in trials the with clinical OPZELURA. trials withConsider OPZELURA. the benefits Consider the for prior up to to 24 hours. for upThe to 24 AUC hours. for total The radioactivity AUC for totalinradioactivity milk was approximately in milk was approximately 13 times 13 times c mycoses; and risks for and individual risks for patients individual who patients have a known who have history a known of these history events of these prior toevents the maternal the maternal AUC. Additional plasma AUC. analysis Additional showed analysis the presence showed the of ruxolitinib presence and of ruxolitinib and on. Closely initiating therapy initiating with OPZELURA. therapy withPerform OPZELURA. CBC Perform monitoring CBCasmonitoring clinically indicated. as clinically If indicated.

If plasma severaland of its metabolites several of itsinmetabolites milk, all at levels in milk,higher all at than levelsthose higher in maternal than thoseplasma. in maternal plasma. symptoms and/orofsymptoms clinically significant of clinicallythrombocytopenia, significant thrombocytopenia, anemia, and anemia, ction during signs and/or signs neutropenia patientsoccur, should patients discontinue shouldOPZELURA. discontinue OPZELURA. Pediatric Use:Pediatric Nonsegmental Use: Nonsegmental Vitiligo: The safety Vitiligo: andThe effectiveness safety and effectiveness of OPZELURAofforOPZELURA for develops a neutropenia occur, topical treatment the topical of treatment nonsegmental of nonsegmental vitiligo have been vitiligoestablished have been inestablished pediatric in pediatric OPZELURA Lipid Elevations: LipidTreatment Elevations: with Treatment oral ruxolitinib with oral hasruxolitinib been associated has been with associated increaseswiththe increases patients agedpatients 12 to 17aged years12oftoage.

17 Use yearsofofOPZELURA age. Use ofin OPZELURA this age group in this is supported age group is supported in lipid parameters in lipid including parameterstotal including cholesterol, total low-density cholesterol, lipoprotein low-density (LDL) lipoprotein (LDL) by evidence from by evidence TRuE-V1from and TRuE-V1 TRuE-V2,and which TRuE-V2, included which 55 pediatric includedsubjects 55 pediatric agedsubjects aged cholesterol, triglycerides. and triglycerides. al trials with cholesterol, and 12 to 17 years 12 with to 17nonsegmental years with nonsegmental vitiligo. No clinically vitiligo. meaningful No clinicallydifferences meaningfulindifferences in anus kinase ADVERSE REACTIONS ADVERSE REACTIONS safety or effectiveness safety or effectiveness were observed were between observed adultbetween and pediatric adult and subjects. pediatric Thesubjects. The nts for latent Clinical TrialsClinical Experience: Trials Because Experience: clinical Because trials are clinical conducted trials are under conducted widely varying under widely varying safety and effectiveness safety and effectiveness of OPZELURAofin OPZELURA pediatric patients in pediatric younger patients than younger 12 yearsthan of 12 years of ELURA use, conditions, adverse conditions, reaction adverse rates observed reaction rates in theobserved clinical trials in theofclinical a drugtrials cannot of be a drug directly cannotage be directly with nonsegmental age with nonsegmental vitiligo have not vitiligo beenhave established. not been established. compared to rates compared in the clinical to ratestrials in theofclinical anothertrials drugofand another may not drugreflect and may the rates not reflect observed the rates observed Animal ToxicityAnimal Data: Oral Toxicity administration Data: Oral administration of ruxolitinib toofjuvenile ruxolitinib ratstoresulted juvenileinrats resulted in Juvenile Juvenile practice. double-blind, In two vehicle-controlled double-blind, vehicle-controlled clinical trials (TRuE-V1 clinical trials and (TRuE-V1 TRuE-V2),andeffects TRuE-V2), reactivation in practice. In intwo on growth effects andonbone growth measures. and bone When measures. administered When starting administered at postnatal startingday at postnatal 7 day 7 449 adult and 449 pediatric adult subjects and pediatric 12 years subjects of age 12 and years older of with age and nonsegmental older with nonsegmental vitiligo were vitiligo were ibitors used (the equivalent(the of equivalent a human newborn) of a human at doses newborn) of 1.5 at doses to 75 mg/kg/day, of 1.5 to 75evidence mg/kg/day, of evidence of treated with twice OPZELURA daily for twice 24 weeks. daily In forthe 24OPZELURA weeks. In the group, OPZELURA 55% of group, subjects 55% fractures of subjects lops herpes treated with OPZELURA occurred fractures at doses occurred ≥ 30 at mg/kg/day, doses ≥ 30 and mg/kg/day, effects onand body effects weightonand body other weight boneand other bone were females, were and 81% females, of subjects and 81% were of subjects White, 5% were were White, Black, 5%and were 4%Black, were Asian. and 4%The weremeasures Asian. The[e.g.,measures es. bone mineral [e.g.,content, bone mineral peripheral content, quantitative peripheralcomputed quantitative tomography, computedand tomography, and adverse reactions adverse reported reactions

by OPZELURA reported by treated OPZELURA subjectstreated with an subjects incidence withofan≥ 1% incidence and atof ≥x-ray 1% and at analysis]x-ray occurred analysis] at doses occurred ≥ 5 mg/kg/day. at doses ≥When 5 mg/kg/day. administered Whenstarting administered at postnatal starting at postnatal flammatory least 1% greater least incidence 1% greater than incidence in the vehicle thanarm in the in the vehicle 24-week arm indouble-blind the 24-weekperiod double-blind are as period are as day 21 (the equivalent day 21 (the of aequivalent human 2-3ofyears a human of age) 2-3atyears doses ofof age) 5 toat60 doses mg/kg/day, of 5 to 60 effects mg/kg/day, effects s unknown. follows for OPZELURA follows (N=449) for OPZELURA vs Vehicle (N=449) (N=224), vs Vehicle respectively: (N=224),Subjects respectively: with any Subjects treatment with anyontreatment body weight on and bodybone weight occurred and bone at doses occurred ≥ 15atmg/kg/day, doses ≥ 15which mg/kg/day, were considered which were considered nical trials. emergent adverse emergent event adverse (TEAE) 214 event (48%) (TEAE) vs 79 214(35%), (48%)Application vs 79 (35%), siteApplication acne 26 (6%) site vs acne 2 26adverse (6%) vsat2 60adverse mg/kg/day. at 60Males mg/kg/day. were more Malesseverely were more affected severely than affected females than in all females age in all age (1%), siteApplication pruritus 23site (5%)pruritus vs 6 (3%), 23 (5%) Nasopharyngitis vs 6 (3%), Nasopharyngitis 19 (4%) vs 5 (2%), 19 (4%) Headache vs 5 (2%),groups, Headache d elevations (1%), Application and effects groups, were andgenerally effects were moregenerally severe when moreadministration severe when administration was initiated earlier was initiated earlier 17 (4%) vs 6 (3%), 17 (4%) Urinary vs 6 tract (3%), infection Urinary 7 tract (2%) infection vs 1 (<1%), 7 (2%) Application vs 1 (<1%), site Application erythema 7 site (2%) erythema 7 (2%) reported in in the postnatal in period. the postnatal These period. findingsThese were findings observedwere at systemic observedexposures at systemic thatexposures are at that are at 1 (<1%), 6 (1%) and Pyrexia vs 0 (0%).

6 (1%) vs 0 (0%). iation is not vs 1 (<1%), andvsPyrexia least 40% the least MRHD 40% clinical the MRHD systemic clinical exposure. systemic exposure.

Adverse reactions Adverse that occurred reactionsinthat TRuE-V1 occurred andinTRuE-V2 TRuE-V1inand ≥ 0.5% TRuE-V2 to <in1% ≥ 0.5% of subjects to < 1% in ofGeriatric subjects inUse:Geriatric Of the 831 Use: total Of subjects the 831 total enrolled subjects with nonsegmental enrolled with nonsegmental vitiligo in clinical vitiligo in clinical OPZELURA and none group in the andvehicle none ingroup the vehicle were: application group were: siteapplication dermatitis,site trials dermatitis, AK inhibitor the OPZELURAthegroup with OPZELURA, trials with65OPZELURA, (8%) were6565(8%) years were of age 65 years and older. of ageClinical and older. trials Clinical of trials of hypertension, application anxiety, siteapplication discoloration, site application discoloration, siteapplication folliculitis, site contusion, folliculitis,OPZELURA contusion, in OPZELURA subjects with in subjects nonsegmental with nonsegmental vitiligo did notvitiligo includedid sufficient not include numbers sufficient of numbers of at least one hypertension, anxiety, dermatitis contact, dermatitis diarrhea, contact, ear diarrhea, infection, ear gastritis, infection, gastroenteritis, gastritis, gastroenteritis, hordeolum, hordeolum, subjects 65 years subjects of age 65and years older of age to determine and older whether to determine they respond whether differently they respond from differently from ing sudden influenza-like insomnia, illness, nasalinsomnia, congestion, nasal and congestion, vomiting. and vomiting. younger adult younger subjects.adult subjects.

AK inhibitor influenza-like illness, DRUG INTERACTIONS dual patient DRUG INTERACTIONS PATIENT COUNSELING PATIENT COUNSELING INFORMATION INFORMATION Drug interaction Drugstudies interaction with studies OPZELURA withhave OPZELURA not been have conducted. not beenRuxolitinib conducted.is Ruxolitinib is patient Advise the Advise or the caregivers patient or tocaregivers read the toFDA-approved read the FDA-approved patient labeling patient labeling substrate to befor a substrate cytochrome forP450 cytochrome 3A4 (CYP3A4).

P450 3A4 Inhibitors (CYP3A4). of CYP3A4 Inhibitors of CYP3A4 Guide).

(Medication (Medication Guide). , including known to be aknown ruxolitinib increase systemic ruxolitinib concentrations systemic concentrations whereas inducers whereas of CYP3A4 inducersmay of CYP3A4 may ed to treat may increase may Infections: Inform Infections: patientsInform that they patients may that be at they increased may be risk at increased for developing risk for infections, developing infections, decrease systemic ruxolitinib concentrations. systemic concentrations. at additional decrease ruxolitinib including serious including infections, serious when infections, taking Janus whenkinase takinginhibitors.

Janus kinase Instruct inhibitors. patients Instruct to tell their patients to tell their Strong of Inhibitors CYP3A4: Avoid of CYP3A4: concomitant Avoid concomitant use of OPZELURA use of with OPZELURA strong with strongprovider in patients Strong Inhibitors healthcare healthcare if they provider develop any if they signs develop or symptoms any signsoforansymptoms infection. of Advise an infection. patientsAdvise that patients that inhibitorsasofthere CYP3A4 is a as potential there istoaincrease potentialthe to increase systemic the exposure systemic of exposure of inhibitors n a large, inhibitors of CYP3A4 Janus kinase Janus kinase increase inhibitors the risk increase of herpes thezoster, risk of and herpes some zoster, casesand cansome be serious cases can [seebe serious [see could increase and could the risk increase of OPZELURA the risk ofadverse OPZELURA reactions. adverse reactions. Warnings and Precautions].

Warnings and Precautions]. patients, a ruxolitinib andruxolitinib s observed USE IN SPECIFIC USE POPULATIONS IN SPECIFIC POPULATIONS Malignancies Malignancies and Lymphoproliferative and Lymphoproliferative Disorders: Inform Disorders: patients Inform that patients Janus kinase that Janus kinase d with TNF Pregnancy Pregnancy inhibitors mayinhibitors increase may the increase risk for developing the risk forlymphomas developingand lymphomas other malignancies and other malignancies ed with the including skin cancer. includingInstruct skin cancer. patients Instruct to inform patients their to health inform care their provider healthifcare theyprovider have ever if they have ever Pregnancy Exposure Pregnancy Registry: Exposure There Registry: is a pregnancy There isregistry a pregnancy that monitors registry that pregnancy monitors pregnancy rate of lung had any typehad of cancer. any typeInform of cancer. patients Inform that patients periodic that skin periodic examinations skin examinations should be should be outcomes in pregnant outcomes persons in pregnant exposed persons to OPZELURA exposed toduring OPZELURA pregnancy. duringPregnant pregnancy. Pregnant AK inhibitor performed while performed using OPZELURA. while usingAdvise OPZELURA. patientsAdvise that exposure patients to that sunlight, exposure andtoUV sunlight, light and UV light persons exposed persons to OPZELURA exposed toand OPZELURA healthcare andproviders healthcare should providers reportshould OPZELURA report OPZELURA should be limited should by wearing be limited protective by wearing clothing protective and using clothing a broad-spectrum and using a broad-spectrum sunscreen sunscreen ast smokers exposure by calling exposure 1-855-463-3463. by calling 1-855-463-3463. [see Warnings [see and Precautions].

Warnings and Precautions]. enefits and Available Summary: data Available from pregnancies data fromreported pregnancies in clinical reported trialsinwith clinical OPZELURA trials with OPZELURA erapy with Risk Summary:Risk Major AdverseMajor Cardiovascular Adverse Cardiovascular Events: AdviseEvents: patients Advise that patients events ofthat major events adverse of major adverse are to notevaluate sufficient a drug-associated to evaluate a drug-associated risk for major birth risk for defects, major miscarriage, birth defects, miscarriage, other than are not sufficient cardiovascularcardiovascular events (MACE) events including (MACE) non-fatal including myocardial non-fatalinfarction, myocardialnon-fatal infarction, non-fatal or other adverse or other maternal adverse or fetal maternal outcomes. or fetal In outcomes. animal reproduction In animal studies, reproduction oral studies, oral develop a stroke, and cardiovascular stroke, and cardiovascular death, have been death, reported have been in clinical reported studies in clinical with Janus studies with Janus administrationadministration of ruxolitinib toofpregnant ruxolitinib rats toand pregnant rabbitsrats during and the rabbits period during of organogenesis the period of organogenesis kinase inhibitors kinase usedinhibitors to treat inflammatory used to treat inflammatory conditions. Instruct conditions. all patients, Instructespecially all patients, especially mokers. resulted in adverse resulted developmental in adverse developmental outcomes at doses outcomes associated at doses with associated maternal with toxicity. maternal toxicity. current or pastcurrent smokers or past or patients smokers with or patients other cardiovascular with other cardiovascular risk factors, torisk be factors, alert to be alert sal cell and The background The risks background of major risks birthof defects major birth and defects miscarriage and for miscarriage the indicated for theforindicated the development for the of development signs and symptoms of signs and of symptoms cardiovascular of cardiovascular events [see Warnings events [see Warnings RA. Perform populations are populations unknown.are All unknown. pregnancies All carry pregnancies some risk carry of birth somedefects, risk of birth loss,defects, or andloss, or and Precautions].

Precautions]. eatment as other adverseother outcomes. adverse Theoutcomes. background Therisk background in the U.S.risk general in thepopulation U.S. general of population major Thrombosis: of major Advise Thrombosis: patientsAdvise that events patientsofthat DVTevents and PEof have DVT been and PE reported have been in clinical reported in clinical g protective birth defects and birthmiscarriage defects andismiscarriage 2-4% and 15-20%, is 2-4% and respectively.

15-20%, respectively. studies with Janus studies kinase withinhibitors Janus kinase usedinhibitors to treat inflammatory used to treatconditions. inflammatory Instruct conditions. patients Instruct patients to tell their healthcare to tell their provider healthcare if theyprovider developifany theysigns develop or symptoms any signsoforasymptoms DVT or PEof[see a DVT or PE [see Data Data andomized, Warnings and Precautions].

Animal Data: Ruxolitinib Animal Data: wasRuxolitinib administered wasorally administered to pregnant orally ratstoorpregnant rabbits during rats or the rabbits period duringWarnings the periodand Precautions]. ears of age Anemia, andAnemia, Neutropenia: and Neutropenia: Advise patients Advise of the patients risk of of the risk of of organogenesis, of organogenesis, at doses of 15,at30, doses or 60ofmg/kg/day 15, 30, or 60 in rats mg/kg/day and 10, in30,rats or and 60 mg/kg/day 10, 30, or 60 Thrombocytopenia, mg/kg/day Thrombocytopenia, ajor adverse in rabbits. There thrombocytopenia, anemia, and neutropenia anemia, andwith neutropenia OPZELURA. withInstruct OPZELURA. patients Instruct to tellpatients to tell in rabbits. were noThere treatment-related were no treatment-related malformations malformations at any dose. A at decrease any dose. in fetal A decrease in fetal thrombocytopenia, non-fatal weight of approximately theirdose healthcare provider healthcare if theyprovider developif any theysigns develop or symptoms any signs of or thrombocytopenia, symptoms of thrombocytopenia, weight of approximately 9% was noted9% in rats wasatnoted the highest in rats at andthematernally highest and toxicmaternally dose of toxic of their AK inhibitor 60 mg/kg/day.60 or neutropenia anemia, or[see neutropenia Warnings[see and Warnings Precautions]. and Precautions].

This mg/kg/day. dose resulted This in dose systemic resulted exposure in systemic approximately exposure approximately 22 times the clinical 22 timesanemia, the clinical ent or past systemic exposure systemic at theexposure maximum atrecommended the maximum recommended human dose (MRHD; humanthe dose clinical (MRHD; systemic the clinical systemic Administration Administration Instructions: Advise Instructions: patients Advise or caregivers patients that or caregivers OPZELURA that is OPZELURA for topical is for topical sks for the exposure fromexposure ruxolitinibfrom cream, ruxolitinib 1.5% applied cream, twice 1.5% applied daily to twice 25-40% dailyatopic to 25-40% dermatitisatopic use dermatitisonly [see use Dosage onlyand [seeAdministration].

Dosage and Administration].

OPZELURA, affected body surface affectedarea bodyissurface used forarea calculation is used of formultiples calculation of human of multiples exposure). of human In rabbits, exposure).Advise In rabbits, patients Advise to limit patients treatment to limit to one treatment 60 gram to tube one 60 pergram weektube or one per100 week gram or one tube100 gram tube with other lower fetal weights loweroffetal approximately weights of approximately 8% and increased 8% and late increased resorptionslate were resorptions noted at were the noted the [see per 2atweeks per 2Dosage weeksand [seeAdministration].

Dosage and Administration]. ymptoms of highest and maternally highest and toxicmaternally dose of 60toxic mg/kg/day. dose of 60 This mg/kg/day. dose resulted Thisindose systemic resulted exposure in systemic exposure Pregnancy: patients Inform to report patientstheir to pregnancy report theirtopregnancy Incyte Corporation to Incyte at Corporation at Discontinue approximately approximately 70% the MRHD 70%clinical the MRHD systemic clinical exposure. systemic In exposure. a pre-and Inpost-natal a pre-and Pregnancy: post-natal Inform 1-855-463-3463 1-855-463-3463 [see Use in Specific [see Use Populations]. in Specific Populations]. stroke. development study development in rats, pregnant study in rats, animals pregnant were dosed animals with were ruxolitinib dosed with fromruxolitinib implantation from implantation Lactation: Lactation: a patient Advise not toa patient breastfeed not to during breastfeed treatment during withtreatment OPZELURA with and OPZELURA for and for through at doses lactation up to at 30doses mg/kg/day. up to 30 There mg/kg/day. were no There drug-related were noadverse drug-related effectsadverse effectsAdvise OPZELURA. through lactation about four weeks about after fourthe weeks last dose after [see the last Usedose in Specific [see Use Populations]. in Specific Populations]. survival, embryofetal postnatal survival, growth, postnatal development growth,parameters development or offspring parameters reproductive or offspring reproductive m (PE), and on embryofetalon highest dose at theevaluated highest dose (3.1 times evaluated the MRHD (3.1 times clinical the systemic MRHD clinical exposure). systemic exposure).

ManufacturedManufactured for: for: ors used to function at the function Incyte Corporation Incyte Corporation serious and Lactation Lactation 1801 Augustine 1801 Cut-off Augustine Cut-off dy of an oral Risk Summary:Risk There Summary: are no data There onare theno presence data onofthe ruxolitinib presenceinofhuman ruxolitinib milk,inthe human effects milk,Wilmington, the effects DE Wilmington, 19803 DE 19803 rdiovascular on the breastfed onchild, the breastfed or the effects child,on or milk the effects production. on milk Ruxolitinib production. wasRuxolitinib present inwas the milk present in the milk of lactating When a drug rats. isWhen present a drug in animal is present milk,initanimal is likelymilk, thatitthe is likely drug will thatbe the drug will be compared to of lactating rats.

OPZELURA is OPZELURA a registeredistrademark a registered of Incyte. trademark All rights of Incyte. reserved.

All rights reserved. present milk.inBecause human milk. of theBecause serious adverse of the serious findings adverse in adults, findings including in adults, risksincluding of risks of at increased present in human U.S. Patent Nos. U.S.7598257; Patent Nos. 8415362; 7598257; 8722693; 8415362; 8822481; 8722693; 9079912; 8822481; 9079912; serious thrombocytopenia, infections, thrombocytopenia, anemia, and neutropenia, anemia, and advise neutropenia, womenadvise not towomen not to 9974790; 10639310; 9974790; 10610530; 10639310; 10758543; 10610530; 10869870; 10758543; 11219624 10869870; 11219624 ZELURA and serious infections, breastfeed during breastfeed treatment during withtreatment OPZELURA with andOPZELURA for approximately and for approximately four weeks after fourthe weeks after the © 2022-2023©Incyte 2022-2023 Corporation.

IncyteAll Corporation. rights reserved.

All rights reserved.

Issued: July 2022 Issued: PLR-OPZ-00018-JUN23 July 2022 PLR-OPZ-00018-JUN23 last dose (approximately last dose (approximately 5-6 elimination5-6 half-lives). elimination half-lives).

22_31_JBCOD_4pgs Streamline the Process Sept/Oct_2023.indd 31

9/18/23 2:47 PM

2023

Biologic Coordinator

SURVEY

Our latest career report focuses on this important role, along with some key findings about the job and how the BC community helps patients get the care they need.

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

32

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 32

9/18/23 2:11 PM

WHO YOU ARE gender

age

≤ 24 3% 25-29 9% 30-34 17% 93% FEMALE

7% MALE

35-39 17% 40-44 13% 45-49 14% ≥ 50 26%

education

ADVANCED DEGREE

11%

36%

30%

HIGH SCHOOL

TWO-YEAR COLLEGE/ VOCATIONAL SCHOOL

CERTIFICATE PROGRAM (MA)

3%

19%

FOUR-YEAR COLLEGE

bcofdermatology.com

33

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 33

9/18/23 2:11 PM

time spent working in access role 35%

WHAT INSPIRES YOU? Motivating factors to carry out the BC role

28% 19% 13% 33% 7%

18%

“Being a resource for patients to provide a better quality of life.”

“Helping patients get the medication they need and seeing how it changes their lives!”

PATIENT OUTCOMES

“Patient access and relationships—Iʼm here for the patient.”

OFFICE RELATIONSHIPS

THE SCIENCE BEHIND MEDICINE

“Beating payors to gain approvals and the patients, especially when they come back and show you the biologic that you worked on paid off because their condition has cleared.”

6%

COLLABORATING WITH SPECIALTY PHARMACIES AND DRUG MANUFACTURERS

6-10

2-5

≤ 1 year

21-50 PATIENTS

26% 38% ≥ 100 PATIENTS

“Helping patients navigate a complex process of insurance, pharmacies and manufacturers.”

Do you consult dermatologists when it comes to the patient access landscape?

70% YES

≥ 10

number of patients managed per month

“Helping patients with severe disease navigate the system and gain access to a life-changing drug. Particularly the elderly medicare patients, as the system is (in my opinion) designed to make them give up on getting the medications due to cost.”

BEATING PAYORS TO GAIN APPROVALS

21%

51-100 PATIENTS

≤ 20 PATIENTS

26% 10%

30% NO

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

34

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 34

9/18/23 2:11 PM

PATIENT ACCESS Do you manage patient access outside of biologics?

Biggest challenges getting medication into patients’ hands...

35% 31% 12% 12% <1%

INSURANCE REQUIREMENTS

documentation and notes; step therapy; PA process; appeal process

86% 14% YES

COST: HIGH COPAYS

accumulator/maximizer plans

NO

How many prior approvals do you have per month?

25 – 50

50 – 100 ≥ 100

≥ 25 31%

27%

18%

24%

SPECIALTY PHARMACIES communication; prescription clarifications; ease of use

“Doctors not working with staff to address or work around insurance company requirements but rather rely on the appeal of “I’M A DOCTOR...THEY ARE NOT.” “Insurance step therapy requirements and specialty pharmacy communication.”

“My Specialty Pharmacy Accredo’s 5-8 business day script processing time.”

PATIENT ENGAGEMENT not answering phones; not completing forms

MANUFACTURERS

access to resources; benefit verifications’ bridge programs and process

What factors negatively affect your job satisfaction?

14%

Working conditions: hours and office staff

6% Career advancement

16% Specialty pharmacy interaction 17% Payor interaction 15% Challenges with patient communication

22% Compensation

bcofdermatology.com

35

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 35

9/18/23 2:11 PM

OFFICE DYNAMICS

Do you have OTC-product discussions with patients?

74% 26%

What Electronic Medical Record program are you utilizing in your practice?

YES

NEXTECH

12

NO

Do you oversee patients and medications in more than one location?

MODERNIZING MEDICINE (EMA)

63

46% 54% YES

EPIC

How many access staff professionals are in your office?

EZDERM

3

NO

ALLSCRIPTS

32

56% 1 (Me)

ATHENA 45%

2

21% ≥ 2

SPECIAL NOTE: Any additional programs represented made up less than 1%.

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

36

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 36

9/18/23 2:11 PM

Most visited media platforms LinkedIn

11%

Instagram 11%

X

TikTok 13%

1% 9%

YouTube

None

4%

61% 39% YES

50%

NEARLY

50%

Where do you look most to gain additional job-related information/learnings?

SAY YES

PEER-TO-PEER PROGRAMS

Are you as interested in (and do you look for) advertisements in dermatology journals as much as you are focused on the articles?

CONFERENCES 2

MANUFACTURER REPRESENTATIVES 3

NO

Do advertisements make you consider utilizing its drug access program or service?

Facebook

1

Do dermatology magazine advertisements increase brand recall and awareness?

JOURNAL ARTICLES

SELFRESEARCH

4

5

67% 33% YES

NO

bcofdermatology.com

37

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 37

9/18/23 2:11 PM

A first-in-class,* selective TYK2 inhibitor for moderate-to-severe plaque psoriasis1,2

Clearer skin

INDICATION SOTYKTU™ (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU. WARNINGS AND PRECAUTIONS Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU. Please see additional Important Safety Information and Brief Summary of U.S. Full Prescribing Information for SOTYKTU on the following pages. *TYK2 is a member of the Janus kinase (JAK) family.

1787-US-2300018_SOT_Journal_Ad_Access_Dermatology_Resize_3_23_P0476610_v0_01.indd 1-2 32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 38

9/18/23 2:11 PM

Clearer choice AT LAST...SOTYKTU Superior skin clearance vs Otezla® (apremilast)†‡ in a once-daily, oral pill1

STUDY DESIGNS1

SELECT IMPORTANT SAFETY INFORMATION

POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic therapy or phototherapy. Patients had a body surface area (BSA) involvement of ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥12, and a static Physician’s Global Assessment (sPGA) ≥3 (moderate or severe).

In the PSO-1 and PSO-2 trials, through Week 16, the most common adverse reactions (≥1% and higher than placebo) in patients taking SOTYKTU (n=840) were upper respiratory infections (19.2%), blood creatine phosphokinase increase (2.7%), herpes simplex (2.0%), mouth ulcers (1.9%), folliculitis (1.7%), and acne (1.4%).

†

Both studies assessed the responses at Week 16 compared with placebo for the two co-primary endpoints: • The proportion of patients who achieved at least a 75% improvement in PASI scores from baseline (PASI 75) • The proportion of patients who achieved an sPGA score of 0 (clear) or 1 (almost clear) There were multiple ranked secondary endpoints, including: • The proportion of patients who achieved PASI 75 at Week 16 vs apremilast STUDY RESULTS 1,3,4 ‡ Comparison between SOTYKTU and apremilast was a secondary endpoint.

Co-primary endpoints: • PASI 75 at Week 16 for SOTYKTU vs placebo: PSO-1: 58% (193/330) vs 13% (21/166), P<0.0001; PSO-2: 53% (271/511) vs 9% (24/255), P<0.0001 • sPGA 0/1 at Week 16 for SOTYKTU vs placebo: PSO-1: 54% (178/330) vs 7% (12/166), P<0.0001; PSO-2: 50% (253/511) vs 9% (22/255), P<0.0001 Select secondary endpoints: • PASI 75 at Week 16 for SOTYKTU vs apremilast: PSO-1: 58% (193/330) vs 35% (59/168); P<0.0001; PSO-2: 53% (271/511) vs 40% (101/254); P=0.0004.

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 39

BSA=body surface area; PASI=psoriasis area and severity index; PASI 75=75% reduction from baseline in PASI; sPGA=static Physician’s Global Assessment; TYK2=tyrosine kinase 2.

Otezla® is a registered trademark of Amgen, Inc. SOTYKTU tablet is not actual size.

Shown for illustrative purposes only.

Scan to learn more or visit SOTYKTUHCP.com

03/02/2023 PM 9/18/23 12:23 2:11 PM

SOTYKTU (deucravacitinib) INDICATION AND IMPORTANT SAFETY INFORMATION INDICATION SOTYKTU™ (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU. WARNINGS AND PRECAUTIONS Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU. Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients: • with chronic or recurrent infection • who have been exposed to tuberculosis • with a history of a serious or an opportunistic infection • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patientyears) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C. Tuberculosis (TB): In clinical trials, of 4 patients with latent TB who were treated with SOTYKTU and received appropriate TB prophylaxis, no patients developed active TB (during the mean follow-up of 34 weeks). One patient, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during treatment.

Malignancy including Lymphomas: Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU.

1787-US-2300018_SOT_Journal_Ad_Access_Dermatology_Resize_3_23_P0476610_v0_01.indd 3-4 32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 40

9/18/23 2:11 PM

Rhabdomyolysis and Elevated CPK: Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to placebo. Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

Laboratory Abnormalities: Treatment with SOTYKTU was associated with increases in triglyceride levels. Periodically evaluate serum triglycerides according to clinical guidelines during treatment. SOTYKTU treatment was associated with an increase in the incidence of liver enzyme elevation compared to placebo. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded.

Immunizations: Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated.

Potential Risks Related to JAK Inhibition: It is not known whether tyrosine kinase 2 (TYK2) inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA. ADVERSE REACTIONS Most common adverse reactions (≥1% of patients on SOTYKTU and more frequently than with placebo) include upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis and acne.

SPECIFIC POPULATIONS Pregnancy: Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Report pregnancies to the BristolMyers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.

Lactation: There are no data on the presence of SOTYKTU in human milk, the effects on the breastfed infant, or the effects on milk production. SOTYKTU is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.

Hepatic Impairment: SOTYKTU is not recommended for use in patients with severe hepatic impairment.

SOTYKTU is available in 6 mg tablets.

Please see Brief Summary of U.S. Full Prescribing Information for SOTYKTU on the following pages.

References: 1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022. 2. Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763-1776.

3. Data on file. BMS-REF-DEU-0020. Princeton, NJ: Bristol-Myers Squibb Company; 2022. 4. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40-51.

SOTYKTU and the related logo are trademarks of Bristol-Myers Squibb Company. © 2023 Bristol-Myers Squibb Company.

1787-US-2300018 02/23

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 41

03/02/2023 PM 9/18/23 12:23 2:11 PM

SOTYKTU™ (deucravacitinib)

tablets, for oral use

Brief Summary of Prescribing Information. For complete prescribing information consult official package insert.

INDICATIONS AND USAGE SOTYKTU™ (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

DOSAGE AND ADMINISTRATION Recommended Evaluations and Immunizations Prior to Treatment Initiation Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with SOTYKTU. If positive, start treatment for TB prior to SOTYKTU use [see Warnings and Precautions].

Update immunizations according to current immunization guidelines [see Warnings and Precautions].

Recommended Dosage The recommended dosage of SOTYKTU is 6 mg taken orally once daily, with or without food.

Do not crush, cut, or chew the tablets.

Recommended Dosage in Patients with Hepatic Impairment SOTYKTU is not recommended in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations and Clinical Pharmacology (12.3) in full Prescribing Information].

No dosage adjustment is needed for patients with mild to moderate hepatic impairment.

CONTRAINDICATIONS SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU [see Warnings and Precautions].

WARNINGS AND PRECAUTIONS Hypersensitivity Hypersensitivity reactions such as angioedema have been reported in subjects receiving SOTYKTU. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU [see Adverse Reactions].

Infections SOTYKTU may increase the risk of infections.

Serious infections have been reported in subjects with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19 [see Adverse Reactions].

Avoid use of SOTYKTU in patients with an active or serious infection.

Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients: • with chronic or recurrent infection • who have been exposed to tuberculosis • with a history of a serious or an opportunistic infection • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with SOTYKTU. A patient who develops a new infection during treatment with SOTYKTU should undergo prompt and complete diagnostic testing; appropriate antimicrobial therapy should be initiated; and the patient should be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection.

Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation Herpes virus reactivation (e.g., herpes zoster, herpes simplex), was reported in clinical trials with SOTYKTU. In the 16-week placebo-controlled period, herpes simplex infections were reported in 17 subjects (6.8 per 100 patient-years) treated with SOTYKTU, and 1 subject (0.8 per 100 patient-years) treated with placebo.

Multidermatomal herpes zoster was reported in an immunocompetent subject who received SOTYKTU. During PSO-1, PSO-2, and the open-label extension trial in which subjects who completed the controlled trials could enroll, the majority of subjects who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age.

The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Subjects with positive screening tests for hepatitis B or C, or chronic hepatitis B, or untreated hepatitis C were excluded from clinical trials.

Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C. Tuberculosis In clinical trials, of 4 subjects with latent tuberculosis (TB) who were treated with SOTYKTU and received appropriate TB prophylaxis, no subjects developed active TB (during the mean follow-up of 34 weeks).

One subject, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients receiving SOTYKTU for signs and symptoms of active TB during treatment.

1787-US-2300018_SOT_Journal_Ad_Access_Dermatology_Resize_3_23_P0476610_v0_01.indd 5-6 32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 42

Malignancy including Lymphomas Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU (deucravacitinib) [see Adverse Reactions].

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU. Rhabdomyolysis and Elevated CPK Cases of rhabdomyolysis were reported in subjects treated with SOTYKTU resulting in interruption or discontinuation of SOTYKTU dosing.

Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to treatment with placebo. Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever [see Adverse Reactions].

Laboratory Abnormalities Triglyceride Elevations - Treatment with SOTYKTU was associated with increases in triglyceride levels.

The effect of this elevated parameter on cardiovascular morbidity and mortality has not been determined.

Periodically evaluate serum triglycerides according to the clinical guidelines for hyperlipidemia while patients are receiving treatment with SOTYKTU. Manage patients according to clinical guidelines for the management of hyperlipidemia [see Adverse Reactions].

Liver Enzyme Elevations - Treatment with SOTYKTU was associated with an increase in the incidence of liver enzyme elevation compared to treatment with placebo. Liver serum transaminase elevations ≥3 times the ULN were reported in subjects treated with SOTYKTU. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine patient management.

If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded [see Adverse Reactions].

Immunizations Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated.

Potential Risks Related to JAK Inhibition It is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA. ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of labeling: • Infections [see Warnings and Precautions] • Malignancy including lymphomas [see Warnings and Precautions] • Laboratory Abnormalities [see Warnings and Precautions]

Table

Upper r Blood c Herpes Mouth Follicul Acned

a Inclu

(inclu trach b Includ c Includ d Includ

Advers

Specifi Exposu

Infectio In the per 10 The m discon

In the patient

The m and CO

Malign During 986 pa 3 subje hepato

During trials c SOTYK

Labora

Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of SOTYKTU was evaluated in two placebo- and active-controlled trials (PSO-1 and PSO-2) and an open-label extension trial in which subjects who completed PSO-1 or PSO-2 could enroll [see Clinical Studies (14) in full Prescribing Information]. In these clinical trials, a total of 1,519 subjects with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy received SOTYKTU 6 mg orally once daily. Of these, 1,141 subjects were exposed to SOTYKTU for at least one year.

In trials PSO-1 and PSO-2, 1,681 subjects were randomized to receive SOTYKTU 6 mg (840 subjects), placebo (419 subjects), or apremilast 30 mg twice daily (422 subjects). All subjects randomized to placebo switched to SOTYKTU at Week 16. All other subjects remained in their original treatment group until Week 24, at which point subjects could have continued on the same treatment or be switched to SOTYKTU or placebo. The mean age of subjects was 47 years. The majority of subjects were White (87%) and male (67%).

In the 16-week placebo-controlled period of the pooled clinical trials (PSO-1 and PSO-2), discontinuation of therapy due to adverse reactions in subjects who received SOTYKTU was 2.4%, compared to 3.8% for placebo.

Table 1 summarizes the adverse reactions that occurred in at least 1% of subjects in the SOTYKTU group and at a higher rate than the placebo group during the 16-week controlled period.

Creatin In the 1 (9.3 pe with pl

Liver E Events [see W • •

Decrea In the 30-59 treated deucra

Lipid E Mean with S

Safety In PSO SOTYK rate ob

USE IN

Pregn

Risk Su Availab associ

9/18/23 2:11 PM

Table 1:

citinib)

herapy reated YKTU.

tion or

reatine ontinue atients nied by

Adverse Reactions that Occurred in ≥1% of Subjects with Plaque Psoriasis in the SOTYKTU (deucravacitinib) Group and More Frequently than in the Placebo Group in Trials PSO-1 and PSO-2 through Week 16 Adverse Reaction

Upper respiratory infectionsa Blood creatine phosphokinase increased Herpes simplexb Mouth ulcersc Folliculitis Acned

SOTYKTU 6 mg once daily N=840 n (%)

Placebo

161 (19.2) 23 (2.7) 17 (2.0) 16 (1.9) 14 (1.7) 12 (1.4)

62 (14.8) 5 (1.2) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.2)

N=419 n (%)

a Includes upper respiratory tract infection (viral, bacterial, and unspecified), nasopharyngitis, pharyngitis

levels. mined. a while for the

(including viral, streptococcal, and unspecified), sinusitis (includes acute, viral, bacterial), rhinitis, rhinotracheitis, tracheitis, laryngitis, and tonsillitis (including bacterial, streptococcal) b Includes oral herpes, genital herpes, herpes simplex, and herpes virus infection c Includes mouth ulceration, aphthous ulcer, tongue ulceration, and stomatitis d Includes acne, acne cystic, and dermatitis acneiform

idence vations ne and ement. terrupt

Adverse reactions that occurred in <1% of subjects in the SOTYKTU group were herpes zoster.

zations oid use ot been

actions bitor in factor, ascular cluding o those

rved in ug and

PSO-2) enroll ubjects herapy U for at

bjects), zed to group hed to (87%)

nuation o 3.8%

U group

Specific Adverse Reactions Exposure adjusted incidence rates are reported for all the adverse reactions presented below.

Infections In the 16-week placebo-controlled period, infections occurred in 29% of the SOTYKTU group (116 events per 100 person-years) compared to 22% of the placebo group (83.7 events per 100 person-years).

The majority of infections were non-serious and mild to moderate in severity and did not lead to discontinuation of SOTYKTU. In the 16-week placebo-controlled period, serious infections were reported in 5 subjects (2.0 per 100 patient-years) treated with SOTYKTU, and 2 subjects (1.6 per 100 patient-years) treated with placebo.

The most common serious infections reported during the 52-week treatment period were pneumonia and COVID-19.

Malignancies During the 0-to-52-week treatment period of the two clinical trials, PSO-1 and PSO-2 (total exposure of 986 patient-years with SOTYKTU), malignancies (excluding non-melanoma skin cancer) were reported in 3 subjects treated with SOTYKTU (0.3 per 100 patient-years), including single cases each of breast cancer, hepatocellular carcinoma, and lymphoma after 24, 32, and 25 weeks of treatment, respectively.

During PSO-1, PSO-2, and the open-label extension trial in which subjects who completed the controlled trials could enroll, a total of 3 subjects (0.1 per 100 patient-years), developed lymphoma while receiving SOTYKTU after 25, 77, and 98 weeks of treatment.

Laboratory Abnormalities Creatine Phosphokinase (CPK) In the 16-week placebo-controlled period, increased CPK (including Grade 4) was reported in 23 subjects (9.3 per 100 patient-years) treated with SOTYKTU, and 5 subjects (4.1 per 100 patient-years) treated with placebo.

Liver Enzyme Elevations Events of increases in liver enzymes ≥3 times the ULN were observed in subjects treated with SOTYKTU [see Warnings and Precautions]. In the 16-week placebo-controlled period:

In animal reproduction studies, no effects on embryo-fetal development were observed with oral administration of deucravacitinib to rats and rabbits during organogenesis at doses that were at least 91 times the maximum recommended human dose (MRHD) of 6 mg once daily (see Data).

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.

Data Animal data Deucravacitinib was administered orally during the period of organogenesis at doses of 5, 15, or 75 mg/kg/day in rats and 1, 3, or 10 mg/kg/day in rabbits. Deucravacitinib was not associated with embryo-fetal lethality or fetal malformations in either species. These doses resulted in maternal exposures (AUC) that were 266 times (rat) or 91 times (rabbit) the exposure at the MRHD. In a pre- and post-natal development study in rats, deucravacitinib was administered orally from gestation day 6 through lactation day 20, at doses of 5, 15, or 50 mg/kg/day. At 50 mg/kg/day, F1 offspring had reduced body weight gains during the pre-weaning period. After weaning, body weights of affected F1 offspring gradually normalized to control levels. No maternal effects were observed at 50 mg/kg/day (110 times the MRHD based on AUC comparison). No deucravacitinib-related effects on postnatal developmental, neurobehavioral, or reproductive performance of offspring were noted at doses up to 15 mg/kg/day (19 times the MRHD based on AUC comparison).

Lactation Risk Summary There are no data on the presence of deucravacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Deucravacitinib is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU (deucravacitinib) and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.

Data Animal Data A single oral dose of 5 mg/kg radiolabeled deucravacitinib was administered to lactating (post-partum days 8 to 12) rats. Deucravacitinib and/or its metabolites were present in the milk of lactating rats.

Pediatric Use The safety and effectiveness of SOTYKTU in pediatric patients have not been established.

Geriatric Use Of the 1,519 subjects with plaque psoriasis treated with SOTYKTU, 152 (10%) subjects were 65 years or older and 21 (1.4%) subjects were 75 years or older.

During the Week 0-16 period, for those subjects (80 subjects ≥65 years old, including 12 subjects ≥75 years old) who received SOTYKTU without switching treatment arms, there was a higher rate of overall serious adverse reactions, including serious infections, and discontinuations due to adverse reactions compared with younger adults.

No overall differences in effectiveness of SOTYKTU have been observed between patients 65 years of age and older and younger adult patients.

Renal Impairment No dose adjustment of SOTYKTU is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis [see Clinical Pharmacology (12.3) in full Prescribing Information].

•

ALT elevations ≥3 times the ULN was reported in 9 subjects (3.6 per 100 patient-years) treated with SOTYKTU, and 2 subjects (1.6 per 100 patient-years) treated with placebo.

•

AST elevations ≥3 times the ULN was reported in 13 subjects (5.2 per 100 patient-years) treated with SOTYKTU, and 2 subjects (1.6 per 100 patient-years) treated with placebo.

Hepatic Impairment No dose adjustment of SOTYKTU is recommended in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. SOTYKTU is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) [see Adverse Reactions and Clinical Pharmacology (12.3) in full Prescribing Information].

Decreased Glomerular Filtration Rate (GFR) In the 16-week placebo-controlled period in subjects who had moderate renal impairment (eGFR 30-59 mL/min) at baseline, decreased GFR was reported in 4 subjects (1.6 per 100 patient-years) treated with SOTYKTU, and 1 subject (0.8 per 100 patient-years) treated with placebo. Two of the deucravacitinib-treated subjects had worsening of baseline proteinuria.

OVERDOSAGE There is no experience regarding human overdosage with SOTYKTU. In case of overdose, consider contacting the Poison Help line (1-800-222-1222) for additional overdosage management recommendations.

The extent of deucravacitinib elimination by hemodialysis was small (5.4% of dose per dialysis treatment), and thus hemodialysis for treatment of overdose with SOTYKTU is limited.

Lipid Elevations Mean triglycerides increased by 10.3 mg/dL during the 16-week treatment period in subjects treated with SOTYKTU and by 9.1 mg/dL during the 52-week treatment period.

NONCLINICAL TOXICOLOGY Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of deucravacitinib was assessed in 2-year rat and 6-month rasH2 transgenic mouse studies. No evidence of tumorigenicity was observed in male or female rats that received deucravacitinib at oral doses up to 15 mg/kg/day (51 times the MRHD based on AUC comparison).

No evidence of tumorigenicity was observed in male or female Tg.rasH2 mice that received deucravacitinib at oral doses up to 60 mg/kg/day.

Deucravacitinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in an in vitro chromosomal aberration assay (cultured Chinese hamster ovary cells) or in an in vivo rat peripheral blood micronucleus assay.

In male rats, deucravacitinib had no effects on reproductive parameters (mating, fertility, and sperm morphology) or early embryonic development of their offspring at oral doses up to 50 mg/kg/day (224 times the MRHD based on AUC comparison).

Safety Through Week 52 In PSO-1 and PSO-2, the exposure adjusted incidence rate of adverse reactions in subjects treated with SOTYKTU from Week 0 through Week 52 without switching treatment did not increase compared to the rate observed during the first 16 weeks of treatment.

USE IN SPECIFIC POPULATIONS Pregnancy Risk Summary Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drugassociated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 43

03/02/2023 PM 9/18/23 12:23 2:11 PM

In female rats, deucravacitinib had no effects on mating, fertility, or early embryonic parameters at oral doses up to 50 mg/kg/day (171 times the MRHD based on AUC comparison).

PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide) before starting SOTYKTU (deucravacitinib) therapy and each time the prescription is renewed, as there may be new information they need to know. Advise patients of the potential benefits and risks of SOTYKTU. Hypersensitivity Reactions Advise patients to discontinue SOTYKTU and seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see Warnings and Precautions].

Infections Inform patients that SOTYKTU may lower the ability of their immune system to fight infections and to contact their healthcare provider immediately if they develop any signs or symptoms of infection [see Warnings and Precautions].

Inform patients that herpes infections, including serious, may occur with use of SOTYKTU [see Warnings and Precautions].

Malignancies including Lymphomas Inform patients that SOTYKTU may increase their risk of developing malignancies including lymphomas.

Instruct patients to inform their healthcare provider if they have ever had any type of cancer [see Warnings and Precautions].

Rhabdomyolysis Inform patients that SOTYKTU may increase their risk of developing rhabdomyolysis. Instruct patients to immediately inform their healthcare provider if they develop unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever [see Warnings and Precautions].

1787-US-2300018_SOT_Journal_Ad_Access_Dermatology_Resize_3_23_P0476610_v0_01.indd 7 32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 44

Laboratory Abnormalities Inform patients that SOTYKTU (deucravacitinib) may affect certain lab tests, and that blood tests may be required before and during SOTYKTU treatment [see Warnings and Precautions].

Immunizations Advise patients that vaccination with live vaccines is not recommended during SOTYKTU treatment.

Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Instruct patients to inform the healthcare practitioner that they are taking SOTYKTU prior to a potential vaccination [see Warnings and Precautions].

Pregnancy Advise patients to report their pregnancy to Bristol-Myers Squibb Company at 1-800-721-5072 [see Use in Specific Populations].

Manufactured by: Bristol-Myers Squibb Company Princeton, NJ 08543 USA U.S. License No. 1713 © 2022 Bristol-Myers Squibb Company.

SOTYKTU and the Bristol Myers Squibb logo are trademarks of Bristol-Myers Squibb Company.

Issued: September 2022 1787-US-2200566 09/22

03/02/2023 12:23 PM 9/18/23 2:11 PM

may be

tment. lowing taking

ee Use

r 2022 09/22

23 12:23 PM

EMPOWERS MEMBERS THROUGH

EDUCATION & NETWORKING Join our network of biologic coordinators landscape of drug access together.

Sign up today at bcofdermatology.com Connect with BCoD:

32_45_JBCOD_6pgs Membership Survey_Sept/Oct 2023.indd 45

9/18/23 2:11 PM

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

46

46_47_JBCOD_2pgs Drug Charts_Sept/Oct_2023.indd 46

9/18/23 2:12 PM

bcofdermatology.com

47

46_47_JBCOD_2pgs Drug Charts_Sept/Oct_2023.indd 47

9/18/23 2:12 PM

Streamline Medication Approval & Improve Patient Communication

More Than Software – A Practice Management Solution for Biologics Coordination Key Features • Realtime updates for clinic team, patients and industry

• Improves patient outcomes

• Single view dashboard of all patients for both coverage and follow up tasks throughout the entire journey

• Prevents patients “lost to follow-up”

• Advanced patient engagement with alerts and noritications

• And much more…

• Reduces time spent on paperwork and phone calls • Ensures that patient “follow through”

www.rxnexus.com 48_53_JBCOD_5pgs Conference Letter_Sept/Oct_2023.indd 48

9/18/23 2:12 PM

BC OD

Make a Connection Make a Difference

2023 BCOD ANNUAL

CONFERENCE RAWPIXEL.COM - STOCK.ADOBE.COM; CONTRIBUTED

San Antonio, Texas • November 5 – 7, 2023

bcofdermatology.com

49Hill Country Resort JW Marriott San Antonio

48_53_JBCOD_5pgs Conference Letter_Sept/Oct_2023.indd 49

9/18/23 2:12 PM

PRESIDENT'S LETTER

Diagnosed with a Passion to Serve

48_53_JBCOD_5pgs Conference Letter_Sept/Oct_2023.indd 50

Dear BCoD Members, There's a saying that you should walk in someone's shoes to understand their experiences, challenges, and thinking. That advice reminds us to be empathetic to those around us. While you don't have to be a dermatology patient suffering from a skin disease, you can say it fuels my passion daily. BCoD is filled with incredible BCs who aim to improve the patient experience, as a community. I was in those shoes at a young age, and I remain a biologic patient to this day. So, it is personal for me. And it is truly our privilege to bring forth information to members aimed at educating, simplifying, and enhancing processes.

November is approaching, and I couldn't be more excited. The air is brisk, and my son is playing post-season football. Moreover, there is the BCoD Conference! In its third year, BCoD has seen tremendous growth and transformation, and our mission to educate and empower our members has never been stronger.

Those in attendance last year can attest to the energy and engagement of BCs and the saturation of insightful content. I can't wait to see everyone in San Antonio. We say, "Together We Advance," and we mean it.

And to our members and industry partners, we thank you for taking the journey with us to advance patient access. You are vital to our mission, and we truly appreciate your partnership.

HEATHER SAWREY President BCoD, Biologic Coordinator George Washington University, Dermatology ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

50

9/18/23 2:12 PM

WHAT ARE YOU LOOKING FORWARD TO AT THE 2023 BCOD NATIONAL CONFERENCE? “I'm looking forward to expanding my knowledge of the biologic industry and learning more helpful tips that I can bring back not only to my providers and staff, but also to my patients. We strive to give our patients top quality care and I believe that continuing to learn new techniques and staying informed on new information is key. Also looking forward to networking and meeting new BCs. Last year was my first year, and I've kept in touch and reached out when I needed it. Happy to be a part of such a great group of people that strive for the same goal.”

Stephanie Poznanski HIGHTOWER DERMATOLOGY SUN CITY CENTER, FL

“I’m very eager to learn and gather new information and apply it to help me work more efficiently in the field of patient access.

I look forward to learning the utilization of insurance, specialty pharmacy and manufacturer portals that can help my workflow and save me from spending countless hours on the phone. With manufacturer companies making changes to their bridge programs and insurance companies often updating their formularies, there are many changes to step edits and other requirements, and attending this conference opens up a great opportunity to learn from the BC community as to what is working well for our patients.

This will also create bonding, and learning their thoughts and sharing tips on documentation, insurance intricacies and streamlining the process of the workflow.”

Lisa Morris Biologic Coordinator COASTAL SKIN CARE AND WELLNESS CENTER VICTORIA, TX

“I am looking forward to meeting and networking with other biologic coordinators to learn from them and see what their processes are for best practice to help increase efficiency and productivity HALFPOINT - STOCK.ADOBE.COM

to best help and serve the patients. I recognize the importance of these medications and the difficulties that face the patients and practices.

I think the more we can learn from each other and the nuances that we face, the more productive and efficient we can be.”

Leea Rink, Practice Manager DERMATOLOGY AND SKIN SURGERY ERIE, PA bcofdermatology.com

51

48_53_JBCOD_5pgs Conference Letter_Sept/Oct_2023.indd 51

9/18/23 2:13 PM

BC OD We are grateful to these PARTNERS WHO SUPPORT the mission of advancing PATIENT ACCESS. Your information, resources, and technologies empower our members every day.

THANK YOU! 48_53_JBCOD_5pgs Conference Letter_Sept/Oct_2023.indd 52

9/18/23 2:13 PM

AS OF SEPTEMBER 1

48_53_JBCOD_5pgs Conference Letter_Sept/Oct_2023.indd 53

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

ABBVIE ABBVIE abbvie.com abbvie.com

A A

bbVie a global, global, research-driven research-driven biopharmaceutical biopharmaceutical company company committed committed to to bbVie is is a developing developing innovative innovative advanced advanced therapies therapies for for some some of of the the world’s world’s most most complex complex

and The company’s company’s mission mission is is to to use use its its expertise, expertise, dedicated dedicated and critical critical conditions. conditions. The people unique approach approach to to innovation innovation to to markedly markedly improve improve treatments treatments across across four four people and and unique

primary primary therapeutic therapeutic areas: areas: immunology, immunology, oncology, oncology, virology virology and and neuroscience. neuroscience. In In more more than than 75 countries, AbbVie employees are working every day to advance health solutions for 75 countries, AbbVie employees are working every day to advance health solutions for people @abbvie on on Twitter, Twitter, Facebook Facebook or or LinkedIn. LinkedIn. people around around the the world. world. Follow Follow @abbvie

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

54

1787-US-2 54_65_JBCOD_11pages_Spotlight 2023.indd 54

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

Simply committed to patient support We’re working to support eligible patients to access their medication by offering affordability and individualized assistance.

Please scan QR code to learn more about SOTYKTU 360 SUPPORT and to view the terms and conditions.

1-888-SOTYKTU (1-888-768-9588)

SOTYKTU and the related logo are trademarks of Bristol-Myers Squibb Company. © 2023 Bristol-Myers Squibb Company. 1787-US-2300608 08/23

bcofdermatology.com

55

1787-US-2300608_BCOD_Magazine_Ad_R07.indd 1

9/1/23 12:38 PM

54_65_JBCOD_11pages_Spotlight 2023.indd 55

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

DERMAVANT dermavant.com

@DERMAVANT DERMAVANT SCIENCES

D

ermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology.

Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development.

The company’s medical dermatology pipeline includes commercialized, late-stage and earlier-development

product candidates that target specific unmet needs in two of the largest growing immunodermatology markets, plaque psoriasis and atopic dermatitis, as well as other immunological and inflammatory diseases. Dermavant is marketing VTAMA® (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults. The FDA approved VTAMA cream for the topical treatment of mild, moderate, and severe plaque psoriasis in May 2022. For more information, please visit dermavant.com

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

56

54_65_JBCOD_11pages_Spotlight 2023.indd 56

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

GALDERMA galderma.com

G

alderma is a pure-play dermatology category leader, present in approximately 90 countries. We deliver a science-based portfolio of premium brands and services that span the full spectrum of dermatology through Injectable Aesthetics, Dermatological

Skincare and Therapeutic Dermatology. Through our purpose to advance dermatology for every skin story, we are dedicated to meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals.

bcofdermatology.com

57

54_65_JBCOD_11pages_Spotlight 2023.indd 57

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

GENEFIC SPECIALTY PHARMACY: Redefining Personalized Healthcare

G

enefic Specialty Pharmacy stands at the forefront of transforming personalized healthcare. With a clear and unwavering mission to redefine the Specialty Pharmacy experience by providing every patient with high-touch care, Genefic sets the standard in patientcentricity, process efficiency, and improvement of outcomes. This mission serves as a guiding light, ultimately propelling the pharmacy forward in its pursuit of excellence.

Driven by a vision to become the epitome of a best-in-class Specialty Pharmacy solution, Genefic draws from more than 30 years

of knowledge and experience in the field. Genefic is well-prepared to lead the charge in reshaping healthcare delivery and holds a 50-state license while upholding all necessary URAC and NABP accreditations. The commitment to reduce workloads and ensure a hassle-free experience for all stakeholders underscores Genefic's dedication to setting new standards of quality.

Genefic's philosophy revolves around harnessing the power of technology to transform and improve processes and outcomes.

By creating innovative solutions that enhance the lives of patients

and streamline operations for healthcare professionals, the company epitomizes the synergy of healthcare expertise and technological innovation.

Genefic Specialty Pharmacy is poised to revolutionize the specialty biologics space, promising a future where personalized healthcare is accessible, seamless, and patientfocused. With its unwavering mission, visionary goals, and innovative philosophy, Genefic Specialty Pharmacy stands as a beacon of progress in the healthcare industry.

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

58

54_65_JBCOD_11pages_Spotlight 2023.indd 58

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

NAVIGATING PATIENT ACCESS Get the help you need.

You may be treating patients for atopic dermatitis or nonsegmental vitiligo with a treatment from Incyte Dermatology. As you know, Payers often have specific requirements – like prior authorizations – that can make patient access part of your workday.

Meet your Field Pharmacy Manager (FPM).

It’s easy to connect with your FPM.

Incyte FPMs are experts on insurance and reimbursement requirements.

• Log into the BCoD members portal • Search “Incyte Field Pharmacy Manager Support” • Reach out to your FPM for the information and assistance you need to help your patients access their prescribed medication

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

Incyte and the Incyte logo are registered trademarks of Incyte. © 2023, Incyte Corporation. MAT-DRM-01041 08/23

bcofdermatology.com

59

54_65_JBCOD_11pages_Spotlight 2023.indd 59

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

NATIONAL BIOLOGIC COORDINATORS D A Y NOVEMBER 1

Janssen Supports and Celebrates Biologic Coordinators Like You

Biologic coordinators are some of the most important advocates for patients in health care–yet too often, their work goes unrecognized. A biologic coordinator is an essential member of a medical practice’s office staff–a doctor, nurse, physician’s assistant, medical assistant and/or an office/practice manager–that helps patients navigate the sometimes complex process of obtaining access to prescribed biologic medications.

As a connecting force between the patient, prescribing healthcare provider, specialty pharmacy, manufacturer

and insurance company, biologic coordinators work hard to ensure patients are able to start and stay on their prescribed biologic treatments.

November 1, 2023, marks the third annual National Biologic Coordinators Day–a day established by The Janssen Pharmaceutical Companies of Johnson & Johnson to recognize the daily commitment of biologic coordinators who go above and beyond for the patients they serve. We are proud to shine a light on these unsung heroes of patient care.

6 2

© Janssen Biotech, Inc. 2023 08/23 cp-334516v2

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

60

54_65_JBCOD_11pages_Spotlight 2023.indd 60

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

F DA A p p r

ove d

DISCOVER THE DIFFERENCE AT TALTZ.COM/HCP 6CNV\ KU C TGIKUVGTGF VTCFGOCTM QYPGF QT NKEGPUGF D[ 'NK .KNN[ CPF %QORCP[ KVU UWDUKFKCTKGU QT CHƂNKCVGU 22 +: 75 .KNN[ 75# ..% #NN TKIJVU TGUGTXGF

LILLY 1-800-545-5979 (1-800-LillyRx)

lilly.com olumiant.com

L

illy is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those

who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit lilly.com and newsroom.lilly.com/social-channels.

ELI LILLY AND COMPANY

@ELILILLYCO

ELI LILLY AND COMPANY

bcofdermatology.com

61

54_65_JBCOD_11pages_Spotlight 2023.indd 61

9/18/23 2:13 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

NEXTECH

landing.nextech.com/bcod-demo

N

extech understands each physician has specific needs that must be fulfilled by their Practice Management and EMR vendor in order to meet and exceed the demands of their patients and

the general healthcare industry. That is why Nextech continues to evolve its product with the thoughtful and strategic input of specialty physicians.

Nextech’s Electronic Medical Record and Practice Management software is fully integrated to boost workflow efficiencies, manage practice revenue trends, enhance patient engagement and increase productivity through its innovative mobile platform.

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

62

54_65_JBCOD_11pages_Spotlight 2023.indd 62

9/18/23 2:14 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

PFIZER DERMATOLOGY PATIENT ACCESS

T

he Pfizer Dermatology Patient Access™ program is designed to provide savings and support resources for patients, and to help

them access the Pfizer dermatology medication that’s been prescribed for them. We can help patients along their dermatology treatment access journey by supporting them every step of the way.

bcofdermatology.com

63

54_65_JBCOD_11pages_Spotlight 2023.indd 63

9/18/23 2:14 PM

Help eligible patients start and stay on track with their therapy The DUPIXENT MyWay® patient support program can help facilitate patient access to DUPIXENT® (dupilumab) throughout the treatment journey.

DUPIXENT

myway)

Coverage support DUPIXENT MyWay provides assistance navigating the insurance process with benefits investigations, prior authorization support, and education about the appeals process.

Patient access support DUPIXENT MyWay may have support for eligible patients who need help with their out-of-pocket costs.

Education and support Every enrolled patient is assigned a dedicated DUPIXENT MyWay Case Manager, who takes a patient-centric approach to providing tools, support, resources, and education throughout the treatment journey.

Support for your patients begins with a complete DUPIXENT MyWay Enrollment Form You can help patients enroll in DUPIXENT MyWay by: • Faxing the form to DUPIXENT MyWay at 844-387-9370 • Submitting the form through the DUPIXENT MyWay Document Drop at www.patientsupportnow.org

For more information: Visit us on the exhibit floor Call DUPIXENT MyWay at 1-844-DUPIXEN(T) (1-844-387-4936) Option 1, Monday–Friday, 8 am – 9 pm ET Learn more at DUPIXENThcp.com For any questions or concerns, or to report side effects with DUPIXENT® (dupilumab), please contact 1-844-DUPIXEN(T) (1-844-387-4936) Option 1, Monday–Friday, 8 am – 9 pm ET

sanofi |

DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology. © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

DUP.23.08.0466 09/2023

54_65_JBCOD_11pages_Spotlight 2023.indd 64

D UPIXEN

ry

(dupilumab) Injection

9/18/23 2:14 PM

S PECIAL CO N F E RE NCE P A R T N E R SECT I O N

t

o

UCB

ucb-usa.com

A

t UCB, we come together every day to work, laserfocused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. It is our culture of care, embodied by our patient value strategy. That’s because how we do business— from discovery to development to delivery—has been transformed and redesigned around the patient and

their individual experience. Patients are at the heart of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, more impactful solutions are on the horizon.

With a team of approximately 8,300 employees and operations in nearly 40 countries, we are a global biopharmaceutical company

investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia.

Additional U.S. UCB sites include R&D in Raleigh and Durham, North Carolina, Bedford and Cambridge, Massachusetts and Seattle, Washington, and a policy office in Washington, D.C.

bcofdermatology.com

65

54_65_JBCOD_11pages_Spotlight 2023.indd 65

9/18/23 2:14 PM

BUILDING A NOTE

MONKEY BUSINESS - STOCK.ADOBE.COM

KEYS TO SUCCESS FOR GETTING BIOLOGIC THERAPIES APPROVED

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

66

66_69_JBCOD_4pgs Building a Note_Sept/Oct_2023.indd 66

9/18/23 2:14 PM

By Kereen Crider BS, PACS, BIOLOGICAL COORDINATOR, PORTER PREMIERE DERMATOLOGY AND SURGERY CENTER

In a conversation with Dr. Anthony Porter of Porter Premiere Dermatology and Surgery Center in Melbourne, Florida, Biologic Coordinator Kereen Crider discusses why a stellar note is critical for obtaining approved biologic therapies.

“It is so important we aren’t just producing words on a page. The note should have substance and specificity. THE END GOAL IS TO GET THE PATIENT THE MEDICATION THEY NEED.” —DR. ANTHONY PORTER, PORTER PREMIERE DERMATOLOGY AND SURGERY CENTER

What is HPI? HPI stands for “history of present illness.” This is important so that a complete narrative portrays what is going on with the patient. HPI is usually recorded by the medical assistant, and it’s a good idea to put everything in a patient’s own words to relay what they are currently experiencing. Plan to make this the well-rounded bulk of the note.

The medical assistant should ask pertinent information related to the condition including disease symptoms, severity and length of time the patient has present symptoms. bcofdermatology.com

67

66_69_JBCOD_4pgs Building a Note_Sept/Oct_2023.indd 67

9/18/23 2:14 PM

Diagnosis Section

The next key part of the note a BC should look for is the diagnosis section. This is where the prescriber diagnoses the actual condition. It may also include a biopsy to confirm or substantiate the diagnosis. (Obviously, HS is a clinical diagnosis only.) When I speak with a patient, this is where good scribing comes in to play.

I ask the patient to reiterate some of the questions they may have already been asked. For this portion of the note, use the acronym “OLD CARTS.”

ONSET L O C AT I O N D U R AT I O N CHARACTERISTICS A L L E V I AT I N G A N D A G G R A V AT I N G FA C T O R S (What triggers it?)

R A D I AT I N G O R R E L I E V I N G FAC T O R S (What helps, what calms it down?)

TIMING (How long have they had it?)

Disease-Specific Key Points Within the Note Most insurances have standard information necessary to approve certain medications, so I make sure to address this within the note. BCs should keep an eye out for these and draw attention them. Examples of things to highlight, include: 20 NODULAR LESIONS FOR PN SALT SCORE OF 50 OR HIGHER FOR ALOPECIA AREATA PASI SCORE FOR PSORIASIS BODY SURFACE AREA AND ITCH INTENSITY SCALE IGA SCORE FOR ANY INFLAMMATORY CONDITION

SEVERITY (Constant or gradual?)

MASTER1305 - STOCK.ADOBE.COM

OLD CARTS:

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

68

66_69_JBCOD_4pgs Building a Note_Sept/Oct_2023.indd 68

9/18/23 2:14 PM

BC PEARLS Look for the provider cues that relay how the disease affects sleep patterns.

(This is a big one. If your sleep patterns are off, it affects the patient’s quality of life immensely.)

Family history of the same condition.

Dr. Anthony Porter jumps for joy knowing biologics were approved for his patients.

What else affects the condition?

(Hopefully this is documented, i.e. stress.)

What Helps Aid Approvals?

Look for the documentation of significant discomfort and pain.

Clear documentation of what has been tried and failed for their disease specifically.

Length and intensity of itching; itch scale.

(10 being the worst)

A good HPI with a quality physical exam that documents the intensity and severity of the disease.

Good communication between the provider and biologic coordinator. (I set aside time weekly to discuss with my BC any issues, denials or pharmacy faux pas, to come up with solutions that best fit a patient’s specific needs.

This can include starting patient on samples, addressing reactions and signing appeal letters.)

Quality of life.

(Stress this point and highlight.)

If the provider can dictate a letter of medical necessity within the note or separately, this helps bolster the case.

Paint the best picture of your patient’s condition so that the insurance companies have no other choice but to approve the requested therapy.

bcofdermatology.com

69

66_69_JBCOD_4pgs Building a Note_Sept/Oct_2023.indd 69

9/18/23 2:14 PM

RECOGNIZING BIOLOGIC COORDINATORS B

iologic Coordinators of Dermatology (BCoD) applauds our members and

access managers who ensure a positive patient experience. These dedicated

professionals are committed to their patients, helping them secure the types of therapy needed. For our fall issue, we would like to recognize four stand-out biologic coordinators through the words of their dermatology offices. BCoD salutes these individuals for their valiant effort in advancing patient access.

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

70

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 70

9/18/23 2:15 PM

LETTER of RECOGNITION BC OD

Tammy Dennison

BIOLOGIC COORDINATOR DermSpecialists A FOREFRONT DERMATOLOGY PRACTICE Elizabethtown, KY

“I would like to nominate our team lead and biologic coordinator Tammy Dennison.

She has worked in our office for over 15 years, and for the last 8-10 years, she has managed biologic access for patients. She is tireless in her efforts to gain access for patients and help them receive their needed medication.

I can think of many instances where she found ways to help get medication approved or get financial assistance for patients when it seemed that they were out of luck. She finds creative ways to help them and personally communicates progress with them. I often hear compliments from patients about how much she has helped them. I also hear accolades from drug company representatives that she is one of the best coordinators in their region or the country.”

—CHAD A BROWN, MD

bcofdermatology.com

71

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 71

9/18/23 2:15 PM

LETTER of RECOGNITION BC OD

Patrice Kane

BIOLOGIC COORDINATOR PENNSYLVANIA DERMATOLOGY GROUP, P.C. Huntingdon Valley, PA

“The biologic coordinator position is integral to any successful dermatology practice. It’s also one of the hardest jobs in the dermatology practice. Our biologic coordinator, Patrice Kane, works tirelessly day after day spending hours on the phone with insurance companies to make sure our patients get the medication they need as quickly as possible. I know there are days that she is extremely frustrated, yet she continues to push forward, knowing that the job is bigger than her and the patients are the ones who suffer with any delayed access to medicines. This job is sometimes thankless, as the expectations of the patients are different than the reality of the timeline it takes to coordinate these medications and get approvals from insurance.

We are so appreciative of everything she does for our practice and everything that she does to fight for our patients. Our practice would not be the same without her.

Although she knows this, we would love to highlight her as someone who has worked so hard and will continue to work hard for the betterment of our patients. Other biologic coordinators could learn a lesson from Patrice, as she has all the tricks from supplementing patients with samples, to writing stellar letters of appeal, to checking on status daily until she gets approvals.”

— LYNNE JASTRZEBSKI, OFFICE MANAGER

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

72

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 72

9/18/23 2:15 PM

LETTER of RECOGNITION BC OD

Verna Maltese

,

BIOLOGIC COORDINATOR NOMS DERMATOLOGY Sandusky, OH

“Verna goes above and beyond to make sure our patients continue to get their medications, whether that means spending hours on the phone with a pharmacy fighting for the patient, combing through the literature to find new and creative arguments for insurance companies to get patients coverage, or mastering the numerous patient assistance programs out there to make sure medications stay covered and affordable. Our patients and office staff enjoy working with her, and we are so lucky to have her on staff.”

— EMILY PETITTI, MD

bcofdermatology.com

73

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 73

9/18/23 2:15 PM

LETTER of RECOGNITION BC OD

Ysabel Capuzi BIOLOGIC COORDINATOR DUNDEE DERMATOLOGY West Dundee, IL

“It is delightfully satisfying to have the opportunity to nominate our biologic coordinator, Ysabel Capuzi, for recognition of her many years of contribution in her increasingly crucial role at Dundee Dermatology.

Medical staff and patients alike continually share their high esteem and confidence in Ysabel’s expert handling of all aspects of specialty medication coordination. What makes Ysabel stand out is her ability to connect with patients of all backgrounds, especially our large population of native Spanish-speakers.

As a Spanish speaker of Mexican heritage, Ysabel understands the cultural needs and challenges our non-English speaking patients face. She can explain complex treatment plans in a patient’s native tongue, ensuring full understanding. Patients immediately feel at ease with Ysabel and trust her guidance and her confident demeanor.

Beyond invaluable bilingual skills, Ysabel is unwaveringly dedicated to each patient. She helps them navigate a challenging, confusing and often adversarial system. In the past year, Ysabel confirmed insurance benefits, assisted with copay applications, coordinated injection training and handled all medication logistics for well over 100 patients, ensuring access to essential care.

Ysabel’s grace under pressure, reassuring and confident demeanor, and problem-solving skills are invaluable to our patients. Even when dealing with insurance denials or pharmacy delays, Ysabel handles every obstacle with professionalism and care, and she advocates fiercely for patients. Also, her commitment as a bicultural and bilingual biologics coordinator has increased health equity and the quality of care we provide.

Ysabel Capuzi deserves recognition and acknowledgement for her tireless advocacy for the medical needs of dermatology patients in a very diverse patient population.”

— PAUL GETZ, MD FAAD

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

74

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 74

9/18/23 2:16 PM

LETTER of RECOGNITION BC OD

Zue Dejesus BIOLOGIC COORDINATOR GLICK SKIN INSTITUTE Margate, FL

“I am Dr. Brad Glick, and I've been in practice for 28 years. We provide comprehensive care for our patients with immune-mediated diseases, and we utilize a lot of systemic therapies. I'd like to highly recommend a biologic/systemic therapy coordinator, Zue Dejesus, who is a dedicated staff member in my dermatology practice.

While Zue has been with our practice for less than a year, what she has accomplished is remarkable.

Her turnaround time for most stomach therapies with a definitive answer is about 48 to 72 hours, sometimes even sooner. Moreover, she cares about patients, converses with them regularly and keeps them in the loop about the sometimes-challenging activities we face with drug approvals these days.

Additionally, in simplistic terms, as part of the mantra of our practice, she 'fights the fight' to get the systemic therapies for our patients.

I'd like to recognize Zue for her efforts, going far above and beyond for our practice and patients.”

— BRAD P. GLICK, DO, MPH, FAAD

bcofdermatology.com

75

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 75

9/18/23 2:16 PM

BIOLOGIC COORDINATORS OF DERMATOLOGY

2023 NATIONAL CONFERENCE

Join the largest community of biologic coordinators and office staff supporting the patient access journey. The BCoD conference is the premier experience for members and industry partners to come together for education, training, networking, and thoughtful insight exchanges.

W

•

CONFERENCE HIGHLIGHTS!

•

• First-of-its-kind Certification • Industry Networking Pavilion • 25+ Educational Talks • Touch Cases Blitz

NOV

5– 7

•

•

•

JW MARRIOTT COUNTRY HILL RESORT SAN ANTONIO, TX

C q m

Meet peers and market expects while making lasting industry connections!

N

NO REGISTRATION FEE Register here today!

Rev.G

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 76

9/18/23 2:16 PM

Redefining Personalized Healthcare

A biologic-focused pharmacy experience like no other.

The Choice of Biologic Coordinators and a Proud Benefactor Sponsor of BCoD!

WHY GENEFIC SPECIALTY PHARMACY? •

LICENSED IN 50 STATES

•

Optimal management across ALL patient populations

•

Rigorous care management, patient engagement, and critical data reporting

•

Cutting-edge technology for streamlined operations and improved efficiency

•

Removes burden from office staff, effectively freeing up employees

Office: (833) 928-7660 Fax: (833) 928-7661 www.GeneficRx.com

ELEVATED PATIENT CARE UNMATCHED EXPERTISE 30+ years of providing specialty pharmacy services with proven results.

HASSLE-FREE EXPERIENCE Streamlined processes and improved efficiency for patients and providers.

Care for your complex patients, improve clinical quality and safety, harness clinical data, and manage associated costs more effectively.

REGULAR COMMUNICATION

NATIONALLY-LICENSED AND ACCREDITED

PATIENT-CENTERED EXCELLENCE

Constant communication and updates throughout the treatment journey.

Tailored, high-quality experience that enhances patient healthcare outcomes.

Rev.GSP_MM1016_09/11/23

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 77

Join Genefic Specialty Pharmacy in redefining personalized healthcare!

9/18/23 2:16 PM

NOMINATE A BIOLOGIC COORDINATOR FOR THEIR SERVICE

Biologic Coordinators of Dermatology (BCoD) understands the commitment to patient care. Our members are at the forefront of access, helping achieve patients’ confidence within their skin.

BCoD would like to acknowledge biologic coordinators across the country who are advocates for their patients, work tirelessly to find solutions and resources to assist in drug access, and create an atmosphere focused on celebrating the patient.

To all the biologic coordinators working for the dermatology patient, we applaud you!

Please submit nominations to contact@bcofdermatology.com with a description and example of how the biologic coordinator demonstrates a dedication and work ethic for patient care.

Individuals will be highlighted in future publications.

Any content will be reviewed with offices for compliance and privacy purposes.

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 78

9/18/23 2:16 PM

Guiding You Every Step of the Way We offer personalized care for patients living with complex and chronic conditions, including:

> Limited distribution medications and biosimilars access

> Home infusion and support from our pharmacists and nurses

> Educational resources to help patients manage their medication

> Benefits investigation and financial assistance support

Learn more by contacting us today Sales@AcariaHealth.com | 800.511.5144 © 2023 AcariaHealth. All rights reserved. A2018_230404

70_79_JBCOD_5pgs Recommendation Letters_Sept/Oct_2023.indd 79

AcariaHealth.com

9/18/23 2:16 PM

tgrheeat n i k p pum

KRIINA2000 - STOCK.ADOBE.COM

KNIVES OUT! ’TIS THE SEASON TO GET CRAFTY AND CARVE UP SOME SPOOKY FUN

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

80

80_83_JBCOD_3pgs Pumpkin Carving Sept/Oct_2023.indd 80

9/18/23 2:16 PM

By Eileen Bartels

B

ring on the pumpkin-spiced lattes, scary movies and pet costumes. Symbolic of every Halloween is the humble pumpkin. (More than 150 million Americans

buy one every October.) The tradition of carving pumpkins dates back to ancient Celtic times, with the Irish bringing the practice to America. This year, join Linus in

PUMPKINS BY MICHAEL FLIPPO - STOCK.ADOBE.COM

the pumpkin patch and get ready to create your very own great pumpkin.

PICK OF THE CROP

TOOLS OF THE TRADE

Selecting a fresh healthy pumpkin ensures longer lasting decor.

The ideal pumpkin is firm to the touch with a deep orange color and hard rind. The greener the stem, the fresher the pumpkin. A stem that’s too dry or brown is an older pumpkin. Thump the side and listen for a hallow sound, indicating health. Look for a flat bottom to prevent rolling. And, obviously, avoid those with soft spots or visible decay.

Also think outside of the round-pumpkin box. Many farmers grow heirloom pumpkins and gourds in a variety of colors and with rinds featuring bumpy skin—ideal for Halloween.

You’ll need a good pumpkin carving kit. Drugstores sell cheap plastic kits for under $10, but this year consider an upgrade. Amazon offers a number of higher-quality carving sets. The better the tool, the less chance the handle breaks mid-spooky smile cut. I purchased a kit from Williams Sonoma over a decade ago, and every October I roll out the orange canvas filled with every carving tool I need. A good kit will last you a lifetime of Halloweens.

bcofdermatology.com

81

80_83_JBCOD_3pgs Pumpkin Carving Sept/Oct_2023.indd 81

9/18/23 2:16 PM

HAVE A VISION Once you have the tools, it’s time to look for inspiration. Are you going for a spooky haunted house vibe, social commentary or way to make first-time trick or treaters smile? Search the internet for ideas. You’ll find templates to carve or paint everything from Baby Yoda to Halloween classics like witches, cats or bats. Print your favorite template, tape it to the pumpkin and carve. Patterns can be found for both carving or painting.

Have a fear of combining sharp objects with small children? Painting a pumpkin is a great option—plus, the pumpkin will last a little longer.

Depending on temperatures, a carved pumpkin will only last three to five days on the counter before drawing fruit flies or on the porch before becoming a squirrel motel.

The key to a lasting coat of paint on pumpkins is to mix tempura or kid-friendly washable paint with school glue in a 50/50 ratio, this allows the paint to stick to the pumpkin skin and prevents peeling and flaking.

Consider adding a little dazzle to your pumpkin with glitter. Let kids apply school glue and top with glitter.

Simple ideas can yield big designs. Paint a pumpkin white, and use a black marker to create a Hello Kitty face; stack a trio of white painted pumpkins and make Frozen’s Olaf; let the kids paint a pumpkin green, and you are just a few black Sharpie marks from Frankenstein.

For added oomph, Crayola makes neon paints that will stand out.

And Glow Magic offers glow-in-the-dark paint. Swap a standard front porch light bulb with a black light bulb available at drug and hardware stores, then pair with a glow-in-the-dark painted pumpkin and you’re Halloween ready.

WHAT’S ON THE INSIDE COUNTS

If you’re carving your pumpkin, you’ll find a tasty treat inside. Once you gut and clean out the interior, don’t toss that treasure trove of goodness. Send the kids to the sink with a strainer to separate the seeds from the pulp. Rinse and dry the seeds. Toss the seeds in bowl with a little olive oil and seasoning. Spread on a cookie sheet and bake at 350 degrees for twenty minutes, shaking the pan occasionally to move seeds. Roasted pumpkin seeds are a great snack or salad topper.

GOURDS © PIXARNO- STOCK.ADOBE.COM ; CHILD PAINTING PUMPKINS © KRIINA2000- STOCK.ADOBE.COM

GLITTER AND GLOW

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

82

80_83_JBCOD_3pgs Pumpkin Carving Sept/Oct_2023.indd 82

9/18/23 2:17 PM

Blank_sin

TA K E A NEW LOOK VISIT INCYTE AT THE 2023 BCoD ANNUAL CONFERENCE Incyte and the Incyte logo are registered trademarks of Incyte. © 2022, Incyte Corporation. MAT-DRM-00755 09/22

Blank_singleAD.indd Pumpkin 1 80_83_JBCOD_3pgs Carving Sept/Oct_2023.indd 83

9/18/23 9/18/23 11:06 2:17 AM PM

IRISSCA - STOCK.ADOBE.COM

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

84

84_89_JBCOD_7pgs Mental Health Tips Sept/Oct_2023.indd 84

9/18/23 2:34 PM

By Dr. Derek Berberian

NORTH JERSEY HEALTH AND WELLNESS

Mental Wellness 1 6 TIPS FOR MAINTAINING YOUR WELL-BEING THIS FALL

N

ow that fall is here, the new season brings a variety of changes to our everyday routines. But we’re not just

talking about swapping flips-flops for boots and iced coffee...

DON’T LET COOLER TEMPERATURES STOP YOU FROM GETTING OUTSIDE

IRISSCA - STOCK.ADOBE.COM

Even if it’s a quick walk around the block, spending time outside to get some fresh air can do wonders for your mental wellness.

Some of our favorite ways to enjoy the outdoors during the fall include picnics with hot apple cider, hiking on new trails, and going apple picking.

The colors will be at their peak this time of year, so it should be easy to find something beautiful wherever you go! bcofdermatology.com

85

84_89_JBCOD_7pgs Mental Health Tips Sept/Oct_2023.indd 85

9/18/23 2:34 PM

SET “NO PHONE ZONE” TIMES FOR YOURSELF

3

phone should stay out of sight, out of mind. By doing so, you will not only be more engaged in the present, but you will also be less preoccupied by things that don’t require your attention at that moment.

Fall is a time of change.

But it is also a reminder that our mental health needs to be taken care of properly.

These tips can help you maintain mental wellness at this turning point in the year, and we encourage you to share them with anyone who may need guidance when it comes to maintaining positive mental wellness in the fall season.

GET IN THOSE ZZZ’S! Because it helps regulate hormones in the brain that affect our emotions, energy levels, cognitive abilities, appetite, and more, sleep plays a role in mental wellness. Sleep deprivation can also cause you to have trouble thinking clearly or remembering things, which makes it hard for your work performance at school or on the job. When this happens, it can cause a lack of confidence and lower self-esteem, which can take a toll on our mental health.

Therefore, creating a sleep schedule and sticking to it is so crucial for staying on top of our day-to-day.

TIM-FOSTER/UNSPLASH.COM; NEW AFRICA - STOCK.ADOBE.COM

2

Do you often feel like your phone is constantly occupying your time, whether that means scrolling social media platforms or checking work emails for hours at a time? It’s common for this to happen to many individuals, especially young adults who have shown an increase in mental health issues due to digital media over the last decade.

While a little technology is okay and occasionally necessary, the goal should be to moderate the amount of time you spend in front of the screen. Family dinners, road trips with friends, and date nights are just a few examples of when our

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

86

84_89_JBCOD_7pgs Mental Health Tips Sept/Oct_2023.indd 86

9/18/23 2:34 PM

4

STUDIO ROMANTIC - STOCK.ADOBE.COM

MOVE YOUR BODY!

84_89_JBCOD_7pgs Mental Health Tips Sept/Oct_2023.indd 87

Exercise is a key part of our physical, mental, and emotional wellness.

Getting in 30 minutes of light, moderate, or vigorous activity can help improve your mood, reduce stress and anxiety, alleviate symptoms of depression, and strengthen the immune system. When you exercise your heart pumps blood throughout the body, which releases endorphins that make us feel good or “high.” Exercise also provides a sense of accomplishment for many people when they set personal goals like finishing a 5K or completing their first marathon. Yoga is another terrific way to get in a more relaxed workout, reset your inner well-being, and keep up your mental wellness in the fall.

9/18/23 2:34 PM

5 MAINTAIN A WELL-BALANCED, NUTRITIOUS DIET

ELLA OLSSON/UNSPLASH.COM

We all know that food can have a significant impact on our physical health. But did you know what we eat can also influence our mental health? For example, eating too much sugar causes mood swings, while fatty foods can slow down blood flow in your body. In contrast, eating a balanced diet that is rich in fruits and vegetables, whole grains, lean protein, and omega-3s may offer a mood boost and help you feel more grounded and less stressed.

It can also give you the fuel you need to function at your best, making for more energized, productive days!

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

88

84_89_JBCOD_7pgs Mental Health Tips Sept/Oct_2023.indd 88

9/18/23 2:34 PM

SET BOUNDARIES FOR YOURSELF AND STICK TO THEM

SNAPVAULT - STOCK.ADOBE.COM

6

It is important to set boundaries for your time so you can focus on giving your energy to what is most important and avoid feeling overwhelmed. Sometimes, it can be extremely difficult to say no to friends, social functions, or big plans that require a lot of your time.

But the key is to remember times in the past when overstretching yourself caused you stress, anxiety, or frustration afterward. By creating a schedule that is healthy and maintainable, you’ll show others that you respect your time, which will teach them how to also respect your time.

To learn more about North Jersey Health and Wellness, visit njhwllc.com or contact (201) 588-3491.

This isn’t just about healthy skin.

It’s helping people feel good in their own skin.

LIVE AREA 8" x 5"

This is one of many moments made possible by the inspirational work of Biologic Coordinators of Dermatology. Your tireless efforts make us glow with pride.

3213877-3919 | ©2023 Walgreen Co. All rights reserved.

bcofdermatology.com

89

84_89_JBCOD_7pgs Mental Health Tips Sept/Oct_2023.indd 89

9/18/23 2:34 PM

A N D DS N I M P , Y OUR WRITER TOM CONNOR HAD THE ROUGH JOB OF VISITING SOME SOUTHERN CONNECTICUT SPAS TO FIND OUT JUST WHAT THE GUYS ARE UP TO.

IT IR

BO D

COMING OFF-SCREEN AND BACK TO IN-PERSON MEETINGS AND DATING, GUYS WANT TO LOOK AND FEEL NOT LIKE THEIR OLD SELVES, BUT LIKE THEIR NEW, POST-PANDEMIC SELVES—YOUTHFUL, HEALTHY AND READY TO RE-ENGAGE WITH THE WORLD

RUSLAN GRUMBLE - STOCK.ADOBE.COM ; OPPOSITE PAGE BY VALUA VITALY - STOCK.ADOBE.COM

HE TIME ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

90

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 90

9/18/23 2:28 PM

Massage is just one of the popular options for men.

W

e’ve been looking at ourselves on-screen for more than three years, and it's not always pretty. The pandemic has left many men with more wrinkles and

weight, less hair and energy, and a general disapproval of the way we look.

“Studies show that the increase of webinars and virtual meetings have led to an increase in facial dissatisfaction overall,” notes Kim Nichols, M.D., the celebrity dermatologist and owner of NicholsMD of Greenwich, CT. So what? We’re guys! Who cares how we look? Well, it’s finally time to admit the obvious: We do! Women, of course, have long known both the benefits and the sublime pleasures of spa treatments. And for almost as long, they’ve been trying to get the men in their lives—husbands, boyfriends, fathers, brothers and sons—to experience them, too. » bcofdermatology.com

91

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 91

9/18/23 2:28 PM

Making changes to one's face takes time— and a strategy.

Men can work on skin perfection with deep-cleansing facials.

ANDREY KISELEV - STOCK.ADOBE.COM

Now, as guys are back to in-person meetings and dates in real time, we’re having to do so without Zoom’s “Touch up my appearance” feature or the filter that smooths wrinkled skin. In fact, we’re steadily leaving virtual rooms and showing up in lightfilled, calm and soothing spas in record numbers. According to the International SPA Association, men’s presence in spas has shot up from 31 percent ten years ago to 47 percent today.

In the past, guys had to travel to the grand spas of Europe for aesthetic treatments or to only a handful of iconic American spas— The Golden Door in Southern California during Men’s Week, for example, or the Homestead in Hot Springs, Virginia (full, obnoxious disclosure: I’ve been to both). But the intersection of Covid, prolonged screen time and men’s growing concern for their health and wellness has given rise not only to new aesthetic centers, but also to the opening of half a dozen or more medical spas across Fairfield County in the past two years alone.

SO WHAT? WE’RE GUYS! WHO CARES HOW WE LOOK? WELL, IT’S FINALLY TIME TO ADMIT THE OBVIOUS: WE DO!

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

92

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 92

9/18/23 2:28 PM

T

BOD

Y

IND A ND SP IR I

,M

THE ZOOM EFFECT

MIRROR,MONTEGO6 - STOCK.ADOBE.COM; ALL OTHERS CONTRIBUTED

L

aunched in 2013, Zoom reported 200 million— both free and paying— daily meeting participants in March 2020, the first official month of the Covid pandemic.

According to Business Insider, by the following month another 100 million users were in daily Zoom meetings. But enough about them! Seeing myself on Zoom one night earlier this year, I realized I looked like Ted Kaczynski, the Unabomber, the day the FBI pulled him from his remote cabin in rural Montana after more than two decades of living in isolation. I felt like turning myself in.

“The Zoom Effect is a real phenomenon,” says Merry Thornton, who opened Element Medical Aesthetics in New Canaan, CT, in March of this year. “The pandemic has increased sensitivity to looking old and tired.”

Bags under the eyes and flabby skin on the neck—these, she and others say, are the result both of the stress from pandemic isolation and from the virus itself.

NICHOLSMD OF FAIRFIELD Fairfield, CT NICHOLSMD OF GREENWICH Greenwich, CT

FACING OURSELVES

G

iven the prominence of the face, an ideal starting point is a thirty-minute Hydrafacial, a deep-cleansing spa treatment that cleans, extracts and hydrates the skin and neck.

And an ideal spa for the treatment is NicholsMD of Fairfield, CT, the third office of celebrity dermatologist Kim Nichols, M.D., who, with perfect skin, has appeared on Today and The Dr. Oz Show. The new office opened in May of this year in the Brick Walk near Fairfield’s downtown.

Alyson, a youthful-looking registered nurse, has me lie back on a comfortable white lounge chair. After she washes my face— something I clearly should be able to do myself—she uses a laser device with HydroPeel Tips and Vortex-Fusion technology on the skin. The device, I learn, creates a vortex-like effect to vacuum up dead skin and extract “debris,” as she calls it, from the pores.(A superficial detail that, nonetheless, preoccupies me: The “debris” from the vacuumed pores gets captured and collected in a trap.

Trust me, you don’t want to know anything more about this.)

The final step in the treatment has her infusing the pores with nourishing serums and intense moisturizers and saturating the surface with antioxidants and peptides. I leave looking fabulous.

below: The calming minimalism of Element Medical Aesthetics

above: The calming minimalism of Element Medical Aesthetics

ELEMENT MEDICAL AESTHETICS New Canaan, CT

GIVEN THE PROMINENCE OF THE FACE, AN IDEAL STARTING POINT FOR POST-ZOOM CARE IS A THIRTY-MINUTE HYDRAFACIAL, A DEEP-CLEANSING SPA TREATMENT THAT CLEANS, EXTRACTS AND HYDRATES THE SKIN AND NECK.

PAINTED-WALL SYNDROME

F

aces are multifaceted, so medical spas like NicholsMD divide treatment sessions into facial units that require different solutions and that offset the potential danger of too much treatment in one area. The problem with these treatments, however, is similar to that of painting one wall of a room: By comparison, the other walls immediately cry out for repainting.

I make an appointment to see Merry Thornton at Element Medical Aesthetics.

Located in a second-floor, 2,000-square-foot space in New Canaan, CT, Element is super-clean, white, bright and uncluttered. After reviewing my medical history and concerns, Merry washes and applies numbing cream to my face and neck. It's a good thing, too, because she now runs the tip of an Ultra laser gun up, down and across the surface of my skin, a procedure that feels like a regiment of mildly agitated yellow jackets stinging me. No matter. The treatment leaves my face feeling warm and tingly and looking slightly sunburned, and far easier for me to face myself onscreen.

For more serious skin issues, Merry suggests the Genius, a system for administering radiofrequency microneedling— forty-nine tiny needles that penetrate the skin and emit radio frequency—to get rid of dead skin and encourage collagen, a structural protein that tightens it.

“It’s a bit uncomfortable,” she tells me. Actually, the Ultra treatment was “a bit uncomfortable,” so I think I’m good for now, I tell her. »

bcofdermatology.com

93

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 93

9/18/23 2:28 PM

HAIR THERE, BUT NOT EVERYWHERE

While many men want hair added to thinning areas, others are interested in removing it from unwanted places.

THE MASSAGE IS THE MESSAGE

E

ven before the pandemic, Stephanie Torres, the manager of the Delamar Greenwich Harbor Spa in Greenwich, CT, saw a significant number of men making appointments for a range of spa treatments, but especially massages—Swedish, Sports, Deep Tissue. “The kind of massage,” she says, “depends on whether clients want to relax or work on specific muscles and areas of the body that need to be stretched and massaged.”

What may be helpful for some guys to know is that spa treatments aren’t only for the high-powered Greenwich male.

For years, one of Torres’s male clients let the gift certificates from his wife pile up before manning up and giving it a try.

“He finally came in, and he was blown away,” she says. “Now he’s booking appointments every two weeks.” The gentleman’s occupation?

Greenwich police officer, which makes a lot of sense: Standing in the middle of Greenwich

“I DON’T KNOW IF YOU’RE READY FOR THIS,” SHE TELLS ME, “BUT WE’LL SOON BE OFFERING MANSCAPING IN THE FORM OF MANZILLIANS— IN OTHER WORDS, BRAZILIANS FOR MEN.”

Avenue directing Range Rovers and well-heeled pedestrians is reason enough for regular, stress-reducing massages.

The problem with scheduling an appointment with Stephanie Torres? She’s so in demand that she’s booked out a month or even more.

Standing appointments for weekly or monthly massages is the norm among male clients at Artistex Salon & Spa in Westport, CT, which merged with Born of Earth Spa earlier this year. “A massage helps male clients de-stress,” says Anna, a masseuse at the spa for the past nine years. “Sitting in a chair all day hunched over a laptop can cause a lot of stress on the neck muscles and back muscles, even leg muscles. But beyond physical stress, there is mental and emotional stress, and I think men see the spa as somewhere they can get away from the world.”

Just off the busy Post Road near downtown, stepping into one of the massage rooms at Artistex feels like a full retreat from life outside. The room is narrow, the dark walls a relief from the stark white of medical spa treatment rooms.

I strip to shorts and lie under warm sheets on the massage table. Anna, who is Polish and has large, strong hands,

WAX STICK BY PIXEL-SHOT - STOCK.ADOBE.COM; MASSAGE BY HBS - STOCK.ADOBE.COM

U

nless we’ve been wearing baseball caps in Zoom meetings, another noticeable fallout from the pandemic has been the fallout of our hair. Spa owners report an uptick in male clients inquiring about medical treatments to encourage hair growth in bald or thinning areas of the scalp.

One of the more popular treatments for hair restoration is PRP (platelet-rich plasma). For the procedure, a patient’s blood is drawn, spun in a centrifuge, then injected into the scalp with microneedling, which opens channels in the follicles to encourage hair growth. (Think of this as a bag of liquid Scott’s Turf Builder dumped onto the bald areas of the scalp then worked in with a sharpened spade.)

For unwanted body hair, medical spa personnel suggest laser treatments, in which the emission of light and heat damages hair follicles.

The drawbacks are that it’s uncomfortable (some have likened it to a rubber band snapping against the skin), and it can be expensive. As many as six treatments may be required, to the tune of roughly $250 each treatment, and then permanent removal isn’t guaranteed.

A faster and far less expensive method of hair deforestation is traditional waxing. Here, strips of cloth dipped in hot wax are laid on a victim’s skin, then ripped off one strip at a time. (On second thought, I may opt for the snapped rubber bands!)

One new treatment at Dream Spa & Salon in Westport, CT, has owner Lori Dodd mincing words.

“I don’t know if you’re ready for this,” she tells me, “but we’ll soon be offering manscaping in the form of manzillians”—in other words, Brazilians for men. (Note: I should have stopped Lori at “I don’t know if you’re ready for this.” I wasn’t.)

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

94

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 94

9/18/23 2:28 PM

T

Y BOD

IND A ND SP IR I

,M

RENEWABLE ENERGY Athletically minded men are trying I.V. vitamin and hydration drip treatments at Elivate Med Spa.

Not all massages are just about relaxation.

Some work on athletic recovery.

KEVIN MAYER - STOCK.ADOBE.COM; CONTRIBUTED

“DEPENDS ON WHETHER CLIENTS WANT TO RELAX OR WORK ON SPECIFIC MUSCLES AND AREAS OF THE BODY THAT NEED TO BE STRETCHED AND MASSAGED.”

DELAMAR GREENWICH HARBOR SPA Greenwich, CT ARTISTEX SALON & SPA Westport, CT

attended university to become a teacher but found her calling in this country when her son was diagnosed at age four with rheumatoid arthritis.

“I always hid my big hands,” she says, “until I realized why I was given them.” After seven years of massaging her son’s limbs and joints to relieve his pain, she accepted her calling to become a massage therapist.

Employing a mix of soft Swedish massage and harder deep-tissue massage, she uses long sweeping strokes to massage the back and leg muscles, and her fingers find and relieve tension knots in the shoulders and neck. “When we are stressed, we lower our heads and raise our shoulders,” she says.

The massage lasts an hour, though time is blurred by the background ambient music— wind, storms and waves mixed with flutes, strings and horns played, it seems to me, by Himalayan spirit sherpas in yurts blowing into yak antlers. Or something.

There’s a term spa workers use to describe the effect of multiple treatments on men and women: “Spa brain.” I think it may be kicking in, because all I want to do is lie on this massage table, talking to Anna and listening to this music.

Y

ounger men are skipping hair treatments, and for good reason: All their hair is on their heads! Instead, they’re making appointments for I.V. vitamin and hydration drip bags.

“I.V. therapy was a hit, especially in the beginning of the pandemic, because everyone wanted to be as strong as possible in case they did get sick from Covid,” says Melissa PulciniButtine, the founder of Elivate in Old Greenwich, CT. As at other spas across the county, men are coming on their own these days as opposed to being dragged in by the women in their lives.

Clients at Elivate lounge in comfortable leather recliners in one of two I.V. rooms and watch movies on a large flatscreen TV as the vitamins—zinc, vitamin C, vitamin D, vitamin B-12 and immune booster cocktails— course through their veins.

The vitamins are custom mixed based on a consultation with Pulcini-Buttine or on blood work done in the on-site lab.

Treatments, which take about an hour, provide multiple benefits—improved mood, energy, weight loss, immune system strengthening, enhanced athletic performance—with the intravenous vitamins absorbed far faster and more effectively than if taken orally. » bcofdermatology.com

95

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 95

9/18/23 2:28 PM

W

ith the ordeal of medical spa treatments behind us, it’s time for treatments that both feel good and are good for us. One of the first steps for guys seeking a new lease on life is a pedicure.

That’s right: A pedicure!

This is because men have slowly been discovering the benefits of well-tended feet that have spent most of their lives imprisoned in boots or shoes, where some of the nastiest conditions on Earth prevail.

Fortunately, spas are as much centers of health information as they are palaces of pleasure, and a little information can go a long way to getting men in the door for this muchneeded treatment. As I learn from Jeannie, who has been rejuvenating feet at Dream Spa & Salon in Westport, CT, for sixteen years, the feet contain more sensory nerve endings per square centimeter than any other part of the body, continually supplying information about the surfaces we’re trodding for better balance, stability and shock absorption. With more than 250,000 sweat glands there, each foot can produce four to six or more ounces of perspiration a day. Enough said.

As with other spa treatments, gift certificates for pedicures are what usually drag men in the door for the first time. “They’ll come in for a pedicure, because they have a gift certificate from a wife or daughter or girlfriend,” Jeannie says. “A lot of the guys will say that when they cut their own toenails, they usually end up bleeding.”

I change my socks and go see her.

The pedicure room at Dream is a small, clean, warm room set off from the rest of the spa so that men don’t feel self-conscious in a sea of chatting women, says Jeannie. She is Greek and has a natural Mediterranean warmth that itself is soothing.

The procedure begins with slipping the bare feet in a warm, shallow bath of powdered milk

DREAM SPA & SALON Westport, CT

water mixed with lemongrass essential oil. After drying them on a towel on her lap, Jeannie clips the nails without blood or digit loss, then applies cuticle eliminator ointment to soften the dead skin on the nails that is pushed back and scraped off.

Next, she files the calluses with soft and gritty sandpaper-like files, and finally washes and massages the feet and calves with a washcloth and vanillaorange and brown sugar scrub, the sugar giving a mild grit to the wash. I feel special.

Jeannie recommends that men come back for a pedicure every four to six weeks, which is when toenails have grown long enough to be in need of clipping. I leave feeling not only grounded, but being able to see my reflection in my polished toenails.

FEET: SANDOR KACSO - STOCK.ADOBE.COM; CONTRIBUTED

GETTING GROUNDED

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

96

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 96

9/18/23 2:28 PM

T

BOD

Y

IND A ND SP IR I

,M

BODY, MIND AND SPIRIT

GUDENKOA - STOCK.ADOBE.COM

O

ne of the best ways to wrap up a program of spa treatments, both medical and aesthetic, might be with a visit to Jane Kohler, a Westport, CT-based structural integration therapist and masseuse, who is much sought after for her holistic approach to bodywork. In addition to feeling really good after one of her long sessions, clients receive an education across a wide, free-ranging spectrum of information—from yoga and meditation to Rolfing, reflexology and qigong, a traditional Chinese medicine that uses movement to optimize energy and maintain healthy mind, body and spirit.

Kohler’s Westport studio is a spacious, sun-dappled space in an old house furnished with antique Oriental carpets and a simple, cushioned massage table.

“Before clients get on the table, I look at their structure— how they’re standing, how they’re breathing and how they’re moving,” she says. “If the ankles and shoulders and ears aren’t aligned, there are issues that will continue until they’re resolved.”

Kohler focuses on the fascia— the connective tissue of the body—to realign posture and to open tissue that’s tightened due to stress, injury or other factors that cause chronic pain and limited mobility. Some issues involve ingrained habits of sitting, walking and breathing that inhibit daily functioning.

Other issues are emotional.

Kohler uses a mix of slow, deep, stretching movements and applied pressure to balance the fascial. The release of emotions, memories and/or traumas that have been stored in the tissue can make clients aware of the opportunity for change.

She stretches the limbs, realigns the frame, gently massages sore spots and applies pressure to tension knots, one area at a time. I leave feeling better than I have in years.

JANE KOHLER Westport, CT

“IF THE ANKLES AND SHOULDERS AND EARS AREN’T ALIGNED, THERE ARE ISSUES THAT WILL CONTINUE UNTIL THEY’RE RESOLVED.”

CAVEAT

O

ne warning, of sorts: Spa services for men aren’t for the faint of wallet. Aside from prescriptions, which PAs can write, most spa treatments are for those with disposable dead skin, tension and income.

“What we do is purely discretionary, so men have to be able to afford it,” says Dream Spa & Salon’s Lori Dodd.

Laser treatments and Hydrafacials can get pricey, while basic pedicures and massages are often more reasonable. As with most treatments, packages of three to six lower the cost per treatment considerably. (A second, more obnoxious disclosure: All of the above services were free for me.

Someone's gotta do it.)

Spa treatments can also be addictive. The Greenwich police officer, who disregarded gift certificates from his wife the way scofflaws disregard parking tickets, now schedules monthly appointments at the Delamar Spa for stresseliminating massages.

Finally, because of that spa brain, you may want to avoid treatments on days when you need to use your brain— like if you've got to give a big presentation. Then again, who cares? Explain that you’ve just come from a massage and pedicure and aren’t wearing shoes so that you can look at yourself in your polished toenails.

Spa men will understand.

bcofdermatology.com

97

90_97_JBCOD_8pgs Men Spa_Sept/Oct_2023.indd 97

9/18/23 2:28 PM

Topical Therapy

CREAM BY IMAGEHUB - STOCK.ADOBE.COM

PSORIASIS, PRIOR AUTHORIZATIONS AND ZORYVE (ROFLUMILAST) CREAM 0.3%

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

98

98_104_JBCOD_7pgs Zoryve Treatment_Sept/Oct_2023.indd 98

9/18/23 2:30 PM

By Neomia “Neo” Cuellar, CCMS, PACS

“If there was ever a time or place to be diagnosed with psoriasis, IT’S NOW.” This is a phrase I tell every patient I meet who is diagnosed with psoriasis.

H

onestly, it’s true. The advances in therapies have come a very long way, and it’s not only the injectable/oral therapies that are evolving, but now topical

therapies, such as ZORYVE, that are an option for some of our younger patients.

ZORYVE is a topical treatment for plaque psoriasis, including intertriginous areas in patients 12 years old and older. With the burdens of burnout and turnover rates growing the last few years, coupled with increasing insurance denials across all drugs from coast to coast, I’m here to help by pursuing a ZORYVE approval for your patients to relieve some of the pressures faced by your office.

As medical professionals in dermatology, we have seen different levels of patients struggling with psoriasis. This creates a negative impact not only on a physical level, bcofdermatology.com

99

98_104_JBCOD_7pgs Zoryve Treatment_Sept/Oct_2023.indd 99

9/18/23 2:30 PM

but on a mental one as well. We must decide which therapy will be effective while keeping in mind location and possible side effects of therapy options. With the release of ZORYVE, there is a non-steroidal option that can be used even in sensitive intertriginous areas, avoiding the risk of atrophy. Additionally, it is an alternative for patients who may have a needle phobia, seen especially in our adolescent patients, those who have no at-home injection help or those who struggle with swallowing pills.

While the options for psoriasis treatment have grown and produced progressive denials in the medical landscape for all drugs. This has caused a burden for our offices, which can lead to burnout and turnover. Some offices are under the impression that an attempt at approval is futile.

KBISCUIT - STOCK.ADOBE.COM

therapies, such as ZORYVE, there has also been an increase in prior authorization

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

100

98_104_JBCOD_7pgs Zoryve Treatment_Sept/Oct_2023.indd 100

9/18/23 2:30 PM

OLGA TERNAVSKAYA - STOCK.ADOBE.COM

WHY PURSUE APPROVAL?

This seems to be the 2023 question of the year. There’s a two-part answer to this. First and foremost, let’s look at the medication, ZORYVE, and explain the benefits of the therapy for our patient to the insurance company. The average psoriasis patient struggles with intense burning, itching and plaques, not just to the exposed skin, but to areas we can’t see. ZORYVE is non-steroidal and has convenient dosing, only needing to be applied once daily, and is not associated with side effects of folliculitis or atrophy. ZORYVE does not contain potentially irritating ingredients such as isopropyl alcohol, propylene glycol, or ethanol, which are concerns we may

have when choosing a topical therapy for our patients. For patients who have several topical drug allergies, this gives them an option where there may not have been one before. I had a call from a patient with a high-gluten sensitivity, not just internally, but to topical items that contained gluten which made her breakout. I was extremely happy to deliver the news that ZORYVE does not have gluten in the ingredients, and we were able to start ZORYVE therapy for her. As healthcare professionals, we want to minimize making a patient who is already suffering from experiencing any more discomfort.

As a provider, you should also have the fundamental right to choose what you feel the appropriate therapy should be for each patient. If you don’t tend to write

for biologics or believe the patient “isn’t there yet,” for injectable/oral therapies for psoriasis, then ZORYVE provides you with an option and/or an intervention pre-biologic initiation. Furthermore, providers may choose to use ZORYVE complementary to a biologic therapy. Even with biologic/oral therapy, there can be breakthroughs and flares of psoriasis. I am a witness to this, living and working in Arizona, where there is pretty much 0% humidity all year. With numerous patients who do get flares, especially in the winter months and need adjunct therapy, I have successfully gotten ZORYVE approved for patients to use alongside their injectable or oral therapies for those breakthrough flares. Additionally, ZORYVE can be used for long-term management for our patients’ psoriasis, where we may have struggled to find a long-term topical therapy before.

The physical manifestation of psoriasis can cause great mental anguish. This leads me to the second part of “Why pursue ZORYVE approval?” Many psoriasis patients are embarrassed about their condition and omit locations such as sensitive skin folds. I have received calls from countless patients over my last almost

“As medical professionals in dermatology, we have seen different levels of patients struggling with psoriasis.

THIS CREATES A NEGATIVE IMPACT NOT ONLY ON A PHYSICAL LEVEL, BUT ON A MENTAL ONE AS WELL.

"

bcofdermatology.com

101

98_104_JBCOD_7pgs Zoryve Treatment_Sept/Oct_2023.indd 101

9/18/23 2:30 PM

In my own practice, we also faced a high burnout rate that led to turnover and ultimately deterred people from doing prior authorizations (PAs) for topical medications, let alone an appeal. We felt as if many of the staff were too new and not educated on the prior authorization/appeal process… or we just simply didn’t have the time and resources to pursue many drugs that were seen as similar. The decision was made from not having a strong topical therapy option. This changed with the release of ZORYVE. I sat with the providers and explained not only the benefits of ZORYVE, but I laid out the facts about the PA and appeal process itself.

Insurance companies have more procedures in place that make it hard to navigate coverage, which can disincentivize us from pursuing an appeal.

The fact of the matter is, according to an AMA survey, “84% of physicians reported seeing an increase of PA requests within

the last five years.”* Ultimately, those who actually sought an appeal had “seen over 80% of those appeals were overturned as approved,” according to a Kaiser analysis of their Medicare patients.

With this knowledge, let’s review what an office can do to pursue a ZORYVE approval.

First and foremost, ensure you are adding any tried and failed therapies into the note/ supporting documentation. This may sound simple, but it is often the simplest tasks that are overlooked. This is one of the most common reasons for a coverage denial by the insurance company. In addition to missing tried and failed medications, we may forget to add the location of the psoriasis. With how fast-paced the visit can be, it is easy to counsel on a condition but forget to click on a body part in our EHR systems, thus leading to a denial.

Adding the clinical information is a great start, but please don’t forget to include anything that speaks to how the condition

KBISCUIT - STOCK.ADOBE.COM

15 years in dermatology who applied a topical steroid to an intertriginous area, because they did not want to tell the provider about flaring under the breasts or buttocks. Since we prescribed a steroid for the locations they did tell us about during the visit, they thought it would work the same, regardless of what area they were applying the topical steroid to, causing atrophy. This humiliation that kept them from telling their healthcare professional about a flare in the groin area also drives how they live on a daily basis, causing social discord and has led to the development of anxiety and depression.

This can cause psychosocial embarrassment—whether the patient is a 14-year-old in class who attends middle school or an adult who simply goes out to buy groceries. If you believe a therapy like ZORYVE could help improve a patient’s psoriasis, in turn, reducing embarrassment in their life, it’s worth fighting for treatment.

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

102

98_104_JBCOD_7pgs Zoryve Treatment_Sept/Oct_2023.indd 102

9/18/23 2:30 PM

TRIOCEAN - STOCK.ADOBE.COM

“The advances in therapies have come a very long way, and it’s not only the injectable/oral therapies that are evolving, but NOW TOPICAL THERAPIES, SUCH AS ZORYVE, THAT ARE AN OPTION FOR SOME OF OUR YOUNGER PATIENTS."

affects the patient, not just physically, but mentally. My passion is fighting for medication approvals, such as ZORYVE. Over the years, one of the most important things I have learned through insurance prior authorizations is that a well-worded statement about how the condition affects a patient’s quality of life can also be a factor in a successful approval.

Psoriasis can cause mental harm when we are forced to go through step therapies, creating frustration in the patient since they are not seeing an improvement.

This experience may inadvertently reflect on their view of the practice/provider. If there is a reason the provider feels the alternative therapy would be ineffective or has a concern about an adverse effect, also add this to your PA or Appeal.

Some of my own tips to get a ZORYVE approval (besides listing locations that are affected and what they have tried and failed) include why this medicine is preferred, along with the provider’s reasons about how it will improve the condition. For example, if a patient does have psoriasis in their intertriginous areas, I want to avoid topical steroids because of the risk of atrophy. If my patient has had problems with rashes before or they

have a large body surface area that would burn with most topical therapies, I explain we need ZORYVE approved since it is an effective treatment option and does not have alcohol, ethanol, or propylene glycol, which would cause irritation to the already open, burning plaques.

Not just compiled from literature, but from real-life experience, I continuously try to remember the impact psoriasis can have on patients and include this in the notes.

For example, I’ve had patients explain they don’t feel like seeking intimacy or a partner because of the sensitive areas affected, such as the intertriginous areas. Alongside these experiences, I have seen some of the same patients who experienced atrophy and feel that “nothing can be done.”

Some of my patients cannot perform job responsibilities because their hands

are affected or they are broken out on an exposed area, causing embarrassment.

Explain in a note how the condition affects the patient both professionally and personally, which can also be used in a PA or appeal.

When I am short on time to do prior authorizations and appeals for medications like ZORYVE, I enlist the help of specialty pharmacies. Working with an experienced specialty pharmacy can be helpful. I work with several that have a tremendous amount of knowledge on payer processes, so our office doesn’t have to navigate it on our own. Since they’re seeing these things multiple times a day, they can help you figure out a complicated process. I understand the strain on an office when we are short-staffed. Specialty pharmacies can assist with the PA or appeal processes for medications such as ZORYVE. With advancements in therapies like ZORYVE, it is important to remember the benefits for patients and the justification of attempting to pursue an approval for it, even with the landscape of burnout and office turnover. Simply listing what a patient has failed helps; however, be sure to remember the greater cause and why we practice medicine. For these patients

bcofdermatology.com

103

98_104_JBCOD_7pgs Zoryve Treatment_Sept/Oct_2023.indd 103

9/18/23 2:30 PM

IMPORTANT SAFETY INFORMATION The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

The most common adverse reactions (≥1%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).

Please see full prescribing information at zoryvehcp.com.

improvement, we are not only improving their physical condition, but also improving their mental quality of life. Preventing embarrassing moments and empowering the patient is critical.

For example, a 16-year-old patient got the courage to try out and successfully made the varsity swim team only after getting clear skin with her ZORYVE prescription. I worked with a 28-year-old autism patient who struggled with alternative therapies, but he was able to switch to ZORYVE and now has the ability to control his disease. What we prescribe and how we pursue these medications can mean the world to our patients.

KBISCUIT - STOCK.ADOBE.COM

who may not have had many options before, or who fear alternatives therapies, ZORYVE may be the treatment that fits them best. We are also taking back the fundamental right to practice medication and prescribing from the hands of the insurance companies, since they may try to dictate therapies that are against our wishes for the patient. If we need assistance pursuing an appeal but don’t want to take too much time from our own staff, specialty pharmacies are out there waiting to help with this.

Lastly, when we do get an approval for a medication like ZORYVE and the patient can adhere to the therapy and sees

REFERENCES *https://www.medicarerights.org/medicare-watch/2023/02/09/prior-authorization-data-and-proposed-rule-reflect-need-for-stronger-medicare-advantage-rules **https://www.medicarerights.org/medicare-watch/2023/02/09/prior-authorization-data-and-proposed-rule-reflect-need-for-stronger-medicare-advantage-rules

“Over the years, one of the MOST IMPORTANT THINGS I HAVE LEARNED THROUGH INSURANCE PRIOR AUTHORIZATIONS IS THAT A WELL-WORDED STATEMENT ABOUT HOW THE CONDITION AFFECTS A PATIENT’S QUALITY OF LIFE

can also

be a factor in a successful approval."

ACCESS DERMATOLOGY SEPTEMBER/OCTOBER 2023

104

98_104_JBCOD_7pgs Zoryve Treatment_Sept/Oct_2023.indd 104

9/18/23 2:30 PM

STILL GOLDEN.

Don’t fall for anything less.

EHR | PM | PATIENT ENGAGEMENT | TELEHEALTH | ASC | INTEGRATED PAYMENTS | CONSULTING

Nextech is still the only EHR to receive the American Academy of Dermatology’s DataDerm™ Gold recognition.

Start anew with the #1 solution for Dermatology

COV3_JBCOD_Sept/Oct_2023.indd 3

9/18/23 2:32 PM

Help eligible patients start and stay on track with their therapy The DUPIXENT MyWay® patient support program can help facilitate patient access to DUPIXENT® (dupilumab) throughout the treatment journey.

DUPIXENT

myway)

Coverage support DUPIXENT MyWay provides assistance navigating the insurance process with benefits investigations, prior authorization support, and education about the appeals process.

Patient access support DUPIXENT MyWay may have support for eligible patients who need help with their out-of-pocket costs.

Education and support Every enrolled patient is assigned a dedicated DUPIXENT MyWay Case Manager, who takes a patient-centric approach to providing tools, support, resources, and education throughout the treatment journey.

Support for your patients begins with a complete DUPIXENT MyWay Enrollment Form You can help patients enroll in DUPIXENT MyWay by: • Faxing the form to DUPIXENT MyWay at 844-387-9370 • Submitting the form through the DUPIXENT MyWay Document Drop at www.patientsupportnow.org

For more information: Visit us on the exhibit floor OR Call DUPIXENT MyWay at 1-844-DUPIXEN(T) (1-844-387-4936) Option 1, Monday–Friday, 8 am–9 pm Eastern time For any questions or concerns, or to report side effects with DUPIXENT® (dupilumab), please contact 1-844-DUPIXEN(T) (1-844-387-4936) Option 1, Monday–Friday, 8 am–9 pm Eastern time.

sanofi | DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology. © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

07/2023 DUP.23.06.0234

COV4_JBCOD_Sept/Oct_2023.indd 4

D

(dupilumab) Injection 9/18/23 2:33 PM